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Abstract 
The use of antibiotics in food animals is of major concern as a purported cause of 
antimicrobial resistance (AMR) in human pathogens; as a result, alternatives to in-feed 
antibiotics such as heavy metals have been proposed.  The effect of copper and CTC 
supplementation in weaned pigs on AMR in the gut microbiota was evaluated.  Four treatment 
groups: control, copper, chlortetracycline (CTC), and copper plus CTC were randomly allocated 
to 32 pens with five pigs per pen.  Fecal samples (n = 576) were collected weekly from three pigs 
per pen over six weeks and two Escherichia coli  isolates per sample were tested phenotypically 
for antimicrobial and copper susceptibilities and genotypically for the presence of tetracycline 
(tet), copper (pcoD) and ceftiofur (blaCMY-2) resistance genes.  CTC-supplementation 
significantly increased tetracycline resistance and susceptibility to copper when compared with 
the control group.  Copper supplementation decreased resistance to most of the antibiotics, 
including cephalosporins, over all treatment periods.  However, copper supplementation did not 
affect minimum inhibitory concentrations of copper or detection of pcoD.  While tetA and 
blaCMY-2 genes were associated with a higher multi-drug resistance (MDR), tetB and pcoD were 
associated with lower MDR.  Supplementations of CTC or copper alone were associated with 
increased tetB prevalence; however, their combination was paradoxically associated with 
reduced prevalence.  These studies indicate that E. coli isolates from the weaned pigs studied 
exhibit high levels of antibiotic resistance with diverse multi-resistant phenotypic profiles.  In a 
related study, total fecal community DNA (n = 569) was used to detect 14 tet genes and to 
quantify gene copies of tetA, tetB, pcoD and blaCMY-2.  CTC and copper plus CTC 
supplementation increased both the prevalence and gene copies of tetA, while decreasing both 
the prevalence and gene copies of tetB, when compared with the control group.  The diversity of 
tet genes were reduced over time in the gut bacterial community.  The roles of copper 
supplementation in pig production and pco-mediated copper resistance in E. coli need to be 
further explored since a strong negative association of pcoD, with both tetA and blaCMY-2, 
suggests there exist opportunities to select for a more innocuous resistance profile. 
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to 32 pens with five pigs per pen.  Fecal samples (n = 576) were collected weekly from three pigs 
per pen over six weeks and two Escherichia coli  isolates per sample were tested phenotypically 
for antimicrobial and copper susceptibilities and genotypically for the presence of tetracycline 
(tet), copper (pcoD) and ceftiofur (blaCMY-2) resistance genes.  CTC-supplementation 
significantly increased tetracycline resistance and susceptibility to copper when compared with 
the control group.  Copper supplementation decreased resistance to most of the antibiotics, 
including cephalosporins, over all treatment periods.  However, copper supplementation did not 
affect minimum inhibitory concentrations of copper or detection of pcoD.  While tetA and 
blaCMY-2 genes were associated with a higher multi-drug resistance (MDR), tetB and pcoD were 
associated with lower MDR.  Supplementations of CTC or copper alone were associated with 
increased tetB prevalence; however, their combination was paradoxically associated with 
reduced prevalence.  These studies indicate that E. coli isolates from the weaned pigs studied 
exhibit high levels of antibiotic resistance with diverse multi-resistant phenotypic profiles.  In a 
related study, total fecal community DNA (n = 569) was used to detect 14 tet genes and to 
quantify gene copies of tetA, tetB, pcoD and blaCMY-2.  CTC and copper plus CTC 
supplementation increased both the prevalence and gene copies of tetA, while decreasing both 
the prevalence and gene copies of tetB, when compared with the control group.  The diversity of 
tet genes were reduced over time in the gut bacterial community.  The roles of copper 
supplementation in pig production and pco-mediated copper resistance in E. coli need to be 
further explored since a strong negative association of pcoD, with both tetA and blaCMY-2, 
suggests there exist opportunities to select for a more innocuous resistance profile. 
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Chapter 1 - General introduction 
Antimicrobial resistance (AMR) is a serious and growing global public health threat of 
the 21st century (1-3), making the treatment of bacterial diseases a challenging task.  
Antimicrobial resistance increases morbidity, mortality and costs of health care systems (4-6).  In 
the United States alone, about 2 million people acquire serious infections with bacteria resistant 
to at least one antibiotic and at least 23,000 people die each year directly from antibiotic resistant 
infections (2).  Studies have shown that the annual direct cost of antibiotic resistant infections to 
the United States health care system ranges from $21 billion to $34 billion per year with more 
than 8 million additional hospital days (7).  The magnitude of the AMR problem is compounded 
by a rapid decline in the discovery of new antibiotics (5, 7).  The widespread use and misuse of 
antibiotics in human medicine is generally accepted to be the principal cause of antibiotic 
resistance for humans (5, 6, 8).  The use of antibiotics in food animals also poses an additional 
public health risk (8, 9).   
Antibiotics form an integral part of animal production, especially in modern livestock and 
poultry production systems.  A large proportion of the antibiotics used in the United States is 
administered to food animals (8, 10).  Antibiotics are used for the treatment of diseases, to 
prevent or control the spread of diseases, and also to increase growth and improve feed 
efficiency.  Of critical public health concern is the use of antibiotics for growth promotion in 
which antibiotics are administered at low doses and for long durations in a large group of 
animals (8).  This practice is believed to cause prolonged selection pressures and thus animals 
can become important reservoirs of AMR.  Antibiotic resistant bacteria can be transferred to 
humans through the food chain (11) or by direct contact with animals, which subsequently can 
become less responsive to treatment in humans over time (9).  However, the actual contribution 
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of such agricultural uses of antibiotics to the antibiotic resistance problem in humans is not 
known (12); to some researchers, the actual contribution is believed to be small (13).   
Tetracyclines are one of the oldest broad spectrum antibiotics with bacteriostatic activity, 
having been discovered in the late 1940s (14).  Tetracyclines inhibit bacterial protein synthesis 
by binding to the 30S ribosomal subunit at the tRNA acceptor site (A-site), thereby sterically 
blocking the binding of aminoacyl-tRNA (15).  Chlortetracycline (CTC) and oxytetracycline are 
the most commonly used forms of tetracyclines in veterinary medicine (16-18).  Tetracycline 
resistance is the most common form of antibiotic resistance observed in bacteria obtained from 
pigs (19-27) and in other animal species and man (28).   Tetracycline resistance commonly 
occurs through efflux, ribosomal protection and enzymatic inactivation, with the first two being 
the two most clinically important resistance mechanisms (15, 28-31).  Widespread tetracycline 
resistance is predominantly due to acquisition of new genes through horizontal gene transfer on 
mobile genetic elements such as plasmids, transposons, and conjugative transposons which may 
also carry resistance determinants to other antibiotics and heavy metals (30).  To date, 43 
tetracycline resistance determinants (tet) and 3 oxytetracycline resistance  determinants (otr) 
have been characterized and published (31)
1
.   
Because of increased concern about the risk of AMR in humans (9), the use of antibiotics 
as antimicrobial growth promoters (AGPs) was banned in EU member countries in 2006 (9) and 
is currently being phased out in the United States (32) on the basis of the “precautionary 
principle” and the concept of “prudent use”.  From the Danish experience, the major initial 
consequences of banning AGP in swine include reduced productivity, poor growth rate and 
increased incidence of diarrheal diseases, particularly during the first two weeks of life (33).  
                                                 
1
 http://faculty.washington.edu/marilynr/tetweb1.pdf 
3 
 
Later, these parameters were observed to return to and exceed baseline values (34).  Limiting the 
use of antibiotics in animals for growth promotion purposes may reduce human health risks 
associated with antibiotic resistant bacteria (8).  However, studies  indicate that such restrictions 
increase the cost of production with decreased productivity and an expected increase in retail 
prices to consumers (8).  A total ban of feed-grade antibiotics from swine production in the U.S. 
would increase cost of production by $2.8-$6.1 per animal produced which is associated with 
increased consumer costs for pork ranging from $180 million/year to over $700 million per year 
(8).  Maintaining animal production in the absence of AGPs would require an increase in the 
total number of animals produced to get the same amount of meat.  This would increase the need 
for more environmental resources, and potentially lead to further proliferation and dissemination 
of some diseases (9).  Moreover, limiting or completely banning the use of antibiotics in animals 
can paradoxically lead to increased microbial load in the environment.  To cope with these 
potential production losses, many alternatives to antibiotics are currently being evaluated (33, 
35).  The metals zinc and copper are commonly used for growth promotion purposes in pig 
production (33).  Growth promotion effects of heavy metals are believed to be mediated through 
improved feed intake, improved growth rate and likely through their known antimicrobial 
activities (33, 36, 37).   
In swine nutrition, copper (Cu), mainly in the form of copper sulfate (CuSO4), is an 
essential trace mineral required for normal physiological activities.  Copper is most commonly 
supplemented at 16 ppm (38), well over double the National Research Council (NRC) 
recommended required dose of 5-6 ppm (39).  Much higher dietary levels, typically at 100-250 
ppm of Cu (fed as CuSO4), are also used to promote growth, increase feed intake and improve 
feed efficiency in weanling pigs in similar magnitude as that seen with antibiotics (40).  
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However, similar to antibiotics, plasmid-coded resistance to heavy metals is widespread (9, 41-
44) and the use of copper has recently been shown to be associated with macrolide, tetracycline, 
and glycopeptide resistance in Gram positive enterococci (41-47).  Copper salts have been 
suggested to select for antibiotic resistance in E. coli (48).  Furthermore, heavy metal use is 
limited by its environmental toxicity of excreted metals as they are not further degraded (48).  
Unlike toxic organic compounds, inorganic forms of metals cannot be degraded (49, 50); 
subsequently, representing a long term selection pressure.  Concerns surrounding the potential of 
metal contamination in maintaining a pool of AMR genes in the environmental and clinical 
settings are growing (50).   
For bacteria, copper also is an essential trace element, though it is toxic at higher 
concentrations (51, 52).  Thus, bacteria have developed various mechanisms for handling copper.  
Heavy metal homeostasis, versus resistance, is a delicate balance between maintaining cells with 
a supply of essential trace elements on one hand and protecting them from their toxic effects on 
the other (46).  Copper resistance in E. coli can be selected as a result of agricultural use of 
copper (52).  Wild type E. coli have developed several chromosomally encoded copper tolerance 
mechanisms and strains with plasmid borne copper resistance (pco) genes are able to survive 
under significantly higher levels of environmental copper and thus be termed as copper resistant 
(46, 53).   
The pco determinant was first identified in 1983 by Tetaz and Richard (54) from E. coli 
strain isolated from the effluent of copper sulfate supplemented pigs in Australia.  The pco gene 
is approximately 6 kilobase pairs and has been found on a conjugative plasmid designated as 
pRJ1004 (36, 54).  The pco gene cluster consists of seven genes designated as pcoABCDRSE 
(46, 51, 55) which are arranged in two operons: pcoABCD and pcoRS, along with a separate 
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pcoE gene.  The pcoABCD and pcoE clusters are structural genes while the pcoRS cluster 
consists of regulatory genes.  PcoA, PcoC and PcoE are periplasmic proteins; on the other hand, 
PcoB and PcoD are, respectively, outer and inner membrane proteins involved in copper 
transport.  PcoRS is a two-component regulatory system that regulates the expression of 
pcoABCD genes (55).  The sensor protein is encoded by pcoS and is phosphorylated by an 
environmental signal (in this case, the presence of copper) which in turn phosphorylates and 
activates the regulator protein encoded by pcoR (51).  The pcoABCD genes are expressed as a  
polycistronic message from the same promoter under the pcoRS regulatory system, with 
stoichiometric production of the four gene products (56); it is believed that the expression of all 
four genes is required for full resistance (55). 
Ceftiofur is an extended-spectrum third-generation cephalosporin, first approved by the 
U.S. Food and Drug Administration (FDA) in 1988 for the treatment of respiratory diseases in 
cattle and pigs (57).  However, its continued use in animals has been closely scrutinized due to 
its cross-resistance with ceftriaxone, a closely related antibiotic that is used as a first-line 
treatment for invasive life threatening diarrheal diseases in children such as can be caused by 
Salmonella enterica (58).  Resistance to ceftiofur is mediated primarily by a widely disseminated 
plasmid-borne AmpC type β-lactamase, the blaCMY-2 cephamycinase gene (59, 60).  E. coli can 
act as an important reservoir of the AmpC blaCMY genes, each of which can later be transferred 
to other, more pathogenic bacteria such as Salmonella enterica (61).   
A previous phenotypic study has shown that sub-therapeutic use of CTC in pigs results in 
the co-selection of third generation cephalosporin resistance (ceftriaxone) among enteric bacteria 
of pigs (23).  It has been also reported that administration of ceftiofur in feedlot cattle is 
associated with increased tetracycline resistance in E. coli (62) and, conversely, administration of 
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in-feed CTC in feedlot cattle is also associated with increased ceftiofur-resistant E. coli (63).  
Furthermore, a complete sequence of some IncA/C plasmids originating from cattle showed the 
presence of blaCMY-2 gene along with multiple other antimicrobial resistance genes such as tetA 
(64); in addition, blaCMY-2 was concomitantly reported with co-resistance to ampicillin, 
chloramphenicol, streptomycin, sulfamethoxazole and other tetracycline resistance genes in 
Salmonella (65).  Based on the above previously reported findings, it can be easily hypothesized 
that CTC supplementation in weaned pigs can select for tetracycline and ceftiofur resistances and 
also to other antibiotics.  Secondly, copper supplementation favoring plasmid-borne pco genes 
also could select for antibiotic resistance such as against tetracycline and ceftiofur (50).  Until 
recently, experimental studies evaluating the effects of feed-grade use of CTC along with 
elevated levels of copper supplementation in weaned pigs on AMR in their fecal flora have been 
lacking. 
The major objective of this cluster-randomized experimental study was to investigate the 
impact of feed grade chlortetracycline and copper supplementation in weaned pigs on AMR in 
the gut bacteria, measured qualitatively both at phenotypic and genotypic levels in E. coli, and 
quantitatively at the microbial ecological level.  Specific objectives were to investigate CTC and 
copper supplementation effects on: 
1. the prevalence of phenotypic antimicrobial resistance of E. coli against copper and a 
panel of 15 antibiotics commonly used for the treatment of Gram negative infections,  
2. the prevalence and distribution of tetracycline (tet), copper (pcoD) and ceftiofur 
(blaCMY-2) resistance genes in E. coli, and association of these genes with multidrug 
resistance and among themselves, and 
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3. the distribution and prevalence of 14 tet genes and the quantities of gene copies of 
tetA, tetB, pcoD and blaCMY-2 in the feces of weaned pigs supplemented with CTC, 
copper, both, or neither.
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Chapter 2 - Antimicrobial resistance: review of epidemiology and 
challenges 
 Introduction 
For over 70 years, the use of antimicrobial agents has reduced mortality and morbidity 
associated with bacterial infections in both humans and animals.  As a consequence, many lives 
have been saved and food safety and security have been improved.  However, due to their 
widespread use and misuse, the effectiveness of these ‘wonder drugs’ has declined due to the 
associated widespread occurrence of antimicrobial resistance (AMR).  Antimicrobial resistance 
has been recognized as a major public health problem by international and national agencies (1, 
66-68).  
Enterococcus (Enterococcus faecium, E. fecalis) and Escherichia coli are the two major 
genera commonly used for AMR monitoring representing Gram positive and Gram negative 
bacteria respectively because: 1) they are ubiquitous, 2) they are common commensals in 
animals and humans, 3) they can easily acquire antimicrobial resistance determinants in response 
to  selective pressures exerted by antimicrobials, and 4) they can assemble mobile genetic 
elements (plasmids, transposons, insertion sequences and gene cassettes) and transfer the 
resistance genes to other more pathogenic bacteria (19, 69).  Thus, commensal bacteria are 
generally regarded to act as important reservoirs for AMR (70).  Furthermore, they also can 
cause opportunistic or nosocomial infections on occasion, especially in hospital environments.  
Commensal bacteria were known to carry the same tet genes, plasmids, transposons, conjugative 
transposons as more pathogenic bacteria.  Moreover, it has been observed that over time Gram 
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positive commensal bacteria carry multiple tet genes with the same mode of action (e.g., efflux 
or ribosomal protection) as those of more pathogenic bacteria (28).  
Feed additives, with or without significant nutritional value, that are commonly added to 
swine diets include acidifiers, anthelmintics, antibiotics, carbohydrate degrading enzymes, 
carcass modifiers, flavors, high dietary levels of copper and zinc, fungicides, phytase, 
phytogenics, probiotics and prebiotics (71).  Copper and antibiotics have been used as growth 
promoters in pig diets for more than 60 years (36).  Early on, it was observed that pigs 
supplemented with antibiotics demonstrated improved average daily weight gain and feed 
conversion efficiency (36).  The effect of antibiotics as growth promoters was serendipitously 
discovered in the late 1940s when the fermentation product of Streptomyces aureofaciens was 
added to the feeds of poultry and pigs, resulting in marked increases in their growth rate (9).  
This increased growth rate was hypothesized to be due to the presence of low levels of 
chlortetracycline in the fermentation products.  This discovery coincided with the transitional 
replacement of pasture production systems with intensive animal production systems (9).   
The use of in-feed antibiotics in animals, at both therapeutic and sub-therapeutic levels, 
to control infections caused by enteric organisms became widely practiced after the late 1940s 
(35, 71).  Antibiotics are added to swine feed for therapeutic purposes at high doses, prophylactic 
purposes at intermediate doses, and for growth promotion purposes at sub-therapeutic doses (9, 
40).  Twelve antibiotics and five synthetic antimicrobial agents are approved by the Food and 
Drug Administration for use in swine feed (40) (Table 2.1).  Chlortetracycline and 
oxytetracycline can also be used in combination with other drugs; for example, as 
chlortetracycline/penicillin/sulfamethazine (or sulfathiazole), neomycin/oxytetracycline) (40).  
With the exception of tetracyclines, sulfa drugs and carbadox which have broad spectra of 
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activity, most growth promoting antibiotics target Gram positive bacteria which predominate in 
the proximal part of the gut (72).  A national swine survey providing data from 712 farms and 
collected by the National Animal Health Monitoring System (NAHMS) from 1989-1991 (18), 
indicted that 60% of the farms included antimicrobials in their swine diets.  It was also reported 
that nursery pigs were more likely to be fed antimicrobial supplemented feeds than the later 
production phases, and for any purpose (9, 17, 18, 40).  In the grower/finisher pigs antibiotics 
were usually fed only for disease prevention or therapy (17).  An Animal Health Institute 2000 
report indicated a decline in the sub-therapeutic use of antibiotics: it was estimated that 18% of 
all antibiotics used in animal production were for growth promotion purposes and 82% were for 
disease prevention and treatment (40).  The proportion of antimicrobial agents used as AGPs fell 
from 17% in 2001 to 5% in 2004 (9).   
Results of a recent study on the estimated use of in-feed antimicrobials in U.S. swine 
production similarly indicated that the proportion of antimicrobials used as AGPs in nursery pigs 
remains lower than that used for grower and finisher pigs (17).  Chlortetracycline was found to 
be the most commonly used in-feed antibiotic in U.S. swine production system, followed by 
tilmicosin and oxytetracycline (17).   
The mechanisms by which antibiotics improve growth have not been entirely elucidated.  
However, some mechanisms by which antibiotics improve growth could be associated with 
changes in intestinal flora including inhibition of subclinical infections caused by pathogenic 
bacteria, reduction of growth depressing microbial metabolites and microbial growth inhibition 
thereby increasing nutrient availability and uptake and utilization through the intestinal mucosa 
(9, 10, 40, 71, 72).   Early studies had shown significant improvements in growth performance of 
pigs when antibiotics were added to swine feed (40, 71).   However, in modern swine production 
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systems with improved production and herd health management practices, the magnitude of the 
growth promotional responses is usually lessened (73).  This difference between early and 
current reports on the efficacy of AGPs is in part attributed to the hygienic status under which 
these sets of studies were conducted.  More recent studies (73, 74), which were arguably 
conducted under better hygienic conditions when compared to studies conducted many decades 
ago, did not find any significant improvement in the growth rate of pigs supplied with tylosin or 
chlortetracycline.  The growth promotion benefits of AGPs likely could be more pronounced 
under field (farm) conditions when compared to controlled research situations (9, 40, 73); 
perhaps as much as twice that obtained under research station conditions where bacterial load 
and environmental stress are lessened (40).  At the farm level, antibiotics have been shown to 
improve growth rate by as much as 25-30% and feed efficiency by 12-15% in weaned pigs, and 
8-10% and 4-5% in finisher pigs, respectively (40).  Furthermore, the magnitude of growth 
promotion response varies with stage of pig growth.  Different studies have shown that 
antibiotics are more effective in nursery pigs in promoting growth than in finishing pigs (9, 40, 
71-73).  The magnitude of response to AGPs varies with age (greater during weaning, breeding 
and farrowing), stage of production, and environmental conditions under which animals are kept 
(9).  Therefore, limiting the use of AGPs only to the nursery phase and restricting to therapeutic 
use of antibiotics in the finishing phase with increased infection control measures should 
decrease the overall use of antimicrobials and thus reduce the risk of AMR under the current 
multisite swine production system paradigm (73).   
Because of increased concern about the risk of AMR in humans (9), the use of AGPs has 
been banned in Europe since 2006 (9, 75) and is being phased out in the United States (32).  
From the Danish experience, banning AGPs was associated with initial increase in the use of 
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therapeutic antibiotics and mortality (33) however in the long term it did not negatively impact 
swine production (34).   To cope with any potential production losses and to control disease, 
many alternatives are being evaluated (35).  Zinc and copper are commonly used for growth 
promotion purposes in swine production (33).  In the United States, the nonessential metal 
arsenic is also used as a feed supplement for chickens, turkeys and pigs (46).  The growth 
promotion effects of heavy metals are thought to be provided through improved feed intake, 
improved growth rate and antimicrobial activities (33, 36, 37) similar to the effects of antibiotics.  
Zinc and copper are used for the treatment of post-weaning scouring in pigs (46).  It has been 
reported that copper supplementation in pigs, especially of CuSO4, reduced the number of 
streptococci and lactobacilli while coliforms either increased in numbers, or else remained 
unaffected (33).  
In swine nutrition, copper (Cu) is an essential trace mineral that is required for  
hemoglobin synthesis, and for the synthesis and activation of oxidative enzymes that are 
important for normal metabolism (39).  A basal level of 5-6 ppm of copper is required in the 
diets of neonatal pigs and at decreased levels in the later ages (39).  However, the actual 
nutritional requirements for copper and zinc are often inflated to account for diet related factors 
that interfere with its absorption (46).  The common forms of Cu salts with high bio-availability 
include the sulfate (CuSO4·5H2O), carbonate (CuCO3) and chloride (Cu2[OH]3Cl); however, the 
oxide and sulfide forms are poorly available to the pig (39, 76).  The form of Cu that is most 
commonly used as a feed additive for growth promotion in pigs is the sulfate salt (76). 
Although copper is not generally classified as an antimicrobial, it has antibacterial 
properties when fed at high levels in the diet (40).  High dietary levels, typically at 100-250 ppm, 
of Cu (fed as CuSO4) promote growth, enhance feed intake and improve feed utilization 
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efficiency in weanling pigs with a similar magnitude as that of antibiotics (40).  These responses 
to high Cu supplementation are either independent of, or else additive to, that obtained from in-
feed antibiotics; however, such  increases are not seen when fed with zinc (37, 39, 76) and 
growth promotion effects of copper decrease with the age of the pigs (37, 40).  The maximum 
tolerable level of Cu for pigs is 250 ppm of diet and excess dietary levels for prolonged periods 
appear to be toxic (39, 46).  Physiological mechanisms by which high dietary Cu stimulates 
growth largely remain unknown; however, some of this has been attributed to its antibacterial 
properties (39).  The realization of the beneficial effects of copper (as CuSO4) came mostly from 
the observed association between elevated copper feeding (100-250 ppm) and increased growth 
rates under experimental studies (77).  In most European countries the maximum amount of 
copper supplement allowed in swine feed is 170 to 175 mg/kg (170-175 ppm) for piglets (up to 
12 weeks of age) and 25 to 35 ppm for growing and finishing pigs (46, 47).  In the United States, 
however, copper supplements are not limited by regulation and when supplemented at elevated 
levels usually range from 100 to 250 ppm, independent of the age of pigs (46, 47).  
Similar to the situation with antibiotics, heavy metal resistance encoded on plasmids is 
widespread (9, 41-44).  Copper salts have been purported to select for antibiotic resistance in E. 
coli (48).  Furthermore, heavy metal use is also limited by the environmental toxicity of excreted 
metals since they are not degraded in the environment (48).  In spite of control measures and 
restricted use of antibiotics, the problem of antibiotic resistance still persists; this indicates the 
need to better understand factors that govern the evolution, dissemination and perpetuation of 
AMR beyond the use of antibiotics (50).  Co-selection between metals and antibiotics occurs 
either through co-resistance or cross-resistance (50).  Co-resistance occurs as a result of physical 
linkage of resistance genes co-located on the same genetic element such as a plasmid, transposon 
14 
 
or integron (50).  It has been known for long time that metal and antibiotic resistance genes are 
linked, particularly on plasmids (50).  Cross-resistance occurs when different antimicrobial 
agents attack the same target, have a common pathway or else share the same route of access to 
their target.  Thus, it occurs in chemically related antimicrobial agents belonging to the same 
class, or between structurally dissimilar compounds through nonspecific efflux using the same 
mechanism (50).  Furthermore, co-regulation is also another means for the maintenance and 
proliferation of antibiotic resistance determinants in which transcriptional and translational 
responses to metal or antibiotic exposure can be linked to form a coordinated response to either 
stressor (50).   
Selective pressure associated with prophylactic or sub-therapeutic doses of antibiotics in 
pig feed has been shown to increase the rate of plasmid transfer during in vivo conjugation 
experiments.  This practice increases selection of plasmid-containing bacteria in the intestinal 
flora since feeding with a single antibiotic agent selects for all genes associated with the plasmid 
specifying resistance to the agent (78).  Such selection could indirectly also be exerted on any 
and all plasmid(s) carried by the same host cell.  Thus, supplementation of CuSO4 in pig feed as 
a growth promoter may lead to selection of copper resistant strains and indirectly to the 
proliferation of resistance or virulence plasmids (54, 79).  When first identified, it was observed 
that a plasmid (pRJ1004) did not carry any other known antibiotic or heavy metal resistance 
genes (36).  However, as has been since shown, feeding of copper to pigs may also serve to 
select E. coli resistant to antibiotics (50, 54, 80).   
Associations between the transferable copper resistance (tcrB) gene in enterococci 
obtained from copper supplemented pigs and resistance to macrolide (erythromycin), 
glycopeptide (vancomycin) and tetracycline antibiotics have been reported (41, 43, 44, 81).  This 
15 
 
suggests that tcrB is likely to be physically linked to vanA, ermB or tetM genes on the same 
plasmid, depending on the jurisdiction.  However, following the ban of the use of antibiotics as 
AGPs, erythromycin and vancomycin resistance declined suggesting that copper 
supplementation alone could not have maintained high levels of antibiotic resistance (45), or that 
the tcrB gene had not fully penetrated the enterococci population in swine and other food-
producing animals.  Holzel et al., 2012 (80) found a positive association between the level of 
detection of copper and elevated β-lactam resistance in E. coli isolated from liquid pig manure in 
Germany.  However, metal resistance plasmids predated the use of antibiotics suggesting that the 
emergence of metal-antibiotic co-selection on genetic elements is a relatively recent 
phenomenon (50).  
 Antimicrobial classes, mode of action and mechanism of resistance 
In veterinary medicine antimicrobials are generally used for three purposes: non-
therapeutic uses such as for growth promotion, prophylactic uses to prevent and control 
infections and therapeutic uses for the treatment of sick animals (82, 83).  The most commonly 
used antimicrobials in food animals belong to one of five major classes: beta-lactams, 
tetracyclines, macrolides, aminoglycosides, and sulphonamides, all of which are also used in 
humans (83).  
Based on the importance of antimicrobials (defined as any antibacterial agent including 
both antibiotics and synthetic agents) used in medical practice, the World Health Organization 
(WHO) (84) categorizes antimicrobials into 3 categories based on two criteria: 1) when the 
antimicrobial agent is the sole therapy, or one of limited alternatives to treat serious human 
disease, and 2) when the antimicrobial agent is used to treat diseases caused by organisms that 
may be transmitted to humans from nonhuman sources or diseases caused by organisms that may 
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acquire resistance genes from nonhuman sources.  Critically important antimicrobials are those 
that meet both criteria (Table 2.2).  Further to this, the top 4 critically important antimicrobial 
classes prioritized by the WHO are 3rd and 4th generation cephalosporins, fluoroquinolones, 
glycopeptides and macrolides.  Highly important antimicrobials are those antimicrobials that 
meet either of the two criteria (Table 2.3).  Important antimicrobials are those antimicrobials 
which do not meet any of the criteria (Table 2.3).  This classification is useful for risk analysis of 
bacterial resistance that can be attributed to the use antimicrobials in food animals (85, 86), to 
prioritize resources for mitigation strategies, to inform regulators and stakeholders for the types 
of antimicrobials to use and for better stewardship of currently available antimicrobials (86).    
Similarly, the World Organization for Animal Health (OIE) has established list of 
important antimicrobials in veterinary medicine based on two criteria (87): 1) when the response 
rate indicating criticality from OIE member countries for antimicrobial agent exceeded 50%, and 
2) when the antimicrobial agent is either the sole therapy for the treatment of serious animal 
disease or if it is one of the available alternative antimicrobials.  Veterinary critically important 
antimicrobials are those that meet both criteria (Table 2.4); veterinary highly important 
antimicrobials are those that meet one of the criteria (Table 2.5); and veterinary important 
antimicrobials are those which meet neither of the criteria (Table 2.5).  
Antimicrobials, especially the antibiotics, exert their antibacterial effect either through 
inhibition of bacterial cell wall synthesis, nucleic acid metabolism (folic acid metabolism, DNA 
gyrase, DNA transcription), or by inhibiting protein synthesis (82, 88).  Antimicrobials that 
inhibit cell wall biosynthesis include the beta lactams (e.g., penicillins, cephalosporins, 
carbapenems and monobactams) and glycopeptides (e.g., vancomycin, avoparcin).  
Antimicrobial classes that inhibit protein synthesis include aminoglycosides, tetracyclines, 
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macrolides, chloramphenicol, clindamycin and oxazolidinones.  Antimicrobial classes that affect 
nucleic acid metabolism include quinolones, rifampicin, sulphonamides and trimethoprim (88).  
With regards to AMR, bacteria display one of three phenotypes: susceptible, intrinsically 
resistant or acquired resistance, with some organizations also utilizing an intermediate 
classification (89).  Intrinsic resistance is a natural phenomenon observed in all members of a 
species whereas acquired resistance occurs only in certain isolates of a given species.  For 
example, Gram negative bacteria are intrinsically resistant to macrolides and glycopeptides since 
due to their larger sizes these molecules cannot easily pass through the outer membrane (89).  
Most clinically important AMR is acquired through genetic exchange mechanisms into a 
completely susceptible population (89).  Resistance to antibiotics can be conferred either on a 
chromosome or else via mobile genetic elements (plasmids, transposons and integrons) (50).  
Antimicrobial resistance can disseminate through clonal expansion of resistant bacteria in which 
a resistant determinant is located on the chromosome and passed vertically into the offspring.  
The most common means, however, is through horizontal transfer (through transformation, 
transduction or conjugation) of the resistance determinants between bacteria.  Bacteria generally 
develop resistance through one or more of four mechanisms: 1) decreased antibiotic 
accumulation as a result of decreased uptake or increased efflux; 2) target modification through 
mutation; 3) enzymatic inactivation or modification; and 4) bypassing metabolic pathways (50, 
82, 88, 89).  Antibiotic sequestration has been also suggested as another potential resistance 
strategy (50). 
 Aminoglycosides 
Aminoglycosides are a major category of drugs used in human and veterinary medicine 
and they were originally isolated from antibiotic producing bacteria: Streptomyces or 
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Micromonospora and thus named with the suffix -mycin or -micin respectively (16).  
Aminoglycosides are bactericidal antibiotics mainly used to treat serious infections caused by 
aerobic Gram negative and Gram positive bacteria (90).  This class includes streptomycin, 
dihydrostreptomycin, kanamycin, gentamicin, tobramycin, amikacin and neomycin, all of which 
are used both in human and veterinary medicine.  Apramycin and fortimicin are only used in 
veterinary medicine (16).  For example, apramycin has been used for the treatment of enteritis 
caused by Gram negative bacteria in farm animals.  
Aminoglycosides are large molecules containing numerous amino acid groups which  
makes them basic poly-cations that are highly ionized at physiological pH (90).  Chemically, 
they are composed of a hexose nucleus (6-carbon aminocyclitol ring) linked by glycosidic bonds 
to one or more amino sugars (16, 90).  The action of aminoglycosides is bactericidal in a dose 
(concentration) dependent killing and their uptake by bacterial cells is possible only in the 
presence of oxygen.  They inhibit bacterial protein synthesis by affecting the various steps in the 
translation process (initiation, elongation and termination) (16, 90).  They bind to the 16S rRNA 
within the 30S ribosomal subunits; specifically, to the aminoacyl site (A-site) for the 4, 6-
substituted 2-deoxystreptamine (2-DOS) (16).  
The major resistance mechanism to aminoglycosides is enzymatic inactivation by 
plasmid specified enzymes broadly classified as phosphotransferases, acetyltransferases and 
adenyltransferases (16, 90, 91).  The aminoglycoside acetyltransferases are usually named as aac 
followed by a numeral in the parenthesis to indicate their enzymatic target on the aminoglycoside 
molecule (eg aacC(3’)).  The aac genes confer resistance to gentamicin, tobramycin, and 
kanamycin.  Aminoglycoside phosphotransferases (named as aph) confer resistance to 
kanamycin and neomycin.  Some aph genes are also designated as strA and strB which encode 
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resistance to streptomycin.  Aminoglycoside nucleotidyltransferases include aad and ant groups 
of genes and confer resistance to gentamicin, tobramycin or streptomycin (92).  Plasmid 
mediated resistance to aminoglycosides is transferable and a single plasmid can facilitate cross-
resistance to multiple aminoglycosides and co-resistance to other structurally unrelated 
antimicrobials, thus easily contributing to the problem of multidrug resistance (90).   
Because of its unique structure, apramycin overcomes plasmid mediated degrading 
enzymes.  Resistance to apramycin is thus far encoded through a single enzyme: aminoglycoside 
3-N-acetyltransferase IV.  This unique feature has been used as a marker to investigate the rate 
of transfer of resistance genes from the use of apramycin in animals to human bacterial isolates 
(90).  Other resistance mechanisms can also occur through chromosomally mediated target 
alteration due to mutations in the 16S RNA.  This is mainly important for streptomycin and 
dihydrostreptomycin resistance, which occurs as a result of a single step mutation conferring 
high level resistance (90).  The third mechanism of resistance to aminoglycosides is reduced up 
take or export (16, 90).  The aminoglycoside resistance genes that have thus far been reported 
among E. coli isolated from food animals in the United States are aac(3’), aac(6’), aadA, aadE, 
strA/B, and aph (92). 
 Beta-lactams 
This class of antimicrobials includes narrow spectrum penicillins and cephalosporins, 
expanded spectrum cephalosporins, and potent broad spectrum carbapenems, monobactams and 
other penams (93).  The first drug in this class to be discovered in 1929 was penicillin G, which 
is the natural product of Penicillium notatum.  This class consists of both narrow spectrum 
antibiotics acting only against Gram positive bacteria and broad spectrum drugs that also act 
against aerobic and anaerobic Gram negative bacteria (93, 94).  Although the originally 
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discovered beta-lactams were natural products, most other beta-lactams are semisynthetic 
products that originate either from 6-aminopenicillanic acid or 7-aminocephalosporanic acid, 
which represent the active moiety essential for their antibacterial activity (93, 94).  Structurally, 
all beta-lactams share a unique four membered beta-lactam ring and rupture of this ring, as a 
result of enzymatic action, results in loss of antibacterial activity of this class (93).  New beta-
lactams have been progressively synthesized through chemical modification of the core beta-
lactam ring.  These drugs include modified penicillins (methicillin and oxacillin), cephalosporins 
(cephalothin, cefoxitin, ceftriaxone and cefipime), and carbapenems (imipenem and meropenem) 
(93, 95, 96).  Since their introduction into clinical practice in 1975, 4 generations (1st, 2nd, 3rd 
and 4th) of cephalosporins have been synthesized through chemical modification of the parent 
drugs (95). 
Beta-lactam antibiotics block cell wall synthesis by interfering with the final stage of 
peptidoglycan synthesis.  This occurs through inhibition of the activity of enzymes collectively 
known as penicillin binding proteins (PBPs), including transpeptidases and carboxypeptidases, 
by specifically binding to terminal D-Ala-D-Ala in the elongating peptidoglycan thereby 
preventing the cross linking of the cell wall (93, 94).  The PBPs catalyze cross linkage of the 
glycopeptide polymers that form the integral part of the bacterial cell wall (93).  Bacterial cell 
wall synthesis is a complex pathway that involves enzymatic linkage of precursors in the 
cytoplasm and transportation onto the outer surface of the cytoplasmic membrane.  The resulting 
N-acetylmuramyl-pentapeptide is incorporated into the growing peptidoglycan structure to form 
a cell wall by specific transglycosylases and transpeptidases for cross linking of the cell wall 
components (94).  Beta lactam antibiotics are bactericidal drugs and their optimal bacterial 
efficacy is time dependent (93).  The difference in susceptibility between Gram positive and 
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Gram negative bacteria to the beta lactams could be attributed to differences in PBP receptor 
sites, amount of peptidoglycan, ability of the drugs to penetrate the outer cell membrane of Gram 
negative bacteria, and molecule resistance to different types of beta-lactamase enzymes produced 
by bacteria (93).  
Three resistance mechanisms have been recognized for beta-lactams: target modification 
(acquisition of new PBPs), reduced permeability and increased efflux, and enzymatic 
inactivation through beta-lactamases (95).  In Gram positive bacteria, the most common 
mechanism of resistance involves the acquisition of new PBPs that have low affinity for common 
beta-lactams.  One notable example is methicillin resistant Staphylococcus aureus that possess 
the PBP2a encoding mecA gene used to produce a low affinity PBP.  Another mechanism of 
resistance in Gram positive bacteria is the production of penicillinase, a specific beta-lactamase 
enzyme against penicillins that degrades the beta-lactam ring.   
Gram negative bacteria are inherently resistant to penicillins due to low permeability of 
their cell wall, lack of PBPs, and production of wide spectrum of beta-lactamase enzymes (93).  
In Gram negative bacteria the major resistance mechanism is the production of β-lactamases.  
Gram negative bacteria inherently express low levels of chromosomally mediated β-lactamases 
that are exported to the periplasmic spaces.  However, the most common β-lactamases that 
confer high level resistance are those borne on plasmids.  More than 1,000 unique β-lactamases 
have been described with varying molecular and functional properties.  At the molecular level, β-
lactamases that utilize serine at their active site are classified as classes A, C and D while those 
that require one or two zinc ions to facilitate hydrolysis of the β-lactam ring are classified as 
class B β-lactamases (i.e., metallo β-lactamases) (94).  The β-lactamases that are of current 
concern are the extended spectrum β-lactamases (ESBLs) which hydrolyze penicillins, early 
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cephalosporins, and expanded spectrum cephalosporins and monobactams (such as aztreonam), 
serine carbapenemases which hydrolyze all β-lactams and the metallo β-lactamases (MBLs) 
which can hydrolyze all β-lactams except monobactams.  These β-lactamases are widespread 
among Gram negative bacteria on mobile genetic elements such as integrons and transposons; 
these, in turn, are commonly carried on transferable plasmids that also convey resistance genes to 
multiple antibiotics (93).   
 Folic acid biosynthesis inhibitors  
In 1932, sulfonamides were the first antimicrobials to be approved for clinical use (14).  
Sulfonamides are broad spectrum bacteriostatic antimicrobials acting against both Gram positive 
and Gram negative bacteria (97, 98).  Sulfonamides interfere with bacterial folic acid 
biosynthetic pathways by competitively blocking the incorporation of para-aminobenzoic acid 
(PABA) into the folic acid molecule.  Sulfonamides specifically compete with PABA for the 
dihydropterate synthetase (DHPS) enzyme (97, 98).  Trimethoprims, however, inhibit 
dihydrofolate reductase (DHFR) enzymes thereby inhibiting the reduction of dihydrofolic acid 
(DHF) to tetrahydrofolic acid (THF); this latter compound is an essential precursor in the 
thymidine pathway leading to inhibition of bacterial DNA synthesis (92).  Resistance to 
sulfonamides can occur as a result of chromosomal mutation which can result in reduced drug 
penetration, production of insensitive DHPS or hyper production of PABA (97).  However, the 
most common resistance is due to the acquisition of plasmid or integron borne resistance genes: 
sul1, sul2, sul3, each of which encodes an insensitive DHPS enzyme (92, 97).  In the U.S., most 
of the reported bacterial resistance to sulfonamides is as a result of sul1 and sul2 (92).  
Resistance to trimethoprim is through the acquisition of the dihydrofolate reductase (DHFR) 
encoding genes, dhfr or dfr (92).  Sulfonamide resistance is widespread among bacteria isolated 
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from animals, which could easily be related to their more than 80 years of use, and also as a 
result of the linkage of the sul genes to other resistance genes such as trimethoprim and 
streptomycin (97).  There is also complete cross-resistance among the different members of the 
sulfonamide class (97).  Sulfonamides are also commonly used as in-feed antimicrobials in pigs 
combined with other antimicrobials such as with chlortetracycline, penicillin G and tylosin (17).  
To potentiate their efficacy, sulfonamides are usually used in combination with trimethoprim, 
and resistance to this combined formulation (trimethoprim/sulfamethoxazole) is relatively rarely 
reported in the U.S. (92).   
 Macrolides 
Macrolides are large molecules characterized by a 12-17 member central lactone ring 
attached to two or more sugar moieties (16, 99).  Natural macrolides are produced by 
Streptomycetes by the action of various polyketide synthase enzymes (16).  Erythromycin was 
the first macrolide to be discovered in 1952 (31).  The 14-membered lactone ring family includes 
clarithromycin, erythromycin and telithromycin, the 15-membered ring family includes 
azithromycin, while the 16-membered ring compounds include spiramycin, tylosin and 
tilmicosin (16, 99).  Macrolides are generally bacteriostatic and their mode of action is through 
inhibition of protein synthesis by reversibly binding to 23S rRNA, adjacent to the peptidyl 
transferase center of the 50S subunit, thus blocking elongation of the peptide chain leading to 
premature dissociation of peptidyl-tRNA (16, 31, 99).  
Three acquired resistance mechanisms to macrolides (and to lincosamides and 
streptogramins-MLS) have been characterized.  The first mechanism is target site modification, 
either through 23S rRNA methylation or mutation in the 23S rRNA or 50S ribosomal subunit 
mediated by rRNA methylases, each of which is encoded by an erythromycin resistant methylase 
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(erm) gene.  Currently, 33 erm genes have been reported, each of which methylates RNA by 
adding one or two methyl groups to a single adenine in 23S rRNA.  The modification of these 
prevents the binding of macrolides, lincosamides and streptogramins (MLS) to the ribosome to 
prevent protein synthesis (31).  The erm gene confers resistance to MLS.  The second 
mechanism of resistance involves two types of efflux pumps (ATP binding (ABC) transporters, 
and major facilitator superfamily (MFS)) that pump the drugs out of the cell.  The most 
commonly found efflux protein coding genes are the mef and msr genes (16, 31, 99).  The third 
resistance mechanism against erythromycin occurs via enzymatic degradation of the lactone ring 
as mediated through esterases and phosphotransferases encoded by ere and mph genes 
respectively (16, 31).  
 Phenicols 
Chloramphenicol, and the related drugs florfenicol and thiamphenicol, inhibit microbial 
protein synthesis by irreversibly binding to the 50S ribosomal subunit (100).  Chloramphenicol 
was the first broad spectrum antibiotic to be discovered (14).  It is a bacteriostatic antibiotic 
active against a wide range of Gram negative and Gram positive bacteria (100).  Though 
chloramphenicol use in humans and animals is nearly completely banned in the developed world 
because of associated rare  toxicity (aplastic anemia), it is still used in developing countries 
(100).  The most frequently encountered chloramphenicol resistance is enzymatic inactivation 
through acetylation by chloramphenicol acetyltransferases (CATs) which inhibit binding of the 
drug to the 50S bacterial ribosomal subunit (100).  The cat genes (cat1) are commonly carried on 
plasmids in Enterobacteriaceae which also usually carry ≥1 other resistance genes (100).  
Resistance to chloramphenicol also occurs through efflux pumps mediated by floR (conferring 
resistance to florfenicol and chloramphenicol) and cmlA which have been detected from the U.S. 
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National Antimicrobial Resistance Monitoring System (NARMS) animal isolates (92).  It has 
been reported that a single dose of florfenicol treatment in feedlot steers can result in a dramatic 
increase in multidrug resistant E. coli (101), likely as a result of selection for plasmids carrying 
the flo gene which is linked with other resistance genes (100).   
 Quinolones  
The fluoroquinolones, also commonly known as quinolones, are synthetic antimicrobial 
agents in which the quinolone nucleus possesses fluorine (102).  Nalidixic acid (a quinolone) 
was the first member of the class to be discovered and approved for clinical use in 1965 (102).  
Norfloxacin was the first fluoroquinolone approved for clinical use, followed by ciprofloxacin.  
The first fluoroquinolone approved for use in animals was enrofloxacin (in 1988) in companion 
animals (102).  The first use of fluoroquinolones in food animals was approved by the FDA in 
1998 (83) in cattle.  Because of the shared mechanism of action, bacteria resistant to 
fluoroquinolones that are used in animals are also resistant to those used in humans through cross 
resistance (92, 102).  Because of their usefulness in humans, these classes require a stringent 
approval procedure with post approval monitoring for the development of resistance (83).  The 
use of enrofloxacin in poultry was banned in the U.S. in 2000 due to increased fluoroquinolone 
resistant Campylobacter species associated with the use of this drug in poultry (103).   
The quinolones and fluoroquinolones inhibit DNA replication and transcription by 
inhibiting the functions of bacterial type II topoisomerases: DNA gyrase and topoisomerase IV 
(92, 98, 102).  Topoisomerase II (also known as DNA gyrase) catalyzes the supercoiling of 
double stranded DNA and consists of two subunits, GyrA and GyrB (102).  The 4-quinolone 
molecule interrupts the DNA breakage-reunion of the DNA supercoiling stage by binding to the 
DNA gyrase-DNA complex (102).  DNA topoisomerase IV (Topo IV), a bacterial type II DNA 
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topoisomerase, is the second target for fluoroquinolones and is a multimeric protein consisting of 
two ParC and two ParE subunits; these, in turn, also exhibit sequence homology to GyrA and 
GyrB respectively (102).  Topo IV mediates the relaxation of duplex DNA and decantation of 
daughter chromosomes after replication (102).  Fluoroquinolone resistance occurs through target 
modification, decreased permeability, efflux pumps and target modification (98, 102).   
The main mechanism of quinolone resistance is associated with chromosomal mutations 
in type II topoisomerase structural genes commonly involving gyrA, parC, or rarely gyrB and 
parE (92, 98, 102).  These mutations usually occur on a chromosomal region called the 
quinolone resistance determining region (QRDR).  In most Gram negative bacteria, quinolone 
resistance develops in a stepwise manner as a result of successive mutations occurring in the 
QRDR (102).  However, in Campylobacter species that lack topoisomerase IV, a single mutation 
in gyrA is often sufficient to confer high levels of resistance (102).  This explains the higher 
prevalence of quinolone resistance in Campylobacter compared to E. coli originating from food 
animals (104). 
 Tetracyclines 
Tetracyclines represent a structurally related class of antibiotics with a broad spectrum of 
activity. Tetracyclines are one of the oldest antibiotics and the second broad spectrum antibiotic 
class (next to chloramphenicol) to be discovered (14).  They are active against both Gram 
positive and Gram negative, aerobic and anaerobic, bacteria both in humans and animals.  They 
are also active against intracellular organisms such as Chlamydia, Mycoplasma, Brucella and 
Rickettsia and several protozoan parasites (28, 105).  Apart from their therapeutic uses in 
animals, tetracyclines are also widely used as feed additives in livestock production as growth 
promoters, and also in plant agriculture and aquaculture (28).  The most commonly used 
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tetracyclines in the veterinary medicine are chlortetracycline and oxytetracycline (16).  These 
natural tetracyclines were isolated from Streptomyces spp. by bacterial type II polyketide 
synthases (16).  Based on the timeline of their discovery, tetracyclines can be grouped into 3 
generations.  The first generation tetracyclines (1948-1963) include chlortetracycline, 
oxytetracycline and tetracycline; the 2nd generation (1965-1972) includes minocycline and 
doxycycline; and the 3rd generation (after 1972) is represented only by tigecycline, a 
glycylcycline antibiotic (15, 28).  
Structurally, tetracyclines are composed of four linearly fused tetracyclic nucleus rings, 
designated as A, B, C and D, to which functional groups are attached (15, 28).  Tetracyclines are 
strong metal chelating agents and contain divalent metal chelation site characteristics of the 
class; these are essential both for their antimicrobial activities and pharmacokinetic properties 
(15, 28, 105).  There is a structure and activity relationship for tetracyclines.  Each of the four 
rings in the linearly fused tetracyclic nucleus must be 6-membered and purely carbocyclic to 
retain full antibacterial activity, with the exception of 6-thiatetracycline, which possesses sulfur 
at position 6 of the C ring (28).  Many drugs have been synthesized through structural 
modification of the parent molecules (28).  The 3rd generation tigecycline, for example, is a 
result of meta-substitution of ring D (15). 
Tetracyclines are bacteriostatic antibiotics that inhibit protein synthesis (15, 16, 28, 105).  
In Gram negative bacteria, tetracyclines traverse the outer membrane through OmpF and OmpC 
porin channels as a positively charged cation (mainly with magnesium) tetracycline complex. 
This is followed by diffusion of uncharged tetracyclines through the inner membrane after being 
liberated in the cytoplasm.  In Gram positive bacteria, tetracyclines diffuse freely as an 
electroneutral molecule through the cytoplasmic membrane (28).  Uptake of tetracyclines across 
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the cytoplasmic membrane is an active process in which a molecule of ATP is spent for every 
proton molecule that is pumped in (28).  In the cell, tetracyclines bind to the 30S ribosomal 
subunit at the tRNA acceptor site (A-site).  This sterically blocks aminoacyl-tRNA binding, 
leading to inhibition of protein synthesis (15).  
 Mechanisms of tetracycline resistance  
Tetracycline resistance is the most common form of antibiotic resistance among bacteria 
(20).  The “resistome” concept refers to the aggregate of all antibiotic resistance mechanisms 
(15).   Resistance to tetracycline can occur through various methods, such as active efflux of 
tetracycline out of the cell, production of ribosomal protection proteins, decreased drug 
permeability, target mutation and enzymatic degradation.  However, the most common 
mechanisms of resistance are efflux, ribosomal protection and enzymatic inactivation, with the 
first two being the two most clinically important resistance mechanisms against tetracyclines (15, 
28-31).  Tetracycline resistance is predominantly due to acquisition of new genes through 
horizontal gene transfer on mobile genetic elements such as plasmids, transposons, and 
conjugative transposons; these, in turn, may also carry resistance determinants to other 
antibiotics and heavy metals (30).  The differences in the host range of the different tetracycline 
resistance determinants can partly be due to the type of element each tet gene is associated with.  
Generally, conjugative transposons have less host specificity than plasmids and thus can be 
transferred to unrelated species and genera.  The tet genes have not been found within integrons 
and gene cassettes ─the mobile elements frequently found in Gram negative bacteria (30, 106, 
107).  Generally, integrons and gene cassettes serve as a gene capture mechanism for multiple 
resistance genes to be linked.  Currently, 43 tetracycline resistance (tet) determinants and 3 
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oxytetracycline resistance (otr) determinants have been characterized
2
 (Table 2.6) that are known 
to confer tetracycline resistance to bacteria.  The protein products of these genes were first 
detected and subsequently given the name tet by Levy and McMurry (108).   
A tetracycline resistance determinant is defined as “a naturally occurring, generally 
contiguous genetic unit which includes all structural and regulatory genes involved in resistance” 
(109).  DNA-DNA hybridization is currently considered a standard method to differentiate 
different tet genes.  Two genes are considered related and thus belong to the same class if they 
show ≥80% amino acid sequence similarity under stringent DNA hybridization conditions.  
Thus, two genes with ≤79% amino acid sequence similarity are considered two different genes 
(28).  The nomenclature for tetracycline resistance determinants was standardized by Levy et al., 
1989 (109); 1999 (110).  Accordingly, each tetracycline resistance class is designated by a 
capital letter or number and placed into the parenthesis with space between Tet and the class 
(example Tet (A).  The first structural gene of a given class is designated as tetA and the 
subsequent structural genes would be designated as tetB as for class P determinant which has 
two structural genes that are designated as tetA(P) and tetB(P).  However, all other classes of 
tetracycline resistance determinants characterized to date have only a single structural gene.  
Accordingly, the structural gene from the Tet (A) determinant can be written as tetA(A), tet(A) 
or tetA (29).  The latter designation was followed throughout the thesis.  Tetracycline resistance 
is inducible with a sub-inhibitory concentration of tetracycline (111).  Furthermore, the presence 
of tetracycline increases horizontal gene transfer of tetracycline resistance genes (16). 
                                                 
2
 http://faculty.washington.edu/marilynr/tetweb1.pdf 
30 
 
 Efflux pumps  
Currently 30 efflux genes have been characterized and comprise 65% of all tet/otr genes.  
They encode membrane associated, energy dependent proteins (approximately 46 kDa) which 
export tetracycline out of the cell; thus, reducing the intracellular concentration of tetracycline.  
A proton is exchanged for a tetracycline magnesium ion that is exported out against a 
concentration gradient.  Though efflux genes are found in both Gram negative and Gram positive 
bacteria, they are the most commonly found tet genes among Gram negative bacteria.  The tetB 
gene is the most common of all efflux genes that has been identified among Gram negative 
bacteria (31).  Most of the efflux proteins confer resistance to naturally occurring tetracyclines 
(tetracycline) but not to the semisynthetic second (minocycline) and third (glycylcyclines) 
generation tetracyclines; that is, except tetB which confers resistance to both tetracycline and 
minocycline (28). 
Although tetracycline efflux proteins share amino acid and protein structure similarity 
with other efflux proteins involved in MDR, quaternary ammonium resistance, chloramphenicol 
and quinolone resistance, they are specific for the export of tetracycline (29, 112).  Nonspecific 
efflux systems, such as those belonging to the resistance nodulation cell division (RND) family, 
also confer tetracycline resistance as a result of  overexpression due to mutation in their 
regulatory sequences (16).  Bacteria have nonspecific innate chromosomally encoded efflux 
proteins which transport molecules in and out of the cell.  These are broadly divided into the 
major facilitator super family (MFS), the resistance nodulation cell division (RND) family, the 
small multidrug resistance (SMR) family and the ATP binding cassette transport (ABC) family. 
Some of these efflux pumps confer lower-level tetracycline resistance.  The RND efflux pumps 
have 12 predicted transmembrane sequences (TMS).  They are mainly found in Gram negative 
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bacteria and are involved in the export of multiple molecules such as antibiotics and toxic metals.  
A chromosomally mediated tetracycline efflux pump has been described in E. coli which is 
encoded by the multiple antibiotic resistance (mar) locus (113). 
Most of the tetracycline efflux pumps are integral membrane proteins and belong to the 
major facilitator super family (MFS) with 12-14 TMS; that is, based on the number of times they 
span the lipid bilayer of the inner cell membrane.  Few efflux genes which code for a predicted 
ABC transporter family have been characterized.  These include, for example, otrC and the 
newly identified tetAB(46) efflux genes (15, 112).  Efflux genes that are exclusively found in 
Gram negative bacteria are tet(A, B, C, D, E, G, H, 30).  In addition to mobile genetic elements, 
the tetB gene can also be found on chromosomes (114, 115).  The tetE gene differs from tetA-D 
genes in that it is associated with large non-conjugative and non-mobile plasmids or else is found 
on the chromosome (28, 114).  Efflux genes that are exclusively found in Gram positive bacteria 
include tetZ, otrB and otrC.  The tetK and tetL genes are predominantly Gram positive efflux 
genes but they are also reported from some Gram negative bacteria (28).  The Gram negative 
efflux genes are widely distributed and mostly associated with large conjugative plasmids (28) of 
various incompatibility groups (116).  The Gram negative tet genes have higher G+C contents 
(>40%) than those of  Gram positive origin, the latter of which have <35% G+C content (28).  
The tetK and tetL genes are generally associated with small transmissible plasmids; however, on 
occasion they can also be found integrated into the chromosomes (28).  In addition to 
tetracycline resistance determinants, most tetracycline resistance gene carrying plasmids also 
carry genes encoding resistance to other antimicrobials, heavy metals and virulence factors.  
Thus, co-selection as a result of selection pressure by any of these factors can have tremendously 
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contributed to the widespread occurrence of tetracycline resistance in association with MDR, 
likely since soon after the beginning of the antibiotic era (28). 
Gram negative efflux determinants consist of two divergently oriented genes: one coding 
for an efflux protein and the other for a repressor protein (15, 20, 28).  It has been shown that in 
the absence of tetracycline constitutive expression of Tn10 (encoding tetB) in E. coli is 
disadvantageous in growth competition with non-expressing cells (20).  Thus, efflux encoding 
determinants are tightly regulated and are inducible.  Both the tet efflux and the tetR genes are 
regulated by tetracycline.  TetR is a tetracycline inducible repressor protein that shuts down the 
transcription of the efflux genes and its own expression in the absence of tetracycline and allows 
the expression of both genes only in the presence of tetracycline (20).  Tetracyclines inhibit 
translation but paradoxically they also induce expression of the efflux proteins.  This is balanced 
by a highly efficient transcriptional regulation system which is only induced in the presence of 
sub-inhibitory concentrations of tetracycline (20).  The two genes share a central regulatory 
region with overlapping promoters and operators.  TetR  is a dimeric DNA binding protein with 
high sequence specificity for the tet operator in the absence of the inducer tetracycline (20).   It 
binds to the upstream operator region of the efflux genes and negatively regulates the expression 
of efflux proteins (15, 111).  In the absence of tetracycline, TetR occurs as a homodimer binding 
to two tandemly oriented tet operators (28).  This blocks the transcription of the structural genes, 
both for the repressor and the efflux protein (28).  The system is induced when a tetracycline- 
Mg
2+
complex binds to the repressor protein and this only requires nanomolar concentrations of 
tetracycline (20, 28).   
The regulation of efflux tet genes is one of the most sensitive and effective effector-
inducible transcriptional regulation systems ever described (20, 28).  The binding of TetR with 
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tetracycline-Mg
2+
complex causes a conformational change weakening its interaction with DNA; 
this then leads to its dissociation from the operator region allowing the expression of the efflux 
proteins (15, 28).  The tet genes are differentially regulated in such a way that TetR expression 
precedes that of the efflux proteins (20).  The repressor protein binds to the DNA only when the 
intracellular tetracycline concentration (< 1 nM concentration) is insufficient (28). 
Repressor proteins have not been found in the Gram positive efflux genes tetK and tetL 
and therefore they are believed to be regulated by translational attenuation (28, 111).  This 
translational attenuation is due to the presence of a leader peptide with stem loop mRNA 
structures with two ribosomal binding sites (RBS: RBS1 and RBS2).  The RBS1 overlaps the 
leader peptide and the RBS2 is downstream of the leader peptide and hides the RBS for the 
structural gene.  In the absence of tetracycline, the ribosome binds to RBS1 and a short leader 
peptide is translated which ends before it reaches RBS2.  However, in the presence of 
tetracycline, a second stem loop structure in the mRNA forms which uncovers the RBS2 site 
allowing translation of the efflux protein (28).  
 Ribosomal protection 
Twelve ribosomal protection genes have been characterized and they code for ribosomal 
protection proteins (RPPs) (Table 2.6).  These proteins are cytoplasmic proteins that protect the 
ribosome from the action of tetracycline and confer resistance to 1st and 2nd generation 
tetracyclines (doxycycline and minocycline) but not to the 3rd generation tetracycline 
(tigecycline).  Generally, RPPs confer a wider spectrum of tetracycline resistance than efflux 
genes, with the exception of tetB.  RPPs are approximately 72.5 kDa in size and share high 
homology with the translation elongation factors EF-Tu and EF-G GTPases (15, 28).  By binding 
to the ribosomes, the RPPs weaken the interaction between tetracycline and the ribosome, 
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resulting in the release of tetracycline so that aa-tRNA can bind to the A-site and protein 
synthesis continues normally (15).  The tetM gene has the widest bacterial host range of all the 
tet genes, presumably because of its association with conjugative transposons (such as Tn916 
and Tn1545) with a very wide host range (30).  Ribosomal protection genes are associated with 
plasmids, transposons and conjugative transposons.  However, they have not been identified in 
integrons which capture and allows multiple resistance genes to be linked (107).   
Generally, the ribosomal protection genes are rarely found in enteric Gram negative 
bacteria (117, 118).  This could be because of the lower level of resistance conferred by 
ribosomal protection versus that is conferred by the efflux pumps (28, 114) which does not offer 
a survival advantage in the presence of tetracycline for the enteric bacteria.  The tetM gene has 
been documented in E. coli obtained from pigs and chicken (117).  However, the ribosomal 
protection genes have been more often detected in non-enteric Gram negative bacteria (28, 30).  
Ribosomal protection is regulated by transcriptional attenuation (16).  
 Enzymatic inactivation 
Only three genes have been characterized that are capable of inactivating tetracyclines 
(Table 2.6).  In 1989, the tetX gene was the first inactivating gene to be identified from Tn4351 
and Tn4400 transposons harbored by the obligate anaerobe Bacteroides fragilis (119).  
Interestingly, its tetracycline resistance activity was discovered when the gene was transferred to 
aerobically growing E. coli that resulted in the destruction of the antibiotic and darkening of the 
growth medium (120, 121).  Tet(X) is a flavin dependent monooxygenase enzyme that 
regioselectively hydroxylates tetracyclines to C-11a hydroxyl-tetracyclines (15, 119-121).  This 
hydroxylation causes an unstable compound that undergoes non-enzymatic degradation (119).  It 
acts on the first and second generation tetracyclines.  Tet(X) requires flavin in the form of flavin 
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adenine dinucleotide (FAD), nicotinamide adenine dinucleotide phosphate (NADPH), Mg
2+
 and 
oxygen for its enzymatic activity (119, 120).  Paradoxically, because of its oxygen requirement 
for its enzymatic activity, TetX expression in the source organism B. fragilis does not confer 
resistance to tetracycline (121).  Though tet(X) has not been isolated from clinically resistant 
bacterial strains, it has been reported to inactivate tigecycline, a 3rd generation tetracycline (15, 
120).  Semisynthetic glycylcyclines that were derived from the modification of tetracyclines at 
position 9 were produced in the 1990s (120).  They are active against tetracycline resistant 
bacteria carrying the tet genes for ribosomal protection and efflux pumps (120).  To date, the 
minocycline derivative tigecycline is the only glycylcycline class of tetracycline that has been 
approved by FDA (in 2005).  
 Copper handling mechanisms in E. coli 
Copper (Cu) is a divalent heavy metal cation that provides important physiological 
functions for living cells, including bacteria (49, 122).  The most important function of Cu is in 
the oxygen-dependent terminal oxidases, such as cytochrome C oxidase, and related enzymes 
which are involved in the respiratory chain of many organisms (49, 122).  At higher 
concentrations, Cu becomes toxic to the cell by forming reactive oxygen species such as 
hydrogen peroxide radicals and through its interaction with cell membranes (49) leading to lipid 
peroxidation, disruption of the cell membrane and protein oxidation and inactivation (79).  Cells 
utilize two different types of uptake systems for heavy metals.  The nonspecific uptake system is 
a constitutively expressed rapid system in which various substrates diffuse across cytoplasmic 
membrane of bacteria across a chemiosmotic gradient.  The second type is a highly substrate 
specific, slower process, using ATP hydrolysis as an energy source and induced only during 
periods of need (49).  Because of the constitutive expression of the nonspecific system, the gate 
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is always open- the first reason that makes heavy metals toxic to cells (49).  As adaptation to 
high concentration of heavy metals, bacteria with heavy metal ion homeostasis and metal 
resistance determinants evolved.   Copper uptake in E. coli is cation specific to ensure adequate 
supply of Cu in the presence of related cations such as zinc or nickel (122).  
High concentrations of Cu in the gastrointestinal tract (GIT), particularly in the stomach 
and duodenum of mammals, coupled with an acidic condition that prevails in this part of the gut 
makes Cu even more toxic to enteric bacteria (46, 52, 122).  Consequently, intestinal bacteria 
have developed elaborate mechanisms for copper homeostasis in adaptation to their specific 
ecological niche of the animal gut (46, 122).  E. coli is a facultative aerobic bacterium that 
resides in the GIT of animals and humans (122).  Bacteria utilize a combination of three possible 
mechanisms for heavy metal resistance (49): 1) active efflux of the heavy metal ion out of the 
cell, 2) segregation of metal ions as complexes, often with sulfur, and, 3) reduction of toxic 
metals to a less toxic oxidation state.  For detoxification by reduction, the redox potential of a 
heavy metal should be within a physiological redox range (-421 mV to +808 mV) of most 
aerobic cells.  The electrochemical potential of Cu (2+)/Cu (+) is -268 mV which renders it to be 
reduced to a less toxic state (Cu (I)).  Since a reduced metal compound should also be diffusible 
out of the cell to prevent re-oxidation, an efflux system should be present if reduction is also 
used as a detoxifying mechanism (49).  
Unlike toxic organic compounds, heavy metals cannot be degraded (49, 50) subsequently 
representing a long term selection pressure.  Concerns surrounding the potential of metal 
contamination in maintaining a pool of AMR genes in the environmental and clinical settings 
(50) are growing.  For bacteria copper is an essential trace element that is required for growth; 
but it also becomes toxic at high concentrations (51, 52).  Thus bacteria with various 
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mechanisms have evolved to for copper handling within bacterial cells.  Copper resistance in E. 
coli can be selected as a result of agricultural use of copper (52).  
 Copper homeostasis systems in E. coli 
Generally, since Cu is toxic at higher concentrations than dosages provided to meet 
normal physiological needs, the intracellular concentration of heavy-metal ions needs to be 
tightly controlled.  In fact, copper resistance is likely just one of many cases reflecting the 
general need of every living cell for heavy metal homeostasis (49).  Heavy metal homeostasis 
versus resistance is a delicate balance between maintaining cells with a supply of essential trace 
elements on one hand, and protection from an excess on the other hand (46).  Since most of the 
early studies were carried out with plasmid encoded systems, there has been a misperception that 
metal resistance and intrinsic metal homeostasis are different; in fact, it is likely that they are two 
sides of the same coin (46). 
Four chromosomally mediated copper homeostasis systems have been described in E. 
coli.  The copper uptake and transport (cut) system is an early attempt to elucidate Cu handling 
in E. coli.  It consists of six structural genes (cutABCDEF) and a regulatory gene (cutR) which 
are involved in the uptake, storage and transport, export and regulation of normal copper 
homeostasis and resistance to excess amounts (49, 122).  Copper uptake involves two copper 
uptake genes: cutA, which also uptakes zinc, and cutB which is specific for copper.  Copper 
storage/transport is achieved through cutE and cutF genes.  Excess Cu is exported by cutC and 
cutD genes.  The expression of the cut genes is regulated through cutR to maintain intracellular 
Cu homeostasis.  In addition to their direct involvement in Cu transport and metabolism, these 
genes also interact with genes involved in copper resistance (79).  Therefore, it has been 
hypothesized that the cut genes are only indirectly involved in Cu homeostasis (122).  
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The second homeostasis system is the cop operon which centers on CopA, a Cu 
translocating P-type ATPase that forms the central component of copper homeostasis in E. coli.  
CopA is required for intrinsic Cu resistance under both aerobic and anaerobic conditions (55, 
122).  The expression of copA and cueO genes is regulated by a copper responsive cueR, which 
is activated by intracellular Cu (I) levels.  The superfamily of P-type ATPases consists of various 
proteins involved in the transport of charged substrates across biological membranes (122).  Well 
studied prokaryotic ATPases include the CopA and CopB of Enterococcus hirae and CopA of 
Helicobacter pylori and E. coli.  In E. coli, CopA is responsible for cytoplasmic copper 
homeostasis that transports excess Cu (I) from the cytoplasm to the periplasm where it is 
oxidized by a multicopper oxidase enzyme, CueO (55).  In Gram positive bacteria (E. hirae), 
copper metabolism is much clearer and involves a cop operon with copA and copB structural 
genes both encoding for P-type ATPase.  CopA is responsible for copper uptake and nutrition 
while CopB is responsible for copper efflux and detoxification (49). 
The cus (copper sensing) system is a proton driven independent copper efflux system on 
the E. coli chromosome that confers resistance to Cu and silver (122, 123).  The cus determinant 
consists of two operons, cusRS and cusCFBA that are transcribed in opposite directions (122, 
123).  The cusRS operon is a two-component signal transduction regulatory system that codes 
for a histidine kinase, CusS sensor protein and a response regulator CusR (122-124).  CusRS 
activates the expression of the cusCFBA operon in response to elevated concentrations of copper 
(123, 124).  The Cus system transports Cu (I) directly from the periplasm (55, 122, 123, 125). 
The cusCFBA operon consists of a tripartite cell wall associated proteins as proton-substrate 
antiporter, CusCBA and a copper (Cu (I)) binding protein, CusF (55).  The Cus system belongs 
to CBA-transport systems, a family of related transport systems, exclusively found in Gram 
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negative bacteria (122).  The CBA transport systems usually transport metals and drugs, and 
consist of three structural proteins encoded by a single operon.  The central pump protein 
belongs to the resistance nodulation division family (RND) (122).  The RND is a protein family 
of membrane bound proton driven transporters (122, 123).  The second component of the CBA 
transporters are the membrane fusion proteins (MFP) which consist of a family of periplasmic 
efflux proteins and periplasmic adaptor proteins (122).  CusA belongs to RND protein 
superfamily (122, 124).  CusC is an outer membrane protein with similar homology to TolC 
stress-responsive protein (124).  CusB belongs to the MFP family which is anchored in the inner 
membrane with a long periplasm spanning domain (124).  The CusCBA transport complex is 
proposed to transport Cu from the cytoplasm to outside of the cell by using proton motive force 
as energy source (124).  The cus system is particularly important under anaerobic conditions 
(46). 
The 4th system is the cue (Cu efflux) system, consisting of a copper responsive 
metalloregulatory protein CueR that upregulates the expression of copA and cueO genes.  CueO 
is a periplasmic multicopper oxidase (124, 126) enzyme which is primarily involved in aerobic 
system for Cu tolerance in E. coli.  The cue confers Cu tolerance under moderate to high copper 
concentrations while the cus augments Cu tolerance under extreme Cu stress conditions (124).  
CueO is not active in the absence of oxygen (46). 
To summarize, there are clearly a number of different systems available to bacteria to 
deal with homeostasis and resistance needs.  While this is evolutionarily and ecologically 
desirable, it can make epidemiological studies difficult to interpret. 
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 Plasmid-borne copper resistance in E. coli 
Though wild type E. coli have several chromosomally encoded copper tolerance loci, as 
mentioned above, strains with plasmid based resistance genes should theoretically be able to 
survive under significantly higher levels of environmental copper and so have been termed as 
copper resistant (46, 53).  These plasmid-borne genes are involved in elaborate periplasmic Cu 
handling and provide additional Cu resistance capacity to those chromosomal systems outlined 
above (46).  On the other hand, plasmid-borne systems remain dependent on the presence of Cu 
homeostasis mechanisms (46).   
Copper resistance in E. coli is believed to be mediated mainly through a plasmid borne 
copper resistance (pco) gene determinant.  The pco gene was first identified in 1983 by Tetaz 
and Richard (54) from E. coli strain isolated from the effluent of copper sulfate supplemented 
pigs in Australia.  The pco gene is approximately 6 kilobase pairs and has been found on a 
conjugative plasmid designated as pRJ1004 (36, 54).  The pco determinant of E. coli plasmid 
pRJ1004 has been cloned and sequenced (52).  The pRJ1004 was found to be incompatible with 
plasmids belonging to two incompatibility groups: IncI1 and IncK groups.  Thus it has been 
hypothesized that it could be a hybrid plasmid formed as a result of illegitimate recombination 
between those two, or that pRJ1004 represents an ancestral type of those two that evolutionarily 
diverged to become compatible to each other (54).  Williams et al., 1993 (36) concluded that 
copper resistance among enteric bacteria (E. coli, Salmonella and Citrobacter freundii isolates) 
isolated from different geographic locations was caused by closely related resistance 
determinants present in non-identical plasmids. 
The pco gene cluster has seven genes designated as pcoABCDRSE (46, 51, 55) which are 
arranged in two operons: pcoABCD and pcoRS, along with a separate pcoE gene.  The 
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pcoABCD and pcoE clusters are structural genes, while the pcoRS cluster consists of regulatory 
genes.  PcoA, PcoC and PcoE are soluble proteins that are expressed into the periplasm; PcoB 
and PcoD are the outer and inner membrane proteins, respectively, that pump copper out of the 
periplasm of the cell.  PcoRS is a two-component system that regulates the expression of 
pcoABCD genes (55).  The pco resistance system is inducible by copper (36, 51).  The sensor 
protein is coded by pcoS that is phosphorylated by an environmental signal (in this case presence 
of copper); this, in turn, phosphorylates and activates the regulator protein encoded by pcoR 
(51).  Since the expression of pco gene has also been found to be regulated in pcoR mutants, the 
presence of regulatory interaction between the plasmid borne pco genes and the presence of other 
chromosomal, or other plasmid, regulatory factors in E. coli has been speculated (49, 51, 79).  
Furthermore, based on the homology observed between cop plasmid genes and chromosomal 
DNA of sensitive strains of pseudomonas species, it has been suggested that the copper 
resistance operon could have evolved from chromosomal genes (36). 
The mechanism of copper resistance in E. coli bearing pRJ1004 is through energy 
dependent active efflux of copper in a modified form which renders copper unavailable to the 
copper uptake system in a bacterial cell wall (36, 51, 79).  This is in contrast to sequestration of 
copper and high accumulation by cop encoded resistance observed in Pseudomonas syringae pv. 
tomato (36).  It was found that expression of all four pco proteins PcoABCD is required for full 
copper resistance and disruption of any of these genes could result in loss of copper resistance, or 
even increased copper susceptibility (55).  On the account of accumulating information, 
Zimmermann et al., 2012 (55) have proposed a model for pco-based copper resistance in E. coli.  
PcoC is a periplasmic copper chaperone with two separate binding sites specific for Cu (I) and 
Cu (II).  PcoA is a multicopper oxidase that oxidizes PcoC-bound Cu (I) to a less toxic form Cu 
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(II).  The pcoE gene is not strictly required for full copper resistance but it reduces the time 
required to recover from copper induced stress.  Like the other genes, it is induced by copper salt 
but unlike pcoABCD structural genes, it is controlled by a separate chromosomal two-
component copper tolerance system cusRS.  It acts as a sponge that sequesters toxic copper ions 
in the periplasmic space (122, 126).  This gives time for the expression of other genes which are 
under the control of the pcoRS regulatory system.  PcoE relays the sequestered Cu (I) to PcoC to 
be imported into the cytosol through the inner membrane (IM) pump PcoD to provide nutrient 
copper for the activation of newly synthesized PcoA, or for the oxidation of Cu (I)
 
to Cu (II)
 
by 
cuprous oxidase PcoA; subsequently, this is then exported out of the cell by the outer membrane 
(OM) PcoB protein.  While Pco proteins are mainly involved in the periplasmic copper efflux in 
E. coli (126), it has also been shown that PcoA can substitute for the chromosomally encoded 
CueO protein (126).  
The pco determinant in E. coli is regulated by a plasmid and a chromosomally encoded 
component regulatory system: pcoRS and cusRS, respectively (126).  On one hand, the copper 
resistance genes must be carefully regulated to ensure their expression is sufficient to protect 
against the toxic effects of increased ambient copper concentrations in the environment, and on 
the other hand must not be so high that the bacterial cell is depleted of copper (79).  Therefore, it 
has been predicted that the induction profile for copper is a linear, or slightly sigmoidal, curve 
against the copper concentration as opposed to that of mercury which is sigmoidal curve (79).  
The pco dependent copper resistance acts in the presence of high external copper (79).  
Therefore, it has been suggested that copper metabolism and resistance genes are coordinately 
regulated (79).  A chromosomal gene which can replace pcoR function encodes a two component 
system and the corresponding sensor component is encoded on the chromosome (79).  Thus, it 
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has been concluded that plasmid borne copper resistance in E. coli is closely linked with 
chromosomal systems for copper management (52).  It has been proposed that copper resistance 
in E. coli requires both plasmid and chromosomal genes to contribute to resistance in an 
integrated fashion so that resistance to high copper concentrations is expressed, while 
homeostasis of intracellular copper concentration is maintained at physiological levels (36).  The 
pco determinant likely can also function in a limited range of bacterial genera which are closely 
related to E. coli, such as Citrobacter, Salmonella and Shigella (36).   
It was reported that many other bacteria are more sensitive to copper than E. coli (127).  
The copper resistance determinants have been found to be homologous in E. coli and 
Pseudomonas species, but they are phenotypically distinct; that is, while resistant E. coli are 
colorless, Pseudomonas appear blue, suggesting that E. coli export excess copper out of the cell 
while Pseudomonas accumulates or sequesters excess copper (49, 51).   
Ecology of antimicrobial resistance: mechanism of dissemination and 
persistence  
Antimicrobial resistance is largely an ecological problem, as opposed to being 
traditionally viewed as an individual human/animal patient problem (128, 129).  The antibiotic 
resistance phenomenon is a function of the selective pressure imposed by the antibiotics, and the 
presence of resistance genes (130, 131).  Agricultural and clinical settings are two environments 
that are important for significant proliferation, maintenance and source of antibiotic resistance 
(50, 128).  Antimicrobial treatment often kills the targeted pathogens, along with most of the 
susceptible commensals in the ecosystem, while paradoxically expanding resistant commensals 
that could harbor resistance genes (128).  The majority of scientific studies of co-selection at the 
population and community level are, however, observational and have relied heavily on culture 
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dependent phenotypic analysis of isolates, making the quantification of co-selection pressures in 
microbial communities difficult (50).  Antimicrobial resistance determinants can be maintained 
in larger elements, such as integrons within transposons and within plasmids; thus, the transfer of 
the larger element also leads to the transfer of the smaller integral elements (50).  
Antibiotic resistance in targeted pathogens was observed very soon after the introduction 
of most of the antibiotics into clinical use (132).  Antibiotic resistance can be as a result of 
spontaneous mutation, which can be transferred vertically, or else be acquired from other 
bacteria and transmitted horizontally (12, 128, 132).  Mutation can simply be an initial step in the 
development of high levels of resistance observed; however, it is also an important mechanism 
for some antibiotics such as streptomycin resistant Mycobacterium tuberculosis, and for the 
widespread development of fluoroquinolone resistance in both Gram positive and Gram negative 
bacteria (132).  But the majority of antibiotic resistance is through acquisition of resistance genes 
from exogenous sources (132).  Thus, horizontal gene transfer plays a primary role in the 
dissemination of antibiotic resistance genes (132).  Multidrug resistance, in particular, results 
from acquisition of tandem arrays of genetically linked resistance genes which often are borne by 
integrons or other transposons that can reside in the chromosome, or else on conjugative or 
mobilizable plasmids (128).  
The use of a specific antibiotic not only affects the targeted organism but also all other 
members of the resident microflora, both cultivable and non-cultivable, as a collateral effect 
(128, 132).  Evidence from the analysis of pre-antibiotic era bacterial populations, in which 
antibiotic resistance strains were largely absent, and analysis of the development of antibiotic 
resistance to antibiotics (such as tetracycline) following their introduction, have suggested a 
direct association between antibiotic use and an increase in the proportion of antibiotic resistant 
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bacteria (132).  Conversely, prevalence of AMR is often reduced, depending on the duration of 
the antibiotic has been marketed, when the use of antibiotics is restricted; however, it never 
disappears (132).  Besides selecting for resistant bacteria, antimicrobial therapy can affect a 
given microbial ecology by changing the types of organisms that comprise it, leading to the 
occurrence of new opportunistic bacteria intrinsically resistant to the antibiotic in use.  For 
instance the use of 2nd and 3rd generation cephalosporins has selected for enterococci which are 
intrinsically resistant to these agents, perhaps with the concomitant emergence of vancomycin 
resistant enterococci (VRE) (129).    
The most significant aspect in the development of antibiotic resistance is tandem 
assembly of resistance genes within a single, mobile genetic element to generate multidrug 
resistance (MDR) clusters (12, 128, 130, 132).  Multidrug resistance can develop as a result of 
one of the following mechanisms (128, 132): 1) a single plasmid or transposon encodes 
resistance to different antibiotics in a cluster, 2) a single gene encodes for similar mechanisms 
that renders resistance to a class of related antibiotics (cross resistance); for example, erm for 
macrolides, bla for β-lactams, 3) a single resistance gene encodes for a group of structurally 
unrelated antibiotics; for example, aad confers resistance to streptomycin (aminoglycoside) and 
spectinomycin (aminocyclitol antibiotic), 4) the use of non-antibiotics such as heavy metals 
(mercury, copper and zinc) selects for the establishment of genetically linked antibiotic 
resistance, and 5) mutations occur stepwise in multiple independent target genes.  The most 
common mechanism by which Enterobacteriaceae assembles tandem arrays of antimicrobial 
resistance genes is through gene capture by integrons (12, 132).   
Horizontal gene transfer (HGT) in bacteria occurs through one of three mechanisms (12, 
130, 133).  Transformation involves the uptake of naked bacterial DNA from the environment, 
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followed by homologous recombination and incorporation into the chromosome of the recipient 
bacteria if the donor and the recipient strains are related (12).  However, unlike transformation, 
transduction and conjugation involve specialized entities, bacteriophages and plasmids, 
respectively, for their transfer (12).  Transformation and bacteriophage mediated transduction 
usually transfer alleles of homologous genes among closely related bacteria (12).  However, 
DNA transferred by conjugation can recombine with the recipient chromosome if it is 
homologous or remains associated with self-replicating plasmid (12).  In conjugative 
transposons, the transfer of a resistant element can be induced by antimicrobial exposure (128).  
An experimental study conducted in pigs has shown that the use of sub-inhibitory or sub-
therapeutic concentrations of antimicrobials increases in vivo transfer of AMR or virulence genes 
from commensal E. coli to pathogenic bacteria such as Salmonella, Yersinia, Proteus and 
Shigella (134).  It was observed that sub-inhibitory concentrations of β-lactams enhanced the 
transfer of tetracycline resistance plasmids in S. aureus by up to 1000 fold (133).  Stress, 
particularly the SOS response (a global response to DNA damage), which is induced by DNA 
damaging agents such as mitomycin C and antibiotics (fluoroquinolones and dihydrofolate 
reductase inhibitors), also has been shown to increase horizontal transfer of antibiotic resistance 
genes by more than 300 fold by inducing the mobility of transposons and insertion sequences 
(133).  Thus, the use of SOS response inducing antibiotics such as fluoroquinolones may co-
select for other antibiotic resistance genes that are physically linked on a mobile genetic element 
(MGE) (133).   
Plasmids can carry antimicrobial resistance determinants; most notably, in the form of 
transposons and integrons (12).  Transposons and integrons are segments of DNA that encode 
genes that promote two different types of specialized recombination (12).  Unlike phages and 
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plasmids, they are not self-replicating and do not carry genes encoding for intercellular transfer 
(12).  They move from one cell to another through phages, or more commonly through plasmids 
(12).  Unlike transposons which can move from one place to another in the same cell, integrons 
cannot move themselves; however, they can move relatively small pieces of DNA called gene 
cassettes into their insertion site (attl).  Integrons provide a genetic platform for capturing and 
allowing the expression of random segments of DNA (gene cassette) which often carry 
antimicrobial resistance genes (12).  Each gene cassette can provide resistance to a chemically 
distinct class of antimicrobial agent (128).  Multiple resistance transfer elements (plasmids, 
transposons and integrons) can collect and recombine resistance gene cassettes in any order 
(128).  Thus, treatment with any antimicrobial agent can select for bacteria resistant not only to 
the specific agent but also to other unrelated antimicrobial agents through genetic linkage (128).  
Selection by treatment with one antimicrobial agent will enrich a population of strains resistant 
to all antimicrobial agents whose resistance genes are genetically linked to that of the 
antimicrobial agent used (128).  In an experimental study conducted in chickens in the mid-
1970s, 70% of E. coli isolates from a tetracycline supplemented group eventually became 
resistant to more than two antibiotics, including ampicillin, sulphonamides and streptomycin 
(135).  Non antimicrobial environmental toxicants such as heavy metals can also select for 
multidrug resistant plasmids (128).  Thus, any use of antimicrobial or other selective agents 
potentially could select for all resistance genes in the genetic arrays as well as for the plasmids 
residing in the bacteria (128).   
Independent of the HGT of the resistance genes, antibiotic resistant bacteria are also 
widely distributed in different macro ecological niches such as human and veterinary health care 
institutions, animal production and global transfer through trade and movement (128, 132).  
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Interactions between human, animal, plant and the environmental bacterial populations lead to 
increase in the incidence of antibiotic resistant pathogens in various populations and reach 
humans through the food chain (132).  One of the first consequences of the use of antibiotics in 
animals was the transfer of resistance genes from bacteria of animal origin to human pathogens 
such as Salmonella and E. coli 0157:H7 (132).  
Any potential for the reversibility of AMR, once developed, is determined by two factors: 
dilution and the fitness cost depending on whether the system is closed or open (6).  In open 
systems, such as hospital settings and farm environments, with a continuous influx and efflux of 
humans and animals, the incoming bacterial population has lower frequency of AMR than the 
resident population (i.e. more selective pressure from antibiotic use).  If antibiotic use is reduced 
at hospital/farm environment, the driving force for reversibility is the dilution effect of resistant 
population by incoming susceptible population.  However, in a closed community, where 
movement in and out is minimal, the driving force for reversibility is the biological fitness cost 
associated with resistance that is any effect the resistant mechanism has on reducing the ability 
of the pathogen to reproduce and spread in the population (6).  Antimicrobial resistance can 
persist through 1) direct selection for resistance marker in the presence of antibiotic selection 
pressure (both at antibiotic concentrations above the MIC and sub-MIC), 2) co-selection between 
resistance markers (within genetic elements and within clones), 3) cost free resistance, 4) when 
fitness increases resistance, 5) compensatory evolution that reduces costs and allows 
maintenance of resistant strains even in the absence of selective pressure and plasmid persistence 
(6, 133).  Under antibiotic selective pressure, the rate of appearance of antibiotic resistant 
bacteria in the susceptible population is a function of the combined rates of de novo mutation and 
HGT of the resistance determinants (6).  The most important measure is the rate at which the 
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existing resistant strains increase in frequency as a function of the level of drug exposure in 
bacterial population (6).   
The release and distribution of large volumes of antibiotics into a larger physical 
environment such as the gut selects for resistance and resistance transfer by HGT (6, 130, 133).  
Large reservoirs of resistance genes in the human and animal microbial community can serve as 
donors for transfer of resistance to other resident bacteria, including pathogens (128, 136).  
Commensal bacteria serve as both the reservoirs of antibiotic resistance genes (128, 133) and as 
a dynamic breeding ground for evolutionary selection.  This occurs  subsequent to the generation 
of novel and diverse resistance genes, such as the mosaic resistance determinant tetO/32/M 
(133), which is believed to have arisen as a result of recombination of two different tet genes.   
Co-selection is a very common feature of resistance that is acquired by HGT through 
mobile genetic elements (MGEs) such as plasmids, transposons and integrons; also through 
multidrug resistant clones (136).  Because of genetic linkages, resistance to one antibiotic can 
remain stable, or even increase, in the absence of that specific antibiotic use (6, 128, 133).  This 
is because many antibiotic resistance genes reside on large self-transmissible genetic elements 
such as conjugative plasmids and transposons, each of which can carry multiple genes encoding 
resistance to antibiotics, heavy metals and biocides (133).  Acquisition of antibiotic resistance 
genotype can actually increase bacterial fitness, even in the absence of antibiotic selective 
pressure, allowing for the rapid emergence and dissemination (6, 133) of resistant strains in a 
given bacterial population.  Thus, amelioration of the fitness cost of antibiotic resistance carriage 
is one reason for the persistence of antibiotic resistance genes in the apparent absence of 
selection pressure from antibiotic use (133). 
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Although a decline in the prevalence of bacteria resistant to specific antimicrobial agents 
can sometimes be seen following restricted or discontinued use of an antimicrobial agent, a 
return to pre-introduction levels does not usually occur (128), or else the decline occurs at a 
slower rate (compared to rate of increase), if at all (129).  The observation that there may appear 
to be little or no correlation between changes in the levels of consumption of any particular 
antibiotic, and the changes detected in the frequency of resistance, has mainly been attributed to 
co-selection (6) or persistence of resistant strains in the commensal microbiota (128).  In one 
two-year prospective intervention study in Sweden, effected through voluntary withdrawal of 
trimethoprim use in a community setting, it was observed that despite an 85% reduction in the 
use of trimethoprim, resistance rates in E. coli and other bacteria were not meaningfully affected 
(137).  Similarly, in Great Britain a 97% reduction in sulphonamide use in humans from 1991-
1999 did not result in a significant reduction in sulfamethoxazole resistance (138).   
 Microbiological approaches for antimicrobial and copper susceptibility 
testing 
 Antibiotic susceptibility testing 
Culture-based antimicrobial susceptibility testing (AST) methods involve the isolation 
and then characterization of bacteria that are tested for phenotypic sensitivity or else the presence 
of resistance genes by molecular methods.  In vitro AST results are reported either qualitatively 
or quantitatively (139).  Qualitative results are reported as susceptible, intermediate, or resistant 
based on either clinical or epidemiological breakpoints.  Quantitative results are reported as 
minimal inhibitory concentrations (MIC), expressed as µg/ml or mg/L (139), for broth dilution 
methods, or zones of inhibition (mm) for disk diffusion assays.  For accuracy and comparison of 
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results, ASTs are usually performed in adherence to one of several possible standardized 
methods (4, 139).  The Clinical and Laboratory Standards Institute (CLSI) and the European 
Union Committee on Antimicrobial Susceptibility Testing (EUCAST) are the two major 
international standard setting organizations for AST (140, 141).  Most ASTs are performed on 
aerobic and facultative anaerobic bacteria with inhibition of bacterial growth, rather than 
bacterial killing, as a measured end point (139).  Phenotypic susceptibility testing methods are 
performed by two methods: diffusion (disk diffusion or concentration gradient) or dilution (agar 
or broth: microdilution or macrodilution) methods.   
The disk diffusion and the broth microdilution methods are the most commonly used 
AST systems in veterinary medicine (139, 140, 142).  The agar disk diffusion method (143) is 
the most widely used method in veterinary medicine because of its flexibility in the type and 
number of antimicrobial agents that can be tested, ease of use, and low cost (139, 142, 144).  The 
disk diffusion test is based on the diffusion of the antimicrobial agent, by form of concentration 
gradient, from an antimicrobial impregnated disk placed on the surface of agar media (CLSI 
recommended medium is Mueller-Hinton agar) that has previously been inoculated with an 
approximate inoculum size of 1 to 2 x 10
8
 colony forming units (CFU)/ml of a pure culture of the 
test bacterium (139, 144, 145).  When the concentration of the antimicrobial agent becomes too 
diluted to inhibit bacterial growth, a zone of inhibition (usually expressed in millimeters from the 
disk) is formed.  This zone of inhibition is inversely proportional to the MIC of the test 
organism: the larger the zone of inhibition, the smaller the concentration of the drug required to 
inhibit the organism (139, 144).  The major drawback of the disk diffusion test is that it gives 
only qualitative results: susceptible, intermediate or resistant (SIR) (139, 142, 144, 145) and it 
can be difficult to make accurate inter-laboratory comparisons.  However, besides the qualitative 
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determination of AST, periodic examination of the distribution of the zones of inhibition for any 
given bacterial population, or the MICs in the case of broth dilution, can suggest early trends in 
emergence of resistance, or reduced susceptibility (4).  
The Epsilometer test (E-test®, AB BIODISK, Solna, Sweden) with a concentration 
gradient strip, is a modification of the disk diffusion test that generates quantitative end points 
(139).  It depends on the diffusion of a continuous concentration gradient of antimicrobial agent 
laterally from a plastic strip into an agar medium inoculated with a pure culture of the test 
bacterium (139).  The plastic strip consists of a defined concentration of the drug on one side, in 
a continuous gradient from top to bottom, and a continuous MIC interpretative scale on the other 
side (139, 145).  The MIC is determined by reading the concentration on the strip where the zone 
of inhibition intersects the strip (139, 145).  Since the E-test uses a concentration gradient, MIC 
values between the standard two-fold dilutions can be obtained (139).  Unlike the disk diffusion 
test this test is relatively expensive (139).  It is best suited for the determination of MIC of only 
one or two drugs, or when a fastidious organism such as Campylobacter is tested (145).  Neither 
of these agar diffusion methods is suitable for high thorough put such as for large-scale 
surveillance programs (139).  
Quantitative susceptibility testing with the dilution methods (agar, broth macrodilution, 
or broth microdilution) are based on serial two-fold dilutions indexed to the log base 2 (139).  
The agar dilution method is considered as a “gold standard”; however, both agar dilution and 
broth macrodilution are cumbersome, especially when large numbers of samples have to be 
processed (139).  The broth macrodilution (tube dilution) method involves the preparation of 
two-fold serial dilutions of each antimicrobial agent in a liquid growth medium, which is then 
dispensed into test tubes (145).  These tubes are then inoculated with a standardized 
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concentration of bacterial suspension (often, of 1 to 5 x 10
5
 CFU/mL), incubated at 35°C 
overnight; thereafter, the tubes are examined for visible bacterial growth as measured by 
turbidity.  The MIC is determined as the lowest concentration of the antimicrobial that inhibits 
visible bacterial growth (145).   
Broth microdilution is increasingly used in diagnostic laboratories and surveillance 
programs (139, 145).  Unlike the diffusion methods, it allows for high sample throughput and 
quantitative inference; however, it generally is more expensive (144).  Broth microdilution can 
be performed with commercially automated susceptibility testing systems such as the Sensititre® 
system (Trek Diagnostic Systems, Westlake, OH) (142).  It is performed in microtiter plates with 
round or truncated V-bottom wells using antimicrobial agents of known potency following 
progressive two-fold dilutions (139).  Commercially available plates can be purchased in a 
dehydrated form, providing a longer shelf life at room temperature (one to two years) or else as 
frozen trays with a shelf life span of approximately six months when stored at -10°C (139).  
Generally, microdilution tests are more expensive than the disk diffusion test and clearly lack 
flexibility in terms of the type and number of antimicrobial agents to be tested (139); that is, they 
are restricted to the number of available wells (e.g., 96) and thus the number of antimicrobials 
and dilutions tested must be carefully considered.  The automated processes for incubation and 
reading using such devices as the Sensititre ARIS
®
 system (Trek Diagnostic Systems, Westlake, 
OH) mean it can be used for high throughput testing (144, 145), and inter-laboratory 
comparisons are facilitated with surveillance systems through use of common control strains and 
common templates for the microtiter plates.   
In the Sensititre® system, the broth microdilution test is performed by making a bacterial 
suspension from an overnight culture, diluted in demineralized water and turbidity adjusted to a 
54 
 
0.5 McFarland turbidity standards which gives approximately 1 to 2 x 10
8
 CFU/ml of inoculum 
size.  This suspension is further diluted in Mueller-Hinton broth to give a final bacterial 
concentration of 5 x 10
4
 CFU per well.  The suspension is then used to inoculate a Sensititre® 
plate containing serial two-fold dilutions of the antimicrobial agents to be tested.  The trays are 
then incubated in a stack of two-four trays at 35°C for 16-20 h.  The Sensititre® plates can be 
read manually, using SensiTouch® Vizion® and SWIN® (Sensititre for Windows) for computer 
assisted reading or automatically using the Sensititre® Automated Reading and Incubation 
System (ARIS
®
, Trek diagnostic system) (145, 146).  The Sensititre ARIS is an automated 
system that detects fluorescence liberated by bacterial enzymes that cleave the fluorogenic 
substrate in the broth, which then is converted to an MIC estimation via a computer algorithm 
(145, 146).  The MIC is recorded as the lowest concentration of antimicrobial agent that 
completely inhibits visible bacterial growth (139, 147).  However, the true MIC of the drug lies 
somewhere between the last concentration with visible growth inhibition and the first 
concentration with no visible growth (i.e. between two consecutive log2 dilutions; that means the 
reported MIC merely represents a range of MIC values (139, 147).  
Breakpoints (interpretative criteria) are usually used to define susceptibility or resistance 
of bacteria to antimicrobials, either expressed as a concentration (mg/L or µg/mL) or a zone of 
inhibition (diameter in mm) (141).  In the United States, the interpretative criteria are based on 
clinical breakpoints according to CLSI efficacy expectations for human pathogens or else based 
on the CLSI’s subcommittee on Veterinary Antimicrobial Susceptibility Testing (CLSI-VAST) 
which is specific for intended drug/bacterial pathogen combinations in the targeted animal 
species (139, 147).  Three different terminologies are commonly used in the literature, which 
often creates confusion in the interpretation of AST results.  The first is wild-type breakpoint 
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(also called microbiological breakpoints or epidemiological breakpoints), commonly used by 
The European Committee on Antimicrobial Susceptibility Testing (EUCAST).  This refers to the 
MIC of an antimicrobial that distinguishes wild type populations of bacteria from those with 
acquired or selected resistance mechanisms.  A wild type strain is defined as a bacterial strain 
that does not harbor any acquired or selected resistance to the particular antimicrobial being 
tested (141).  It is established based on data generated from moderate to large numbers of in vitro 
MIC tests, deemed sufficient to describe the wild type population (141).  The population that 
departs from the often normally distributed population (wild type) is categorized as non-wild 
type (140).  The second term used is clinical breakpoint which refers to MIC concentrations that 
separate strains with a high likelihood of treatment success from those bacterial strains for which 
treatment is more likely to fail (141).  These breakpoints are derived from prospective clinical 
trials comparing outcomes with the MICs of the infecting pathogen (141), such data are 
combined with expected concentrations at the target site.  The third system is based on PK/PD 
breakpoints, referring to antibacterial concentrations calculated from pharmacokinetic (PK) and 
pharmacodynamics (PD) parameters that predict the efficacy of the antimicrobial in vivo.  PK/PD 
breakpoints are derived from data that are generated in animal models and then extrapolated to 
humans (or animals) using mathematical or statistical methods (141).   
According to CLSI clinical guidelines, either an MIC or zone diameter is used to indicate 
susceptible, intermediate and resistant (SIR) categories (140, 147).  A susceptible categorization 
suggests the infection can be treated with the recommended dosing regimen of the antimicrobial 
agent.  An intermediate category implies that infection can be appropriately treated in body sites 
where the drug is physiologically concentrated, or at a higher dosage; however, it also suggests a 
buffer be employed to prevent small, uncontrolled technical factors that may cause major 
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variations in the interpretation and expected results.  Resistant isolates are not inhibited by the 
usually achievable concentrations of the agent with the normal dosage schedule, or else fall in 
the range where specific microbial resistance mechanisms are likely to impede successful 
outcomes (147).   
Of particular note, when the MIC of a WT population is plotted on a histogram, it 
typically follows a log-normal distribution (i.e., WT MICs are normally distributed on a 
logarithmic scale such as logarithm to base 2).  Strains with the same type of acquired resistance 
also often have a log-normal distribution of MICs.  Therefore, in species where a single 
resistance mechanism to a specific antibacterial predominates, it is common to see a bimodal 
distribution (147).  In many cases the breakpoints established by use of epidemiological cut-off 
values and those from clinical cut-offs will be similar; however, in some cases they differ, 
leading to disagreement as to the appropriate values to be interpreted. 
Genotypic approaches using molecular techniques to detect previously known and new 
resistance genes have been used to supplement traditional AST phenotypic methods (139).  
Determination of genotypic resistance allows for rapid and accurate detection of single and 
multiple resistance genes (and variants) in a single test, which can help reduce the emergence of 
antimicrobial resistance by enabling the most appropriate therapy (139).  Large numbers of 
antimicrobial resistance genes can be studied by probing bacterial species, which  yields a great 
advantage for surveillance and monitoring purposes (139).  PCR methods have been used for the 
detection of various resistance genes from bacterial isolates (92, 139).  One major disadvantage 
of the genotypic methods includes they can only detect resistance capacity, not determine 
susceptibility; other disadvantages include that these tests can be expensive, labor intensive, and 
are often non-standardized. 
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On the other hand, culture based methods of antimicrobial susceptibility testing have 
several limitations: 1) they are time and labor intensive, 2) the use of selective media for 
different bacterial species causes a priori selection bias on the type of bacteria, and 3) at this 
time, most bacteria in the mammalian gut cannot be cultivated in the laboratory (72).  Only 20 - 
40% of bacterial species from the mammalian gut can be cultured and identified with the use of 
the currently available cultivation techniques; thus, overlooking the greater proportion (60-80%) 
of intestinal bacterial species (72).  It seems clear that these non-cultivable bacteria could act as 
important reservoirs of antimicrobial resistance genes (136).  Most often, only infection related 
strains of bacteria, or sometimes commensal indicator bacteria, are identified and studied for 
susceptibility to antibiotics in epidemiological studies (132).  Thus, the overall extent and change 
of antibiotic susceptibility in microbial populations cannot fully be analyzed using culture-based 
methods (132).  Therefore, molecular techniques targeting overall microbial ecology allow for 
the identification of difficult to culture pathogens and their resistance genes, perhaps facilitating 
targeted and narrow spectrum use of antibiotics (4).  Metagenomics represents a culture-
independent genomic analytic approach to a population of microorganisms under their natural 
environment.  A typical metagenomic approach involves isolating DNA from an ecological 
sample, cloning the DNA into a suitable vector, transforming the clones into a host bacterium, 
and screening the resulting transformants for phenotypic features (148).  At this time, this 
approach remains time consuming and expensive for the surveillance and monitoring of 
antibiotic resistance.  In contrast, targeted analysis of total community DNA is a rapid and 
relatively cheaper method for the examination of specific resistance genes extracted from 
complex samples such as feces (149).  This method has been used for the detection of resistance 
genes (150-152) and quantification of antibiotic resistance genes (153-155).  However, with this 
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method it is impossible to ascribe the resistance genes to specific bacteria in the bacterial 
community sample (149) as this would clearly present the phenomenon of ecological fallacy.  
Ecological fallacy occurs when inferences are made at individual level from data collected at a 
group level (such as the total community DNA). 
 Determination of copper resistance  
Bacterial metal susceptibility measurements in the laboratory are expressed in terms of 
inhibition of bacteria growth as a function of mg of copper per L of medium, or else in mM units 
(mM per L); for example, 1 mM of copper equals 63.5 mg of copper per L (46).  Determination 
of bacterial copper susceptibility depends on the species or strain of microorganism, the type of 
growth medium, and pH of the medium (46).  Complex media can readily bind copper and make 
it unavailable to bacteria; on the other hand, minimal media can increase bacterial sensitivity to 
copper (46).  Mueller-Hinton medium (broth, or agar), which is commonly used to determine 
resistance to antibiotics, is reported to be the optimal growth medium in which to determine 
copper resistance (46).  Since cupric oxide (Cu (II)) is a weak acid, it causes a drop in the pH of 
the medium when added.  Therefore, the pH of the medium has to be adjusted to 7.0 for optimal 
growth of bacteria (46, 54).  Low pH (~6.0) increases the fraction of unbound Cu (II) availability 
to bacteria, while pH values above 7 favor the formation of insoluble copper hydroxides, which 
also reduce the amount of copper available to bacteria (46).   
Generally speaking, three different assay methods have been used for copper 
susceptibility testing: 1) gradient agar plates (36), 2) an agar dilution assay based on CLSI 
procedures (156, 157), and 3) a broth dilution assay (158).  Disc diffusion methods with 
impregnated discs are rarely used for copper susceptibility testing (46).  In gradient agar 
diffusion two different solid agar layers, in which the first contains pH-adjusted elevated 
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concentrations of Cu, and the second plate contains no Cu, are used.  Bacterial suspensions at 0.5 
McFarland Standard are then applied across the metal gradient by using a inoculating wire after 
the second layer solidifies (46).  The latter two methods are based on serial copper dilutions 
dissolved in agar or broth media, in which linear serial dilutions of copper are made; thereafter, 
the MIC is determined in a method similar to that which is used for antibiotic susceptibility 
testing.  Unlike for antibiotics, there are no universally acceptable resistance breakpoints for 
metal ion concentrations that can be used to designate microbial resistance (tolerance) versus 
susceptibility.  Therefore, the few studies conducted to determine the MIC of copper (and other 
metals) have been based on the MIC distribution of the tested organisms (and thereafter, the 
epidemiological cutoffs) (156). 
 Statistical analysis of antimicrobial susceptibility data 
Minimum inhibitory concentration data from antimicrobial sensitivity test results are 
most often categorized, using established breakpoints, into binary outcomes such as resistant 
versus susceptible (including the intermediate category) for ease of interpretation and to guide 
clinical therapy.  This binary outcome is then analyzed by simple cross tabulation or through the 
use of regression models.  Logistic regression, without accounting for clustering, generalized 
estimating equations (24, 25)  for two-level data, or multilevel logistic regression, are used to 
account for multivariable effects and clustering (23).  Multi-level models are often used to 
account for an existing hierarchical data structure (clustering of observations) and also to 
simultaneously model covariates measured at multiple hierarchical levels which decomposes 
variability across the hierarchical levels (159-161).  Multivariate analysis of multidrug resistance 
is used to account for pharmacological, biological or genetic dependence among multiple binary 
outcomes, though it has rarely been used (25).  For example, a multivariate probit regression 
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model can be used to assess the impact of a set of risk factors simultaneously on multiple binary 
resistance outcome variables.  To model only two binary outcomes together, a simpler bivariate 
probit regression can be used (162).   
The similarity of different antimicrobial phenotypes among bacterial isolates has been 
examined using cluster analysis (163, 164).  Cluster analysis is a classification method that can 
be used to describe multidimensional antimicrobial resistance in bacteria and to classify the 
bacterial isolates according to their similarities, or dissimilarities, to each other depending on the 
binary resistance profiles (164).  Cluster analysis can later be used for risk factor analysis that 
can then ideally be employed for the prevention and reduction of AMR (164, 165).  The 
occurrence of multiple resistance patterns among bacteria of the same species tested against a 
panel of antimicrobial agents is a multivariate problem (165) thus requiring a multivariate 
analysis.  Understanding this complex multivariate analysis is a challenging task.  A univariate 
analysis, considering just one antimicrobial agent at a time (multiple binary outcomes) risks 
underestimating the true situation by ignoring multiple resistances.  On the other hand, analyzing 
unique resistance profiles separately or as multivariate data with a multinomial distribution, often 
suffers from a lack of power as the number of isolates with each unique profile rapidly becomes 
sparse, even with thousands of isolates under examination (165).  As a result, it is often not 
possible to fully assess the benefit of any particular control effort on AMR, especially 
considering the multiple resistances.   
Cluster analysis to deal with the multivariate nature of AMR is made feasible by 
classifying the resistance profiles into clusters (groups) and modeling them either by univariate 
or multivariate regression with multinomial logistic regression (which accounts for the co-
dependence of the resistance profiles in order to identify risk factors that are responsible for their 
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occurrence) (165).  However, the multinomial logistic regression often suffers from a lack of 
power and model instability due to sparse cells.  The classical multivariate analysis approaches 
such as factor analysis suffer from dimensional reduction which makes the interpretation very 
challenging (165).  Bayesian network analysis has been recently applied for the analysis of AMR 
in veterinary medicine (165).  Bayesian networks are graphical statistical frameworks used to 
infer a probabilistic model that best describes the joint probability structure (co-dependence) 
within observed data (165).  Additive Bayesian network (ABN) modeling is comprised of a 
collection of conditionally independent multivariable generalized linear models which can be 
displayed as a directed acyclic graph.  Thus, ABN modeling is analogous to a multivariate GLM 
with multiple dependent variables.   
Multidrug resistance counts (i.e., the number of antimicrobial agents to which a bacterial 
isolate is resistant) are often analyzed as categorical variables, and very often categories must be 
combined due to sparse cells.  In such cases, logistic regression can be used to analyze the 
different established dichotomies comparing each of the categories to a selected baseline 
category (166, 167).  This method results in loss of information as a result of collapsing some 
categories of the response variable with a considerable loss of statistical power (166).  Another 
option is to use multinomial logistic regression and to build a series of logistic regression 
equations together; however, the assumptions required of such a model are often unmet.  Varga 
et al., 2009 (167) used Poisson regression for the analysis of multiple antimicrobial resistances.  
They defined the dependent variable as the number of antimicrobials to which an individual 
isolate was resistant, potentially ranging from zero to the maximum number of antimicrobials 
tested.  However, their methods did not consider the generally ordinal nature of the MDR counts.  
Ordered logistic regression analysis takes this natural ordering into account to examine the effect 
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of different risk factors on MDR count.  When the proportional odds assumptions (i.e., the 
equality of the log-odds across the different cut points (categories) of the outcome variable) are 
met, a cumulative logit model (proportional odds model) can be used for the analysis of such 
ordered data (168).   
In a proportional ordered logistic regression, the log-odds, and thus the odds ratio, are 
assumed to be constant across the order categories of the outcome and assumed only to differ by 
the levels of explanatory variable.  However, the intercepts are allowed to vary across the 
categories of the outcome variable thus giving a series of parallel lines with constant slope but 
with different intercepts.  It is exceedingly rare that these parallel line assumptions are met and 
so a more generalized ordered logit (gologit) model instead is used to relax the proportionality 
assumptions (169).  In this model, both the intercepts and the slope (β’s) are allowed to vary 
across the categories of the outcome variable.  When the ordinal dependent outcome variable has 
more than 2 categories, the gologit model is equivalent to a series of binary logistic regressions 
where the categories of the dependent variable are dichotomized at each cut off.   
In partial proportional odds model, a special case of gologit model, some of the 
explanatory variable coefficients will constant for all values of the categories of the outcome, 
while others will be allowed to vary.  The Brant test provides both a global test of whether any 
variable violates the parallel lines assumptions, as well as tests the assumption for each 
explanatory variable separately (169).  The gologit model compares all the categories greater 
than the current category to those less than or equal to the current category (> vs. ≤ categories).  
Hence, positive coefficients indicate that higher values of the explanatory variable are associated 
with higher category levels of the outcome variable (in this case MDR count) than the level of 
category under consideration; on the other hand, the negative coefficients indicate that higher 
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values of the explanatory variable increase the likelihood of being in the current or else a lower 
category (169).   When interpreting results for each panel, an expressed category of the outcome 
variable and all the lower coded categories serve as a reference group.   
Analysis of MIC outcomes from susceptibility testing may proceed with outcomes treated 
as binary data (after categorizing based on a breakpoint into either susceptible or resistant); this 
is commonly done, though as explained above has certain limitations.  First, there is loss of 
information associated with the binary categorization.  Second, regression models do not 
converge when some of the resistance or susceptible cells defined by the treatment factors are 
sparse (i.e., there are few observations in each cell) or where empty cells exist (when all isolates 
are either susceptible or resistant).  Third, over time there may be a shift in the MIC distribution 
within either or both of the resistant or susceptible populations that would not be evident or 
measured in the change in the proportion of susceptible or resistant bacteria.  To this end, very 
few studies have employed different statistical approaches than the traditional binary 
classification based analysis.   
As one example, Wagner et al., 2008 (22) considered MIC values as ordinal variables and 
modeled susceptibility data using a proportional odds model which evaluates the relative odds of 
increasing or decreasing one MIC level, as opposed to the logistic model which models the 
relative odds of resistance (versus susceptibility).  However, as stated above under the analysis of 
MDR count data, the proportionality assumption for the MIC categories for each risk factor 
should be tested; notably, the authors did not report this test of assumption.  Furthermore, there is 
a problem with handling left or right censored observations with MIC data arising from limited 
dilution plates.  The authors above assigned the next lower or higher values for the MICs (that 
were less than or greater than testable limits) to overcome the problem of left and right 
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censoring.  In another study (63), the MIC values were log2 transformed and modeled with a 
linear regression.  Like the previous study, the MIC was arbitrarily assigned the next higher two 
fold dilution if bacteria grew at the highest concentration of the antimicrobial tested, in order to 
overcome the problem of right censoring.  The MIC values take only limited values of doubling 
dilutions on a log2 scale; therefore, they truly are not continuous data suited to linear regression 
modeling. 
Therefore, to overcome the issues of censoring which are typical of the MIC data in order  
to utilize the full information available from susceptibility testing, survival analysis has recently 
been adapted and introduced for the analysis of antimicrobial resistance data (170) and 
subsequently further refined and used by others (144).  Survival analysis is a collection of 
statistical methods for the analysis of data where the outcome variable is expressed as time until 
an event occurs (171, 172).  In the context of MIC data, the outcome of interest (time to event) is 
replaced by concentration until bacterial growth inhibition occurs (i.e., the MIC determination) 
(170).  If bacterial growth is observed at a particular concentration, it is recorded as surviving at 
that concentration and if it fails to grow it is recorded as failure (an event of interest for the 
survival analysis).  MIC data are left censored when bacteria failed to grow at the lowest 
measured concentration of antimicrobial agent tested and the MIC is reported as ≤ to the lowest 
concentration of the antimicrobial tested.  Right censoring occurs when bacteria grow at the 
highest concentration of antimicrobial agent used and thus are reported as > the highest 
concentration of the antimicrobial tested. 
The MIC data can be graphically expressed, using Kaplan-Meier curves, as failure, 
hazard, or survivor function.  The survival function S(t) represents the probability that a bacterial 
strain survives at least as high as a specified drug concentration, given that it grew at the 
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previous concentration.  The hazard function h(t) is a rate that gives the instantaneous bacterial 
growth inhibition per unit concentration change, as that change approaches zero, conditional on 
the bacterial strain survived up to the current antimicrobial concentration considered.  While the 
hazard function relates to growth inhibition, survivor function relates to surviving the 
antimicrobial concentration being considered given survival up to a certain MIC concentration.  
In survival analysis the effect measure used to evaluate impact of treatments (or other factors) on 
the MIC of bacterial isolates is the hazard ratio (HR) (171).  An HR > 1 can be expressed as 
decreased survival, decreased resistance, increased susceptibility or increased failure (inhibited 
to grow).   
The log-rank test is a nonparametric test that follows a chi-squared distribution and can 
be also used to compare the overall survival experiences of bacterial isolates obtained from 
treatment or control groups (171).  A semi-parametric (with no assumed distribution of the 
outcome), Cox proportional hazards (PH) model (171), similar to typical survival analysis can be 
used to model the effect of treatment on the survival of bacterial isolates at increasing 
concentrations of antimicrobial agent (144, 170).  Shared frailty can be used in the PH models to 
account for repeated measures within groups (such as pens or farms) and within samples (such as 
testing multiple bacterial isolates per sample).  Cox PH model is robust even though the baseline 
hazard is not specified, giving close results to parametric models.  Estimation of the Cox PH 
model uses a partial likelihood function rather than a complete likelihood function such as results 
for parametric-based estimation.  This is because the likelihood formula considers probabilities 
only for those isolates which fail to grow (i.e., with the event of interest) and does not consider 
probabilities for those isolates which are censored (171); however, the survival concentration just 
prior to censorship is in fact used.  Like the proportional odds model for ordinal MDR data 
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described above, Cox PH model assumes that the HR is constant over the MIC concentration 
ranges used, and that the concentration can have any value over the range of MIC values which 
effectively means it assumes that the MIC data are continuously coded.   
Parametric regression models (with specified distributions based on the outcome) such as 
exponential, Weibull, lognormal, logistic and Gamma have also been used in addition to Cox PH 
model for the comparison of both agar disk diffusion and the micro-broth dilution results (144).  
The MIC results typically take only discrete concentrations with many isolates recorded with the 
same MIC values.  The obvious problem of ties can be overcome by using an exact method as 
used by (144) or other methods such as Breslow, Efron and other exact marginal and partial 
likelihoods.  Because of the inherently discrete nature of the data and the presence of many ties 
in the MIC data, discrete time (i.e. discrete concentration) survival (159) analysis is more 
appropriate for the analysis of MIC data.  Discrete concentration survival analysis using a 
logistic regression model was employed for the study of antimicrobial resistance of Enterococcus 
faecium from Dutch broilers (170).  The logistic model for hazards estimates log odds ratios as 
opposed to the HR of the Cox PH model; however, they are interpreted as a ratio of hazards 
(170).  Discrete time survival analysis is generally employed on events that are recorded in 
discrete time and occurring at a relatively few time points; notably, this is exactly typical of MIC 
data.  Discrete time survival models are specified in terms of discrete time hazard i.e. the 
conditional probability of the event occurring at a time point given that it has not already 
occurred. In order to make the concentration steps equidistant (i.e., like time in days) it is often 
necessary to log transform the concentrations to a base of 2, and to shift the values so that zero 
represents the value just below the lowest recorded concentration.  Discrete time survival models 
become models for dichotomous responses after expanding the data to subject-time data (159). 
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 Epidemiology of tetracycline, ceftiofur and copper resistance in E. coli from 
pigs  
The widespread use of tetracyclines in humans, animals and agriculture has led to the 
widespread occurrence of tetracycline resistance, both in the commensal and pathogenic bacteria 
(16).  The carriage of multiple tet genes of different classes is commonly found in Gram positive 
bacteria but is relatively uncommon in facultative Gram negative enteric bacteria (28). 
The first tetracycline resistance was reported in 1953 (a few years after its first clinical 
use) in Shigella dysenteriae in Japan.  The first multidrug resistant Shigella resistant to 
tetracycline, streptomycin and chloramphenicol was subsequently isolated in 1955 from Japan 
and reported at a prevalence of 0.02%.  In 1960, MDR Shigella prevalence increased to 10%.  In 
S. flexneri strains isolated between 1988 and 1993, 60% of the isolates were MDR (28).  The 
magnitude of MDR, both in frequency and phenotype, has been continuously increasing both 
among Gram positive and Gram negative bacteria (28).  Tetracycline resistance, commonly seen 
as part of a MDR phenotype, has become a global problem both in humans and animals.  
In a prospective experimental study conducted in 1974, using 150 tetracycline 
supplemented (200 ppm) chickens and 150 control chicken, Levy et al., 1976 (135) observed that 
eventually all E. coli isolates became tetracycline resistant.  In addition to tetracycline, over 70% 
of E. coli isolates were also resistant to more than two antibiotics, including ampicillin, 
sulfonamides and streptomycin.  Similarly, they observed the eventual transmission of 
tetracycline resistant bacteria from chickens to farm personnel.  The authors experimentally 
established the link between the use of in-feed antimicrobials and the occurrence of antimicrobial 
resistant bacteria in humans.  In another report (173), the same authors also confirmed the spread 
of tetracycline resistance among E. coli through transferable plasmids.  
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The prevalence of tetracycline resistant generic E. coli isolated from pork chops at retail 
markets in the U.S., and tested by the FDA arm of NARMS (19), have indicated a fairly constant 
and established level from 2002-2010 with a mean prevalence of 50% and ranging from 44% in 
2010 to 56% in 2004.  The level of multidrug resistance, defined as resistance to ≥ 3 
antimicrobial classes, has also been relatively constant with mean prevalence of 17% and ranging 
from 15% in 2009 to 21% in 2004 (Fig. 2.1).  
In a retrospective study performed on a historical collection of E. coli isolated from 1950-
2002 from animal and human sources, a significant upward trend in tetracycline resistance was 
observed (21).  Tetracycline resistance was observed in 72% of pig isolates (n = 285) obtained 
during this time period.  About 54% of these E. coli isolates were also resistant to ≥3 different 
antimicrobial classes.  The authors also reported that tetracycline resistance commonly occurred 
as part of an MDR phenotype concurrently with other antimicrobials such as streptomycin, 
sulfonamides, ampicillin and chloramphenicol.   
In the study conducted in finishing pigs to evaluate the effects of chlortetracycline dosage 
regimens on tetracycline resistance in E. coli, tetracycline resistance was 98% both when CTC 
was given continuously and as pulsed, when compared to 95% in the no antimicrobial group 
(22).  This study indicated very high background tetracycline prevalence in the control pigs; 
therefore, the dosage regimens (continuous or pulsed supplementations of CTC) did not result in 
any significant measurable effects on the prevalence of tetracycline resistant E. coli.  However, 
an on farm field trial conducted by Funk et al., 2006 (23) to investigate the effect of sub-
therapeutic use of chlortetracycline on antimicrobial resistance in the fecal flora of swine, 
showed that aerobic Gram negative fecal isolates from the group which received sub-therapeutic 
CTC exhibited higher odds of being resistant to ampicillin (OR = 1.35), ceftriaxone (OR = 2.4) 
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and tetracycline (OR = 7.2) compared to isolates from the control group.  This occurred, despite 
the observation that tetracycline resistance was very common among isolates from both the 
treatment and control groups.  This study illustrates that the use of sub-therapeutic CTC can 
result in the co-selection of third generation cephalosporin resistance (ceftriaxone) among the 
enteric bacteria of pigs measured on phenotypic outcomes.  However, since the study did not 
determine the actual resistance genes involved, nor their genomic locations, the genetic 
mechanism of co-selection was not established.  Another major limitation of this study was that 
it was a cross sectional study where pigs were sampled only once at the end of their finishing 
cycle; thus, it was not possible to discern temporal relations.  Another issue was that although a 
matched case-control study design was used, it was not accounted properly for in the analysis; 
indeed, this also might have affected the observed associations.  
In a cross sectional study conducted among integrated multisite group cohorts of humans 
and animals (24) to investigate various risk factors associated with phenotypic antimicrobial 
resistance of E. coli isolates, the prevalence of tetracycline resistance was significantly (P < 
0.05) higher in the swine fecal E. coli population than in those from the associated human 
cohorts.  Swine isolates were also more multidrug resistant than the human isolates.  In a 
subsequent 3-year longitudinal study (25) at the same facility, following the baseline report, also 
indicated that swine E. coli isolates were more likely to be resistant to tetracycline (OR = 18.8; P 
< 0.001) and ceftiofur (OR = 5.6; P < 0.001) when compared to isolates from humans.  
In another study, 47 purposively sampled farrow-to-finish swine farms in Canada were 
used to assess the association between on farm antimicrobial use, other management factors (26), 
and E. coli resistance to antimicrobials. In this study, 81% of the E. coli population was resistant 
to tetracycline.  Tetracycline resistance was significantly associated with the age of the pigs 
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(higher in the younger weanling pigs as compared to finisher pigs: OR = 3.5; P < 0.0001) and 
with ceftiofur use on the farm (OR = 6.1; P = 0.0), indicating potential co-selection.  In another 
report (27) these same authors found that antimicrobial resistance to a specific antimicrobial 
agent was more frequent on farms that used in-feed medication as compared to those did not, and 
a higher level of resistance prevalence was observed in the weaned pigs than in the finisher pigs.  
This study might have suffered from selection and information biases since the design included 
purposive selection of farms and a questionnaire was used to assess antimicrobial use and other 
management factors.  Such biases could have resulted in overestimated or underestimated 
impacts of the risk factors on the level of antimicrobial resistance.  
In a cross sectional risk factor study conducted to investigate the association between 
antimicrobial use and AMR in E. coli, Varga et al., 2009 (167) found that in-feed use of 
chlortetracycline in pig farms was significantly associated with increased risk of resistance to 
ampicillin and tetracycline.  Importantly, they also found that the intercept in their tetracycline 
model was a positive number, suggesting that tetracycline resistance was not solely explained by 
concurrent tetracycline or other antimicrobial use in the farms.  This positive intercept in the 
absence of the risk factors investigated also could be attributed to the high prevalence of 
tetracycline resistance in farms which did not use in-feed tetracycline; that is, the background 
levels of resistance that can be attributed to historical and cumulative use of antibiotics over the 
past 60 or so years.  These authors also found that whereas in-feed use of any antimicrobial was 
associated with an increased risk of generic E. coli being resistant to multiple antimicrobials, the 
use of injectable trimethoprim-sulfamethoxazole and oxytetracycline were actually negatively 
associated with  multidrug resistance.  Clearly, the study has certain limitations.  First, pig farms 
included in this study were not randomly selected.  Since the study was a cross sectional design, 
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it is impossible to ascertain that the antimicrobial use caused the observed association with 
AMR.  Information on the antimicrobial use practices was collected by questionnaire such that 
the study might have suffered from information (recall) bias.  
In another study, Vieira et al., 2009 (174) investigated the association between on-farm 
tetracycline use patterns and the probability of detecting tetracycline resistant E. coli from 
healthy slaughter pigs in Denmark.  They reported 34% prevalence of tetracycline resistant E. 
coli isolated from healthy pigs at slaughter.  They found that the probability of detecting 
tetracycline resistant E. coli decreased as the interval between treatments increased, while it 
tended to increase with any increase in the treatment incidence rate.  Interestingly, smaller herd 
size was associated with an increased probability of detecting tetracycline resistant E. coli, while 
larger herd size was associated with decreased probability of detecting resistance.   
Ceftiofur, along with cefotaxime, and ceftriaxone (among others) is a 3rd generation 
cephalosporin.  A crystalline free acid (CFA) formulation of ceftiofur is administered to swine 
intramuscularly at postauricular site at a dose of 5 mg/kg for the treatment of respiratory 
infections.  Transferable resistance to 3rd generation cephalosporins is generally due to AmpC 
type beta lactamase hyper production, extended spectrum beta lactamases (ESBLs), and to a 
lesser extent due to metallo beta lactamases (MBLs).  The cephamycinase encoding gene blaCMY-
2 was formed as a result of AmpC beta lactamase hyper-production that became encoded by high 
copy number plasmids suitable for horizontal gene transfer.  On certain plasmid types, the 
blaCMY-2 gene has been reported concomitantly with resistance to ampicillin, chloramphenicol, 
streptomycin, sulfamethoxazole and tetracycline (65).  The blaCMY-2, blaPSE-1, blaTEM-1 genes 
have been reported from Salmonella enterica isolated from U.S. food animals (92).  Lutz et al., 
2011 (58) reported 63% (1193/1899) ceftriaxone resistant E. coli prevalence from swine fecal 
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samples.   Using PCR, 86.8% (n = 159) of the ceftriaxone resistant isolates harbored blaCMY-2 
gene.  Similarly, 9.1% of Salmonella isolates (n = 714) obtained from same swine fecal samples 
were found to be resistant to ceftriaxone and were shown to contain blaCMY-2.  
For copper susceptibility, population-based studies involving wild type strains of E. coli 
or other Gram negative enteric bacteria are scarce, and they have usually been based on banked 
isolates from diagnostic laboratories.  For example, Williams et al., 1993 (36) characterized 33 
historical collections of enteric isolates for copper resistance (E. coli, Salmonella spp. and 
Citrobacter freundii isolates) obtained from Australian and United Kingdom piggeries and 
observed high mean levels of resistance of up to 18 mM of copper .  Historical collections of 
Gram positive (Enterococcus and Staphylococcus species) and Gram negative enteric bacteria 
(Salmonella and E. coli) originating from broilers, cattle, and pigs in Denmark were tested for 
copper susceptibility (156).  Results indicated that whereas the enterococci formed two distinct 
populations with respect to the copper MIC distribution, the other bacterial species formed a 
unimodal population.  Based on this finding, the authors concluded that meaningful acquired 
copper resistance was found only in enterococci and was therefore absent among the 
staphylococci and enteric Gram negative bacterial species tested.  The MIC of all the Salmonella 
isolates (n = 156) tested ranged from 20-28 mM while E. coli isolates (n = 202) exhibited MIC 
ranges of 16-20 mM.  Interestingly, there was a distinct difference in the median MIC 
distribution of the three groups of bacteria.  The enteric Gram negative bacteria had the highest 
median MIC (24 mM for Salmonella and 20 mM for E. coli), followed by the enterococci (16 
mM), while the staphylococcal species exhibited the lowest median MIC (2 mM for S. aureus 
and 8 mM for S. hyicus) (Fig. 2.2).  This suggests that enteric Gram negative bacteria 
(Salmonella species and E. coli) are intrinsically more tolerant to copper, thus providing them a 
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competitive advantage over other bacterial species in the intestinal tract and other environments 
where copper concentrations may be elevated.   
 Mitigating antimicrobial resistance 
Despite an apparently and arguably low risk associated with the use of antibiotics in 
animal production, it is critically important to apply all potential measures that can mitigate 
against and help contain the selection, propagation, and dissemination of AMR (9).  Appropriate 
use of antimicrobial agents, both in humans and animals, combined with the discovery of novel 
antimicrobials, are likely to be the most effective means of combating the issue of antibiotic 
resistance (132).   
Prudent  use (also referred to as judicious use, or antimicrobial stewardship) of 
antimicrobial agents in veterinary medicine comprises all practical measures and 
recommendations that are intended to benefit both animal and public health while also 
preserving and maintaining therapeutic efficacy of the antimicrobials (5, 175, 176).  These 
measures are intended to prevent or reduce the transfer of resistant bacteria (and resistance 
determinants) within animal populations and to humans (175).  Among the ten key principles 
described by the World Veterinary Association are: that antimicrobial agents should not be used 
to mask poor hygienic practices, there is a need for quality assurance, following label directions 
is important, keeping records on the use of specific antimicrobial agent is essential and feeds 
directly into the monitoring and surveillance of antimicrobial resistance (9).  Refinement, 
reduction and replacement of therapeutic prescriptions were all recommended for judicious uses 
of antibiotics for animal welfare (9).  The use of antibiotics can be reduced if they are used only 
where their use is justified by evidence: such as limiting their use for prevention and control in  
nursery pigs, since research has shown that antimicrobials are most effective at this phase of 
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production.  The use of antibiotics can further be refined by following a microbial safety relevant 
withdrawal period, which could minimize resistance dissemination (9).  Replacement of 
antibiotics as growth promoters (AGPs) with possible non-antibiotic alternatives is an area of 
active research and development (9). 
In the United States, the Interagency Task Force on Antimicrobial Resistance, composed 
of multiple agencies and co-chaired by Centers for Disease Control and Prevention (CDC), the 
U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH), was 
formed in 1999 to collaboratively combat AMR by focusing on surveillance, prevention and 
control, research, and drug development (177).  The CDC (2) has recommended four core 
actions that should be taken to fight AMR.  The first action involves infection prevention and 
control of the spread of resistant bacteria in the hospital, community, agriculture and 
environment.  This reduces the amount of antibiotics needed to be used, thus slowing down the 
emergence and spread of AMR.  Measures that could be taken include vaccination and 
improving the environmental hygiene under which animals are produced and thus helping to 
maintain and improve food safety.  The second action is tracking resistant bacteria.  The National 
Antimicrobial Resistance Monitoring System for enteric bacteria (NARMS) was established in 
1996 as a collaboration among the CDC, FDA and the U.S. Department of Agriculture (USDA) 
with the objective of tracking changes in the levels of antimicrobial resistance of enteric bacteria 
(Salmonella, Campylobacter, Shigella, E. coli and Enterococci) from humans (CDC), retail 
meats (FDA – added in 2002) and food animals (USDA).  The external subcommittee of the 
FDA’s Science Advisory Board (178) evaluated the first 10 years of NARMS data and analyses, 
noted the likelihood of sampling bias and recommended the adoption of random selection of 
samples and specific farm data collection that would better enable the investigation of any link 
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between farm use of antibiotics and the development and spread of AMR in human pathogens.  
Sampling of human clinical isolates, along with animal diagnostic laboratory isolates, both suffer 
from prior treatment bias.  These biases limit the external validity of the results at the national 
level (85).  Since 2006, the animal arm of NARMS discontinued the use of isolates from 
veterinary diagnostic laboratories, but continued that of obtaining animal isolates at slaughter 
(85).  Retail samples and isolates that feed into NARMS are derived from the Foodborne 
Diseases Active Surveillance Network (FoodNet), operating under the emerging infectious 
disease program of the CDC.  FoodNet was established in 1995 as a collaborative program 
among CDC, 10 state health departments, the U.S. Department of Agriculture’s Food Safety and 
Inspection Service (USDA-FSIS) and the FDA.  It tracks trends for infections commonly 
transmitted through food and also provides clinical and epidemiologic data on some of the 
NARMS human isolates.    
The third action involves improving the use of the existing antibiotics.  Arguably greater 
amounts of antibiotics are used in the U.S. for food producing animals than for people (179).  
About 50% of antibiotic prescriptions in humans are estimated to be either unnecessary or else 
are misused (2).  The CDC recommends the judicious use of antibiotics both in humans and 
animals since the use of antibiotics in both settings contributes to the emergence, persistence and 
spread of antibiotic resistant bacteria.  Circumstantial evidence has suggested that the use of 
antibiotics in food producing animals can have public health impacts through four chains of 
events: use of antibiotics on the farm selects for antibiotic resistant bacteria while killing 
susceptible bacteria, these resistant bacteria can be transmitted from food producing animals to 
humans through the food supply, resistant bacteria can then cause infections in humans, and 
these infections can result in adverse health consequences for humans when antibiotic therapy is 
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indicated (2).  Thus, because of the link between antibiotic use in food producing animals and the 
occurrence of antibiotic resistant infections in humans, it has been recommended that antibiotics 
should be used in food producing animals only under direct veterinary oversight (2, 180).   
According to recently released documents, the FDA currently recommends that medically 
important antibiotics (including critically important, highly important and important antibiotics) 
should only be used under veterinary oversight for the treatment of infections and should not be 
used as AGPs (180).  The FDA considers the use of medically important antibiotics for growth 
promotion purposes as injudicious (32).  With the provisions of the two guidance documents for 
industry (#209 and 213) FDA, intends to institute voluntary measures to limit the use of 
medically important antibiotics in food producing animals and invoke stricter veterinary 
oversight in the use of these drugs.  Most of the in-feed antimicrobials in the U.S. also are 
currently approved for over the counter use in food producing animals for the purposes of 
treatment, control, prevention of diseases and for growth promotion uses (32).   
The fourth action recommended by CDC is to promote the development of new 
antibiotics and the development of new diagnostic tests for resistant bacteria (early detection and 
control).  Since AMR is part of a natural evolutionary process, though it can be significantly 
slowed down, it cannot be eliminated (2).  That said, the development of new antimicrobial 
agents has been significantly declining when compared to the rapidity with which AMR is 
occurring (2).  
Establishing a direct relationship between the quantity of antibiotics used and 
development and levels of resistance is difficult due, in part, to a lack of specific antibiotic usage 
data at the farm level (181).  Few ecological studies have found correlations between the amount 
of antimicrobials used and the concurrent frequency of antimicrobial resistance (25, 167, 174, 
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182, 183).  Once emerged, antimicrobial resistance often persists even in the absence of direct 
antimicrobial selection pressure, thus minimizing the impact of antimicrobial removal strategies 
(4, 133, 181).  The effect of removing antibiotic use on antimicrobial resistance depends on the 
duration that a specific antimicrobial has been marketed before such removals take place, as well 
as on the underlying mechanisms of resistance that were selected for.  For relatively new 
antibiotics, removal of the antibiotic use can result in a significant reduction of resistance; on the 
other hand, for relatively older drugs, it often does not result in a significant reduction.  For 
example, voluntary withdrawal of ceftiofur from in ovo use in broiler hatcheries in Canada 
resulted in a transient decline in the prevalence of ceftiofur resistant Salmonella Heidelberg and 
E. coli which then increased upon reintroduction of ceftiofur use (184).  The ban on AGP uses of 
glycopeptides and macrolides from pigs in Denmark resulted in a significant reduction of 
resistant E. faecium to these classes of antibiotics (45).  On the other hand, tetracycline resistance 
has remained relatively high despite cessation of the use of chlortetracycline as an AGP in swine 
feed for 13 years (185).  Despite the ban on chloramphenicol use in US livestock production 
since 1980, chloramphenicol resistance has persisted, likely through co-selection with 
tetracycline, sulfonamides and other antimicrobials, though florfenicol is now available on the 
market (21).  
 Summary 
Antimicrobials have been widely used in animal production to treat infectious diseases at 
therapeutic doses, for prevention and control of infections at therapeutic doses, and at 
subtherapeutic doses to enhance growth.  Since many of the antimicrobials used in animals are 
also used in human medicine, there has been great concern that the use of antimicrobials in 
animals (particularly as antibiotic growth promoters (AGPs)) is responsible for much of the 
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antimicrobial resistance problem observed in human pathogens today.   Various studies and 
reports have indicated a qualitative linkage between the use of antimicrobials in animals and the 
occurrence of antimicrobial resistant bacteria in humans.  Since the 1969 Swann report (186) in 
the United Kingdom (U.K.), that ultimately resulted in the U.K. ban of penicillin and tetracycline 
use as AGPs, similar measures have been undertaken in other European countries; these 
eventually resulted in the complete ban of the use of AGPs in animals in EU countries in 2006.  
In the United States, the use of in-feed antibiotics in animal production has been scrutinized and 
the Food and Drug Administration is taking important steps in limiting and regulating the use of 
medically important antibiotics.  
Limiting or completely banning non-therapeutic use of antibiotics in animal production 
could paradoxically lead to reduced productivity, increased costs of production and increased 
foodborne diseases.  Besides biosecurity measures, in order to maintain productivity and cost of 
animal production at optimum conditions under an AGP-free production system, the search for 
alternatives to antibiotics is currently an active research priority.  The use of heavy metals is one 
of many such alternatives.  The use of heavy metals in agriculture predated the discovery of 
antibiotics.  However, there are concerns that heavy metals such as copper and zinc co-select for 
antibiotic resistance.  Studies have shown that copper supplementation is associated with 
macrolide and glycopeptide resistance among enterococci in swine production.  Furthermore, the 
use of zinc in swine production has been found to be associated with increased presence of 
methicillin resistant Staphylococcus aureus (MRSA).  However, experimental studies evaluating 
the impact of elevated copper supplementation in pigs on antimicrobial resistance in Gram 
negative bacteria are lacking.  
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Experimental studies conducted in beef cattle have indicated an association between 
chlortetracycline use and the development of ceftiofur resistance in E. coli.  Conversely, the use 
of ceftiofur in beef cattle has been associated with increased tetracycline resistance in E. coli.  In 
pigs, several observational studies have demonstrated that the use of CTC at farms is associated 
with increased resistance to tetracycline and cephalosporins.  However, experimental studies 
investigating the effects of in-feed CTC on ceftiofur resistance and other antibiotics commonly 
used in swine production are scarce.  Most AMR studies have utilized traditional methods of 
bacterial culture followed by sensitivity testing, and to some extent detection of the resistance 
genes.  Very few studies have used broader micro-ecological approaches for the study of AMR 
by examining the fecal metagenome.   
The three studies described in the following pages are aimed at evaluating the impact of 
in-feed CTC and elevated levels of copper supplementation in weaned pigs on AMR in the gut 
microflora.  The first study was designed to evaluate CTC and copper supplementation, either 
alone or in combination, on phenotypic AMR of Gram negative enteric bacteria using E. coli as 
an indicator organism.  The second study was conducted to investigate the impacts of CTC and 
copper supplementation on the distribution and prevalence of tetracycline (tetA, tetB, tetC and 
tetE), ceftiofur (blaCMY-2) and copper (pcoD) resistance genes in E. coli isolates by using PCR.  
The last study is a micro-ecological study that was aimed at evaluating the impacts of CTC and 
copper supplementation on AMR in the gut microbiome of pigs by detecting the prevalence of 
14 tet genes and quantifying gene copies of tetA, tetB, blaCMY-2 and pcoD genes directly from 
total fecal community DNA.  The dissertation closes with summaries and conclusions of these 
three efforts. 
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Figure 2.1.  Line graph showing the reported prevalence of resistance to ceftiofur and tetracycline, and multidrug resistance of 
E. coli isolated from pork chops at retail market from 2002-2010 in the U.S..  
 
Adapted from the FDA 2010 NARMS report (19)
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Figure 2.2.  Mean minimum inhibitory concentrations (MIC) of copper for a variety of Gram positive and Gram negative 
isolates banked at a European diagnostic laboratory.   
 
Adapted from Aarestrup et al., 2004 (156).
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Table 2.1.  Antibacterial feed additives approved for swine growth promotion in the United States 
Antibiotics Antibiotic class Synthetic antimicrobials Antimicrobial class 
Apramycin Aminoglycoside Arsanilic acid Arsenical 
Bacitracin methylene disalicylate Polypeptide Carbadox Quinoxaline 
Bacitracin zinc Polypeptide Roxarsone Arsenical 
Bambermycins Glycolipid Sulfamethazine Sulfonamide 
Chlortetracycline Tetracycline  Sulfathiazole Sulfonamide 
Lincomycin Lincosamide   
Neomycin Aminoglycoside   
Oxytetracycline Tetracycline   
Penicillin Beta-lactam   
Tiamulin Pleuromutilin   
Tylosin Macrolide   
Virginiamycin Streptogramin   
 
Adapted from Shryock and Page, 2006 (9); Cromwell, 2002 (40) 
83 
 
Table 2.2.  List of WHO critically important human antimicrobials 
Antimicrobial class Antimicrobial(s) Veterinary use only 
Aminoglycosides amikacin, gentamicin, kanamycin, neomycin, streptomycin apramycin, framycetin 
Carbapenems and other penems doripenem, ertapenem, faropenem, imipenem, meropenem  
Cephalosporins (3rd and 4th generations) cefepime, cefoperazone,  cefotaxime, ceftriaxone cefovecin, ceftiofur  
Cyclic esters fosfomycin  
Fluoro and other quinolones ciprofloxacin, nalidixic acid, norfloxacin, ofloxacin danofloxacin, difloxacin, 
enrofloxacin, ibafloxacin, 
marbofloxacin, orbifloxacin 
Glycopeptides dalbavancin, oritavancin, teicoplanin, telavancin, vancomycin avoparcin 
Glycylcyclines tigecycline  
Lipopeptides daptomycin  
Macrolides and ketolides azithromycin, clarithromycin, erythromycin, midecamycin, 
roxithromycin, spiramycin, telithromycin 
gamithromycin, kitasamycin, 
tildipirosin, tilmicosin, 
tulathromycin, tylosin,  
Monobactams aztreonam, carumonam  
Oxazolidinones linezolid  
Penicillins (natural aminopenicillins and 
antipseudomonal) 
amoxicillin, ampicillin, in, penicillin G, penicillin V , 
ticarcillin 
penethamate hydroiodide 
Polymyxins colistin, polymyxin B  
Rifamycins rifabutin, rifampicin, rifaximin, rifapentine, rifamycin  
Tuberculosis and other mycobacterial 
drugs 
ethambutol, isoniazid, terizidone, tiocarlide  
Adapted from WHO, 2012 (84) 
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Table 2.3.  WHO listing of highly important and important human antimicrobials 
Antimicrobials class Antimicrobial(s) Veterinary use only 
Highly important antimicrobials 
Amdinopenicillins mecillinam, pivmecillinam  
Amphenicols chloramphenicol, thiamphenicol florfenicol 
Cephalosporins (1st and 2nd 
generation) and cephamycins 
cephalexin, cefalotin, cefoxitin, cefprozil, cefradine, cefroxadine, ceftezole, 
cefuroxime, flomoxef, loracarbef 
cefalonium 
Lincosamides clindamycin, lincomycin pirlimycin 
Penicillins (antistaphylococcal) cloxacilllin, dicloxacillin, flucloxacillin, oxacillin, nafcillin  
Pleuromutilins retapamulin  
Pseudomonic acids mupirocin  
Riminofenazines clofazimine  
Steroid antibacterials fusidic acid  
Streptogramins quinupristin/dalfopristin pristinamycin virginiamycin 
Sulfonamides sulfadiazine, sulfadimethoxine, sulfadimidine, sulfisoxazole, sulfamethizole, 
sulfamethoxazole, sulfapyridine, sulfathiazole, tetroxoprim, trimethoprim 
ormosulfathiazole,  
phthalylsulfathiazole 
Sulfones dapsone, aldesulfone  
Tetracyclines chlortetracycline, clomocycline, demeclocycline, doxycycline, lymecycline, 
metacycline, minocycline, penimepicycline, oxytetracycline, tetracycline 
 
Important antimicrobials 
Aminocyclitols spectinomycin  
Cyclic polypeptides bacitracin  
Nitrofurantoins furazolidone, nitrofurantoin, nifurtoinol, nitrofural furaltadone 
Nitroimidazoles metronidazole, tinidazole, ornidazole  
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Table 2.4.  OIE list of veterinary critically important antimicrobials 
Antimicrobial class Antimicrobial(s) 
Aminocyclitol spectinomycin 
Aminoglycosides streptomycin, kanamycin, neomycin, apramycin, gentamicin, 
tobramycin, amikacin 
Cephalosporins  
1
st
 generation cefacetrile, cefalexin, cefalotin, cefapyrin, cefazolin, cefalonium 
2
nd
 generation cefuroxime 
3
rd
 generation cefoperazone, ceftiofur, ceftriaxone 
4
th
 generation cefquinome 
Macrolides  
        Azalide tulathromycin 
       Macrolides C14 erythromycin 
       Macrolides C16 josamycin, kitasamycin, spiramycin, tilmicosin, tylosin, 
mirosamycin, terdecamycin 
Penicillins  
    Natural Penicillins benzylpenicillin, penethamate hydroxide, penicillin procaine 
   Amdinopenicillins  mecillinam 
   Aminopenicillins amoxicillin, ampicillin, hetacillin 
    Aminopenicillins+betalactamase inhibitor  amoxicillin/clavulanic acid 
   Carboxypenicillins ticarcillin, tobicillin 
   Ureidopenicillin aspoxicillin 
   Phenoxypenicillins phenoxymethylpenicillin, phenethicillin 
   Antistaphylococcal penicillins  cloxacillin, dicloxacillin, nafcillin, oxacillin 
 Phenicols  florphenicol, thiamphenicol 
Quinolones  
  1
st
 generation flumequin, miloxacin, nalidixic acid, oxolinic acid 
  2
nd
 generation (Fluoroquinolones) ciprofloxacin, danofloxacin, difloxacin, enrofloxacin, 
marbofloxacin, norfloxacin, ofloxacin 
Sulfonamides sulfadiazine, sulfadimethoxine, sulfadimidine, sulfafurazole, 
sulfamethazine, sulfadimethoxazole 
     Sulfonamides+Diaminopyrimidines sulfamethoxypyridazine, trimethoprim+sulfonamide 
     Diaminopyrimidines baquiloprim, trimethoprim 
Tetracyclines chlortetracycline, doxycycline, oxytetracycline, tetracycline 
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Table 2.5.  OIE veterinary highly important and important antimicrobials 
Antimicrobial classes Antimicrobial(s) 
Veterinary highly important antimicrobials 
Ansamycin-Rifamycins rifampicin, rifaximin 
Fosfomycin fosfomycin 
Ionophores lasalocid, maduramycin, monensin, narasin, salinomycin, 
semduramicin 
Lincosamides pirlimycin, lincomycin 
Pleuromutilins   tiamulin, valnemulin 
Polypeptides enramycin, gramicidin, bacitracin 
Cyclic polypeptides colistin, polymixin 
Veterinary important antimicrobials 
Bicyclomycin bicozamycin 
Fusidic acid fusidic acid 
Novobiocin novobiocin 
Orthosomycins avilamycin 
Quinolones carbadox 
Streptogramins virginiamycin 
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Table 2.6.  List of tetracycline resistance genes registered in online databases as of 2013 
Genes Gene bank accession # Genes Gene bank accession # 
Efflux pump coding genes (30) 
tetA AF534183, AJ419171, X75761, AF542061, J517790, AY196695, X00006, L27758,  
AJ313332 
tet31 AJ250203 
tetB J01830, AF223162, V00611, AL513383, AJ277653, AF326777, AP000342 tet33 AJ420072 
tetC AB023657, AY043298, AY28550, X01654, AY046276, Y19114, AF055345, K00005, 
NC_003213, NC_003123, NC_003124, NC_002109, AY043299 
tet35 AF353562 
tetD X65876 , L06798, D16172, AF467074, AF467077 tet38 AY825285 
tetE L06940 tet39 AY743590 
tetG AF071555, S52437, AF133140, AF133139, AJ276217 tet40 AM419751 
tetH U00792, AJ245947, Y15510,  Y16103, tet41 AY264780 
tetJ AF038993 tet42 EU523697 
tetK M16217, U38656, S67449, J01764,  U38428 tet43 GQ244501 
tetL M11036, X08034, D00006, X51366, X60828, D12567, U17153, AY081910, M29725,  
M235948 
tet45 JF837330, GU584222, 
GU584217, JF837331 
tetA(P) AB001076, L20800 tetA(46) HQ652506 
tetV AF030344 tetB(46) HQ652506 
tetY AF070999 otrB AF079900 
tetZ AF121000 otrC AY509111 
tet30 AF090987 tcr3 D38215 
Ribosomal protection protein coding genes (12) 
tetM U08812, X75073, M85225, M21136, M85225, X90939, X92947, X04388, U58985, 
X56353 
tetW AJ222769, AY049983, 
AY196919, AJ427422, 
AY196917, AJ427421, 
AY196918 
tetO M18896, Y07780, M20925 tet32 DQ647324, EF626941, 
EF626942, EF626943, EU722333 
tetB(P) L20800 tet36 AJ514254 
tetQ Z21523, U73497, X58717, L33696 tet44 FN594949, NZ_ABDU01000081 
tetS L09756, X92946 otrA X53401 
tetT L42544 tet M74049 
Inactivating enzymes coding genes (3) 
tetX M37699, EU918344, AB097942 tet37 AF540889 
tet34 AB061440   
Unknown gene function (1) 
tetU U01917   
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Chapter 3 - Effects of chlortetracycline and copper supplementation 
on phenotypic antimicrobial resistance of fecal Escherichia coli from 
weaned pigs 
 Abstract  
Chlortetracycline and copper are commonly used as in-feed antimicrobial growth 
promoters in U.S. pig production systems.  The objective of this study was to evaluate the effects 
of CTC and copper supplementation in weaned pigs on phenotypic antimicrobial resistance 
among Escherichia coli isolated from feces.  One hundred and sixty weaned pigs were 
randomized to 32 pens (5 pigs per pen) which were then randomly allocated to control, copper, 
chlortetracycline (CTC), or copper plus CTC treatment groups.  Phenotypic susceptibilities of 
1,152 E. coli isolates (288 per group) to antimicrobials were determined by broth microdilution.  
Data were analyzed using multilevel mixed effects logistic regression, discrete-time survival 
analysis, or generalized ordered logistic regression, as appropriate.  All isolates were susceptible 
to amikacin, nalidixic acid, and ciprofloxacin.  Tetracycline resistance was significantly (P < 
0.001) higher in the CTC-supplemented group (99.0% [95% CI = 98-100%]) compared to the 
control group (95% [95% CI = 94-97%]) with no significant effect of treatment period.  The 
prevalence of resistance to most of the antibiotics decreased over the 6 weekly sampling periods 
in all treatment groups, likely reflecting the impact of age.  About 91% of the E. coli isolates 
were resistant to ≥3 antimicrobial classes.  CTC- supplementation was significantly associated 
with increased susceptibility of E. coli to copper when compared to the control group (HR = 7 
[95% CI = 2.5–19.5]; P < 0.001).  In conclusion, E. coli isolates from the nursery pigs exhibited 
high levels of antibiotic resistance, with diverse and multidrug resistant phenotypic profiles.  A 
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high level of copper supplementation was associated with decreased prevalence of certain high-
level multidrug resistance phenotypes; however, such associations require further investigation 
under varied field conditions. 
 Introduction 
In swine production, antimicrobials are used, usually in feed or water, for prophylactic, 
therapeutic, or growth promotion purposes (187).  Chlortetracycline (CTC) is the most widely 
used antimicrobial growth promoter (AGP), either alone or in combination with other drugs (e.g., 
with sulfamethazine, sulfathiazole, or penicillin G), in U.S. swine production (17, 18).  
Tetracycline resistance is the most widespread and commonly reported phenotype among both 
Gram positive and Gram negative bacteria (20).  Tetracycline resistance occurs primarily due to 
acquisition of tetracycline resistance (tet) or oxytetracycline resistance (otr) genes and is mainly 
mediated either through active efflux of the molecule or through ribosomal protection (31). 
Copper is an essential micro-mineral, commonly included in swine feed at National 
Research Council (NRC) recommended levels of 5-6 ppm (39).  At increased concentrations well 
beyond its basic requirements, it has been shown to promote the growth of pigs (79).  For 
bacteria, copper is an essential nutrient; however, like most micronutrients it is toxic in excess 
concentrations (56).  Bacteria have developed mechanisms to regulate intracellular copper 
concentrations in the face of varying ambient concentrations.  In addition to chromosomally 
mediated copper handling mechanisms, copper resistance in E. coli is mediated through a 
plasmid-borne copper (pco) resistance cluster consisting of seven genes: pcoABCDRSE (56). 
As a result of escalating debate over whether using AGPs in animals results in a public 
health risk, AGPs were banned in the European Union in 2006 on the basis of the “precautionary 
principle” (75).  More recently, the United States Food and Drug Administration (FDA) has 
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deemed AGP use as “imprudent” and issued a guidance document to industry to voluntarily 
remove such label claims from their products (32).  To compensate for any production losses due 
to AGP bans, non-antibiotic alternatives have become a major focus of attention (35).     
Copper is one of the most commonly used heavy metals for growth promotion in swine 
production.  There is a growing concern that heavy metals, such as copper, help to maintain a 
pool of antibiotic resistance through co-selection and cross-resistance (50).  Transferable copper 
resistance (tcrB) in Enterococcus species has previously been found to be associated with 
macrolide resistance (ermB) and tetM genes (42-44, 156).  Although the effects of metals on 
Gram positive enteric bacteria have been extensively studied in several farm animal species (41, 
42, 44), associations between copper supplementation and antimicrobial resistance (and 
tetracycline resistance in particular) in E. coli have not yet been examined under properly 
controlled experimental conditions reflecting field conditions.  Therefore, we conducted an 
experimental study to investigate the effects of copper and CTC supplementation in pigs on 
phenotypic susceptibilities of E. coli to antibiotics and copper.  
  Materials and methods 
 Experimental design and E. coli isolation   
The study included a full factorial 2-way cluster randomized design using 160 weaned 
piglets that were randomized to 32 pens (5 per pen).  The treatment groups consisted of control 
(basal diet with NRC recommended copper concentration at 16.5 mg/kg of feed), copper (fed 
copper sulfate at an elevated concentration of 125 mg/kg of feed), CTC (basal diet plus CTC at 
550 mg/kg of feed), or copper plus CTC (basal diet plus elevated copper and CTC as above).  
The treatment groups were randomly assigned to pens (8 pens/treatment) while blocking by barn 
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(n = 2) and accounting for the geographical distribution of pens within barn to avoid fecal cross-
contamination between pens.  After two weeks of adaptation to the basal diets and local 
environment, piglets were fed experimental diets for 21 days followed by a washout (i.e., no 
CTC or copper) period of two weeks before being sent to grower operations.  The study was 
performed in the segregated early weaning facility at Kansas State University, and animal 
handling and experimental designs were approved by the University Institutional Animal Care 
and use Committee (IACUC# 2773).   
A total of 576 fecal samples (144 samples/treatment group) were collected weekly from 
three randomly selected piglets per pen over a period of 6 weeks.  Fecal samples were collected 
per rectum, placed into individual WhirlPak bags (Nasco, Ft. Atkinson, WI), and transported on 
ice to the laboratory.  For isolation of E. coli, approximately 1 gram of feces was mixed in 9 ml 
of buffered peptone water, and 0.1 ml of the suspension was spread-plated on MacConkey agar 
(Difco™, Becton Dickinson Co., Sparks, MD) and incubated at 370C for 24 h.  Two distinct 
lactose-fermenting colonies per plate, characteristic of E. coli, were individually re-streaked onto 
blood agar plates (Remel Inc., Lenexa, KS) and incubated at 37°C for 24 h.  E. coli isolates were 
presumptively identified by indole test and stored at -70°C in protect beads (Cryocare®, Key 
Scientific Products, Round Rock, TX) for later analysis.  A total of 1,152 isolates (288 per 
group) were tested for their phenotypic antimicrobial susceptibilities. 
 Antimicrobial susceptibility testing   
For each isolate, minimum inhibitory concentration (MIC) for 15 antibiotics and copper 
was determined by a broth microdilution method following the clinical laboratory standards 
institute (CLSI) veterinary antimicrobial susceptibility testing guidelines (147).  Antimicrobial 
susceptibility testing was performed with the National Antimicrobial Resistance Monitoring 
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System (NARMS) custom-made plates developed for Gram negative bacteria (Trek catalog # 
CMV1AGNF and CMV2AGNF) using the Sensititre system (Trek Diagnostic Systems, 
Cleveland, OH).  Because CMV1AGNF was no longer commercially available after we began 
our laboratory analyses, we used CMV2AGNF for the last 350 isolates.  The sole difference 
between the plates was that on the newer CMV2AGNF NARMS plates, amikacin was replaced 
by azithromycin.  Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, E. 
coli strains ATCC 25922 and 35218, and Pseudomonas aeruginosa ATCC 27853 strains from 
American Type Culture Collections (ATCC) (Manassas, VA) were used as quality controls for 
susceptibility testing.  Based on MIC values, the E. coli isolates were categorized into 
susceptible (included intermediates) or resistant according to CLSI MIC interpretative criteria for 
Enterobacteriaceae (147), except for streptomycin, for which NARMS consensus breakpoints 
were used (19).  The antimicrobial concentration ranges and clinical breakpoints are depicted in 
Table 3.1.  
Susceptibility to copper, in the form of copper sulfate (CuSO4), was determined using 
broth microdilution in Mueller-Hinton II broth (Beckton Dickinson and Co.) from bacteria 
grown on Mueller-Hinton II agar (Beckton, Dickinson and Co.) for 24 h at 37°C according to the 
CLSI procedures described above.  CuSO4 concentrations used were 0, 12, 16, 20, 24, 28, and 
32 mM concentrations.  Because the addition of copper sulfate to the medium causes a 
significant drop in pH (54), the medium was adjusted to a pH of 7.0 by adding NaOH prior to 
inoculation.  To ensure legitimate direct comparison of our results with those from other 
published studies relying on an agar dilution method (156), the agar dilution method was 
performed on 10 isolates selected from each MIC dilution to compare with the broth 
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microdilution method we used.  The results from both methods were comparable (all were 
matched to dilution, with the exception of a very few at one dilution on either side).  
 Statistical analysis 
Data were analyzed using STATA version 12.1 (Stata Corp LP, College Station, TX), 
and P < 0.05 was considered significant.  A full-factorial model evaluating treatment (copper 
treatment, CTC treatment and time) and their two- and three-way interaction effects was used 
throughout the analysis.  Sampling days were categorized into treatment periods as: baseline (day 
0), treatment period (days 7, 14, and 21) and post-treatment period (days 28 and 35).  For 
descriptive statistics, binary outcomes were expressed as proportions with exact 95% binomial 
confidence intervals.  A likelihood ratio chi-square test was used to compare the unadjusted 
effects of treatment and treatment period.  
Multivariable multilevel mixed effects logistic regression was used to model the fixed 
effects of treatments and treatment period (and their interactions) with random effects accounting 
for repeats within pen and fecal sample on phenotypic resistance. This approach was also used to 
model the effects of treatment and treatment period on multidrug resistance (MDR: binary 
classified as resistance to ≥3 classes of antimicrobials) (19).  A generalized ordered logistic 
regression model was used to examine the effects of treatments and treatment period on the 
number of antimicrobial agents and classes (Table 3.1) to which a single isolate was resistant, 
accounting for the ordinal nature of the outcomes.  Clustering effects by pen were adjusted by 
requesting a clustered robust standard error.  Copper MIC data were analyzed using discrete time 
survival analysis (159, 170) with fixed effects of treatment and treatment period and random 
effects of fecal sample and pen.  “Time-to-event” of a typical survival analysis was replaced by 
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“concentration-to-event”, with the “event” being growth inhibition.  The log-rank test was used 
to compare the survival experiences among the treatment groups and treatment periods.  
 Results 
 Antimicrobial susceptibilities  
The prevalence of antimicrobial resistance (AMR) and the MIC of 15 antibiotics for E. 
coli tested across all samples are illustrated in Table 3.2.  The MIC values for ampicillin, 
streptomycin, sulfisoxazole, and tetracycline all were right-censored beyond the highest 
concentration tested for greater than 60% of the isolates.  All isolates were susceptible to 
amikacin (note: present only on CMV1AGNF; n = 802 isolates) and the quinolones 
(ciprofloxacin and nalidixic acid); as a result, these three antimicrobials were excluded from 
subsequent multivariable analyses.  The prevalence of azithromycin resistance did not differ by 
copper (P = 0.122) or CTC (P = 0.826) treatment.  Because not all isolates were tested for 
azithromycin (n = 350 isolates), it too was also excluded from multivariable analysis.  
Individual binary resistance outcomes, cross-tabulated by treatment group and treatment 
period, are provided in Table 3.3.  Resistance to beta-lactams decreased significantly (P < 0.05) 
over time in all three of the treated groups, with no change in the control group.  Kanamycin and 
tetracycline resistances during the treatment period were significantly (P < 0.05) higher in the 
CTC-supplemented group compared with controls.  Multivariable multilevel mixed effects 
logistic regression modeling also illustrated that resistance to most of the antimicrobials tested 
decreased over time in all groups, including the CTC and copper-supplemented groups (Figure 
3.1).  
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A total of 101 unique phenotypic profiles was observed.  Only three isolates (0.35%) 
were pan-susceptible to all 15 antibiotics tested on the NARMS panel, while 7 isolates (0.6%) 
were susceptible to an observed maximum of 12 antibiotics.  The predominant phenotype 
(22.5%; n = 1,152) was of multidrug resistance to 10 drugs, followed by a phenotype with 
resistance to 8 different antibiotics (12%; n = 1,152).  In contrast to these highly MDR 
phenotypes, isolates exhibiting resistance solely to tetracycline were limited to just under 6% of 
the total isolates (n = 1,152) (Table 3.4). 
 Multivariate analysis of E. coli resistance to multiple AMR outcomes   
Six antimicrobial resistance binary outcomes including amikacin/azithromycin, 
kanamycin, trimethoprim/sulfamethoxazole, ciprofloxacin, nalidixic acid, and tetracycline were 
excluded from the multivariate analysis because the model failed to converge due to sparsely 
populated categories.  Copper supplementation was significantly associated with lowered 
resistance to ampicillin (P = 0.007), amoxicillin/clavulanic acid (P = 0.001), ceftriaxone (P = 
0.049), and cefoxitin (P < 0.001) among isolates obtained in the post-treatment period when 
compared with the baseline isolates; however, these differences were not seen during the 
treatment period itself, nor among the remaining five antimicrobials.  Copper plus CTC 
supplementation was significantly associated with increased resistance to amoxicillin/clavulanic 
acid (P = 0.001), cefoxitin (P < 0.001), and ceftiofur (P = 0.013) among post-treatment period 
isolates compared with day 0 isolates; once again, these associations were not significantly 
different during the treatment period when compared with either pretreatment or post-treatment 
period (Table 3.3).  Pairwise correlations (associations) among all possible sets involving the 
nine antibiotics that were included in the multivariate analysis are shown in Table 3.5.  As 
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expected, the beta-lactam resistances were highly correlated (90–98%); furthermore, the 
cephalosporin resistances were especially highly correlated with one another (94–98%).   
 Multidrug resistance   
Defining multidrug resistance (MDR) as the number of antibiotics across all isolates, the 
median MDR count was 8 (95% CI = 8-8).  The frequency distribution of MDR is shown in Fig. 
3.2.  The isolates were most commonly resistant to 10 antibiotics, both across all the samples and 
when subdivided by treatment groups (with the exception of the CTC group, in which an MDR 
count of 8 prevailed).  The distribution of the number of antibiotic resistances appeared 
somewhat bimodal, with peaks at 3–4 and again at 8–10.  Across all the sampling days, but 
subdivided by treatment group, the median count of MDR was 7 (95% CI = 7–8), 8 (95% CI = 
8–8), 8 (95% CI = 7–8) and 8 (95% CI = 8–8) in the control, CTC, copper, and copper plus CTC 
groups, respectively.  Across all treatment groups, the median MDR was 10 (95% CI = 9–10), 8 
(95% CI = 8–8) and 8 (95% CI = 7–8) for pretreatment, during treatment, and post-treatment 
isolates, respectively.  No statistically significant (P = 0.2194) treatment effect was observed on 
the median MDR count (Kruskal-Wallis χ2 = 4.2 with 3 degrees of freedom [df]); however, 
median MDR count was significantly (P = 0.0001) higher among pretreatment isolates (Kruskal-
Wallis χ2 = 36.0 with 2 df).  Results of the generalized ordered logit model also showed that the 
MDR count decreased significantly (P < 0.001) across the treatment periods.  Copper 
supplementation tended to be associated with increased MDR when comparing MDR counts of 
>6 to ≤6 (OR= 1.7; 95% CI = 1.02–2.7; P = 0.041), with no observed CTC effect (P > 0.05).  
 Multidrug resistance count examining the number of different antimicrobial classes (0–8 
classes) to which a single E. coli isolate was resistant was also examined.  Across all sampling 
days, the median count of MDR class count was 6 (95% CI = 5–6), 6 (95% CI = 5–6), 5 (95% CI 
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= 5–6) and 6 (95% CI = 6–7) in the control, CTC, copper, and copper plus CTC groups, 
respectively.  Across all treatment groups, the median MDR class count was 7 (95% CI = 6–7), 6 
(95% CI = 5–6) and 6 (95% CI = 5–6) for pretreatment, during treatment, and post treatment 
isolates, respectively.  No statistically (P = 0.1308) significant treatment effect was observed on 
the median MDR class count (Kruskal-Wallis χ2 = 5.3 with 3 df), but the median MDR class 
count was significantly (P = 0.0001) higher in the pretreatment isolates regardless of treatment 
effect (Kruskal-Wallis χ2 = 24.6 with 2 df).  Generalized ordered logistic regression analysis also 
showed that MDR class significantly (P < 0.05) declined over time, with no apparent treatment 
effect (P > 0.05).  
 Defining MDR as an isolate exhibiting resistance to ≥3 classes of antimicrobials 
(thereafter, a binary classification), 91% (95% CI = 89–92%) of all the isolates (n = 1,152) were 
MDR (Fig. 3.3A).  Univariate analysis (LRχ2 = 8.7; 3 df) suggested, and Fig. 3.3B shows, that E. 
coli isolates in the CTC supplemented group were more likely to be MDR (P = 0.033) when 
compared with the control group (94% [95% CI = 91–97%] versus 88% [95% CI = 84–91%]) 
with no significant (P = 0.363) difference among the treatment periods (LRχ2 = 2.0; 2 df).  
Examined using multivariable multilevel mixed effects logistic regression analysis, CTC 
supplementation significantly (P = 0.040) increased MDR probability among the E. coli isolates 
obtained during the treatment period.  
 Determination of copper susceptibility   
Across all isolates, median MIC was 20 mM, ranging from 12–32 mM (essentially, the 
limits of our assay).  Figure 3.4A shows copper MIC frequency distribution by treatment groups.  
The majority of the isolates had an MIC value of 20 mM; this specific MIC value ranged from 
57% in the control group to 71% in the CTC supplemented group.  The MIC50 and MIC90 of 
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the E. coli were 20 mM and 28 mM across all the isolates, respectively.  Using the log rank test, 
E. coli from the control group generally exhibited higher survival function (thus, were more 
resistant) (P = 0.027, 3 df) when compared with the treatment groups.  Isolates obtained during 
the treatment period exhibited higher survival concentrations (i.e., were less susceptible) (P < 
0.0001).  E. coli isolates in the CTC-only supplemented group obtained during treatment period 
had reduced survival or increased failure rates (P = 0.0018) compared with E. coli obtained from 
the no-CTC group.  By discrete time survival analysis, CTC by period interaction showed a 
significant effect on the survival of the E. coli isolates; that is, E. coli isolates from the CTC-
supplemented group obtained during the treatment period (HR = 7 [95% CI = 2.5–19.5]; P < 
0.001) and post-treatment period (HR= 4.1; 95% CI = 1.2–14.2; P = 0.025) exhibited increased 
susceptibility to copper compared with isolates from the control group.  Figure 3.4B shows the 
survival curves for each of the treatment groups plotted against copper concentration.  
Using the log rank test, copper MIC of the E. coli isolates was significantly associated 
with decreased resistance to gentamicin (P = 0.0092), kanamycin (P < 0.0001), sulfisoxazole (P 
< 0.0001) and trimethoprim/sulfamethoxazole (P = 0.0011).  The susceptibility of E. coli isolates 
to increasing concentrations of copper by four binary antibiotic outcomes is given in Fig.3.5.  
Using the Cox proportional hazards regression model, gentamicin resistance (HR = 1.1 [95% HR 
= 0.97-1.2]) was no longer significantly associated with copper MIC.  However, isolates resistant 
to kanamycin (HR = 1.2 [95% CI = 1.03-1.4]), sulfisoxazole (HR = 1.3 [95% CI = 1.1-1.5) and 
trimethoprim/sulfamethoxazole (HR = 1.3 [95% CI = 0.99-1.78) had increased susceptibility to 
copper.  The kanamycin containing phenotypic profile sulfisoxazole-kanamycin-streptomycin-
tetracycline was significantly (P = 0.008) associated with a higher copper MIC.  Among 83 of 
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the E. coli isolates with this unique profile, 82 isolates had copper MIC of ≥20 mM.  Of these 83 
isolates, 79.5% and 13.3% had copper MIC values of 20 and 24 mM respectively.  
 Discussion 
 Susceptibility to antimicrobials 
Generally speaking, prior to the start of treatment, the AMR levels among the E. coli 
isolated from the study pigs were already extremely high; this makes it very difficult to evaluate 
the effect of CTC supplementation on AMR in pigs of this age group.  At first glance, this might 
appear to be related to the prior use of antimicrobial agents in the breeder farm that supplied the 
study piglets, or else to a persistent, diverse, and resistant E. coli population present in the 
environment of the segregated early weaning facility where this experiment was conducted.  
Otherwise it could be reflective of the widespread dissemination of AMR associated with the use 
of antibiotics for long period of time since their discovery.  Similar results have been reported, 
however, across agricultural production species and systems that point to a strong and 
generalized association between isolates derived from neonatal animals and MDR phenotypes as 
a result of more frequent antimicrobial therapy and/or prophylaxis in neonates than older animals 
(188, 189).   
We did not observe resistance to amikacin, ciprofloxacin, and nalidixic acid, similar to 
other studies in porcine E. coli (19, 24, 25, 185).  Among aminoglycosides, resistance to 
amikacin is rare due to its resistance to enzymatic inactivation (90).  Ciprofloxacin and nalidixic 
acid are not approved in swine, but enrofloxacin has some limited labeled use in swine. The low 
azithromycin resistance (6.3%, n = 350) observed could be also due to lack of direct exposure to 
azithromycin since it is not approved for use in swine in the U.S.  However, there are some 
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macrolides that have been approved, while still others are contraindicated due to toxicity.  The 
fact that copper supplementation was significantly (P = 0.01; OR = 0.08 [95% CI = 0.01–0.67]) 
associated with a decrease in azithromycin resistance suggests that copper supplementation 
might exert an antagonistic effect on azithromycin resistance elements, thus offering a potential 
replacement, at least for macrolide AGPs such as tylosin, in swine production.  
The most common resistance phenotypes were observed to older antimicrobials: 
tetracycline (97%), sulfisoxazole (82%), ampicillin (75%), and streptomycin (71%).  These 
drugs have been used extensively in animals as AGPs, alone and in combination with other 
products, which can facilitate co-selection through genetic linkages.  The percentage (36%; n = 
1,152) of E. coli isolates that specifically included penta-resistant ACSSuT (ampicillin, 
chloramphenicol, streptomycin, sulfisoxazole, and tetracycline) in their resistance phenotype was 
higher than that reported for E. coli isolates from feedlot cattle (63).  About 89% of these isolates 
also were co-resistant to ceftiofur, as is similar to reports from cattle E. coli (62, 63).  Because 
chloramphenicol use in food animals has been prohibited in the U.S. since the 1980s, 
chloramphenicol resistance is likely maintained among E. coli through co-selection with other 
antibiotics in the ACSSuT group.  Because CTC supplementation significantly increased 
phenotypic tetracycline resistance, and ceftiofur and tetracycline resistances were strongly 
associated (P < 0.001; OR= 5.1[95% CI = 2.4-11.2]), we speculate that direct selection for 
tetracycline resistance co-selects for ceftiofur-resistant E. coli.  On the other hand, ceftiofur use 
could also select for tetracycline resistance (62); however, this cephalosporin product was not 
used on study pigs in this facility during the trial period.  
With the exceptions of tetracycline and sulfisoxazole, resistance to the remaining 
antibiotics decreased over time when CTC and copper were supplemented—either alone or in 
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combination—compared with the control group and beyond what would be expected by aging.  
It has been reported elsewhere that AMR decreases as a result of aging; this occurs equally in 
conventional and antibiotic-free swine herds (185, 189).  Interestingly, reductions in kanamycin 
and chloramphenicol resistance during the treatment period were transient; they returned to pre-
exposure levels after the treatments were removed.  The level of kanamycin resistance reported 
here (23.5%) is similar to that reported elsewhere in E. coli isolated from swine (24, 25).  
Acquired resistance to kanamycin, through R-plasmids, is relatively common among E. coli and 
other Gram negative rods.  A single plasmid can confer cross- or co-resistance to other 
aminoglycosides and to other drug classes (90).  Thus, in the absence of direct antibiotic 
pressure, kanamycin resistance could be maintained as a result of co-selection; that is, because it 
was found in association with sulfisoxazole, tetracycline, streptomycin, chloramphenicol, 
amoxicillin/clavulanic acid, ceftriaxone, cefoxitin, and ceftiofur in the present study.  
Using a binary coding system (i.e., susceptible or resistant), for each of the 15 antibiotics 
tested, a theoretical maximum of 2
15
 (32,768) possible phenotypic combinations (profiles) exists.  
However, as reported elsewhere (190), the actual observed phenotypic combinations are limited 
by genetic linkages and the prevalence of the individual resistances.  We observed a total of 101 
unique phenotypic resistance profiles across all the isolates from our study.  There were 60, 45, 
55, and 43 unique resistance profiles observed from control, copper, CTC, and copper plus CTC 
groups, respectively.  This indicates that resistance profiles in the control group are relatively 
more diverse; and in the presence of copper (alone or in combination with CTC) resistance 
profiles tended to be less diverse.  Most of these profiles are common to all treatment groups; 
only one pan-susceptible isolate was observed from the control group, whereas the remaining 
two were from the copper plus CTC group.  Resistance profiles that were unique to each 
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treatment group were sparse.  It is important to note that all of the phenotypic correlations 
between pairs of antibiotics (Table 3.5) are in a positive direction, and although all are 
significantly different from zero (P < 0.05), the width of the confidence limits varies more than 
can be explained simply from the prevalence position on the binomial distribution. 
The E. coli isolates generally were highly multidrug resistant.  On the basis of the count 
of the number of antimicrobials (ignoring antibiotic class, for now) to which isolates were 
resistant, the isolates showed a moderately bimodal distribution, usually at 4 and 10, in all 
treatment groups (Fig. 3.2).  This bimodal distribution was also evidenced elsewhere in E. coli 
derived from feedlot cattle (62).  However, unlike typically reported right-skewed distributions 
in populations at equilibrium (i.e., not under antimicrobial selection pressures), the E. coli 
population in our study exhibited a somewhat left-skewed distribution, thus indicating that E. 
coli populations from our study pigs were highly MDR.  About 25% (n = 1,152) of the E. coli 
isolates were resistant to 10 different antimicrobial agents.   
On the basis of NARMS classification criteria (19), 15 antimicrobials were collapsed into 
8 classes (Table 3.1); of these, the highest proportion (34.4%) of the E. coli isolates (n = 1,152) 
was resistant to 7 different classes (Fig 3.3).  The tendency to be resistant to many antimicrobial 
agents and classes exhibited a decreasing temporal trend when examined both by descriptive and 
analytic techniques; this, in turn is highly likely to be due to an aging effect as has been 
previously reported elsewhere (185, 189).  Ceftiofur and tetracycline resistances were associated 
with MDR class count.  The median number of antibiotics to which ceftiofur-resistant isolates (n 
= 746) were resistant was 9, compared with a median of 4 for a typical ceftiofur-susceptible 
isolate (n = 406).  Similarly, median MDR based on the number of antibiotic resistance was 8 
(95% CI = 8-8) and 3 (95% CI = 2–3) among tetracycline-resistant (n = 1,119) and susceptible (n 
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= 33) E. coli, respectively.  The median number of antibiotics to which both tetracycline- and 
ceftiofur-resistant isolates (n = 737) were resistant was also 9, compared with a median of 2 
antimicrobials for isolates (n = 24) susceptible to both drugs.  On the basis of binary definition 
(resistance to ≥3 classes), a great majority (91%) of E. coli isolates (n = 1,152) were also MDR.  
 Copper resistance 
With respect to the copper MIC distribution of isolates, the E. coli isolates tended to form 
a unimodal population in all the treatment groups.  Collapsed across all isolates, 93% of the 
isolates had an MIC of ≥20 mM, which suggests little to no acquired resistance mediated through 
the pco gene among the isolates (156).  Population-based studies on copper susceptibilities in E. 
coli are limited; most studies are based on banked isolates, and these often are from diagnostic 
laboratory submissions.  Williams et al., 1993 (36) reported the ready growth of E. coli isolates 
at 18 mM of CuSO4 from an Australian pig farm.  If this cutoff value was considered, 93% of 
the isolates in the present study, with an MIC of ≥20 mM, would have been categorized as 
resistant.  Since there is no consensus breakpoint for copper susceptibility among E. coli, we 
used survival analysis to analyze the full MIC range.  The MIC distribution of the E. coli isolates 
we studied is almost identical to that reported from livestock-associated E. coli in Denmark 
(156), and our E. coli population was generally able to tolerate high concentrations of CuSO4 
similar to that study.  Paradoxically, our study isolates from the control group were able to 
tolerate higher concentrations of CuSO4 than the treated groups, including those with 
supplemented copper in the feed, with as of yet no verifiable biological explanation.  It seems 
plausible that the population of E. coli selected by the two treatments and combination was 
prioritized on antibiotic resistance phenotype much more than on copper MIC since the MIC 
distribution is so narrow when contrasted with that of Enterococcus species for example (41-44). 
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The survival experience differed significantly (P = 0.027) among the groups at an MIC 
value of 20 mM, as seen in Fig. 3.4B.  Similar to our finding, Aarestrup and Hasman (156) 
reported that E. coli and Salmonella tolerated higher concentrations of copper than other 
bacteria, which could provide them a survival advantage in a high-copper environment.  Copper 
has been used for growth promotion purposes in swine production for over 60 years (36), and 
bacteria can also be exposed to metal contamination in the environment (50), though this is less 
likely in modern confinement operations.  Unlike in Europe, the level of copper used in swine 
feed in the U.S. is not regulated and is sometimes higher, ranging typically from 125 to 250 ppm 
(46).  This suggests that the pig gut flora, and E. coli in particular, could be well adapted to high 
levels of copper due to constant exposure to copper through feed or from the swine production 
environment.    
In conclusion, the E. coli population derived from post-weaned pigs that we studied 
exhibited resistance to most antimicrobials, with a few notable exceptions such as to 
fluoroquinolones.  These isolates were highly multidrug resistant, exhibiting a diverse range of 
resistance profiles.  As expected, CTC supplementation was associated with increased 
tetracycline resistance beyond the already high levels of tetracycline resistance at baseline.  It 
appeared that higher levels of copper supplementation as were used in this experiment decrease 
multidrug resistance counts; however,  this needs to be further investigated under these and other 
field conditions and, ideally, using additional culture and non-culture-dependent genotypic 
endpoints.   
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Figure 3.1.  Model-adjusted resistance prevalence of 1,152 E. coli isolated from feces of 
weaned pigs supplemented with chlortetracycline (CTC), copper, both or neither to the 
antibiotics tested.
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Figure 3.1 (Continued) 
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Figure 3.2.  Multidrug resistance count distribution of fecal E. coli isolates obtained from weaned pigs experimentally 
supplemented with chlortetracycline (CTC), copper, both or neither.   
 
Frequency distribution of phenotypic resistance shown on the basis of the number of antimicrobial agents across all isolates (n = 
1,152) (A), and by treatment group (n = 288/group) (B).
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Figure 3.3.  Multidrug resistance class count distribution of fecal E. coli isolates obtained from feces of weaned pigs 
experimentally supplemented with chlortetracycline (CTC), copper, both or neither.   
 
Frequency distribution of phenotypic resistance on the basis of the number of antimicrobial classes across all isolates (n = 1,152) (A), 
and by treatment group (n = 288/ group) (B).  Vertical bars at ≥3 represent cutoff value for MDR classification.
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Figure 3.4.  Copper susceptibilities of 1,152 E. coli isolates obtained from feces of weaned pigs that received chlortetracycline 
(CTC), copper, both or neither. 
 
(A) Distribution of the minimum inhibitory concentration (MIC) of E. coli isolates by treatment group (n = 288/group).  Numbers on 
the bar graph represent the number of isolates with a particular MIC value.  
 
(B) Survival plot against increasing mM concentration of copper only for isolates obtained during the treatment period.  *isolates from 
the CTC group were more susceptible.
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Figure 3.5.  Kaplan-Meier survival function illustrating cumulative susceptibilities of antibiotic resistant and susceptible E. 
coli (n = 1,152) isolates to increasing concentrations of copper.  
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Table 3.1.  Antibiotic concentration ranges and resistance break points used for susceptibility testing of E. coli (n = 1,152) 
isolated from fecal samples of weaned pigs experimentally fed chlortetracycline, copper, both or neither 
Antimicrobial class 
(FDA, 2012 (19)) 
Antimicrobial 
agent
 
Abbreviations  
 
WHO classification 
(WHO, 2012 (84)) 
Concentrations 
used (µg/mL) 
Resistance  
break point 
(µg/mL)
a 
Aminoglycosides Amikacin AMI Critically important 0.5 - 64 ≥ 64 
Gentamicin GEN Critically important 0.25 - 16 ≥ 16 
Kanamycin KAN Critically important 8 - 64 ≥ 64 
Streptomycin
b 
STR Critically important 32 - 64 ≥ 64 
β -lactam/β- lactamase 
 inhibitor combinations 
Amoxicillin/ 
clavulanic acid 
AUG Critically important 1/0.5 - 32/16 ≥ 32/ 16 
Cephems Cefoxitin FOX Highly important 0.5 - 32 ≥ 32 
Ceftiofur TIO Critically important 0.12 - 8 ≥ 8 
Ceftriaxone AXO Critically important 0.25 - 64 ≥ 4 
Folate pathway inhibitors Sulfisoxazole FIS Highly important 16 - 256 ≥ 512 
Trimethoprim/ 
sulfamethoxazole 
SXT Highly important 0.12/ 2.38 - 4/ 
76 
≥ 4/ 76 
Macrolides Azithromycin AZI Critically important 0.12 - 16 ≥ 8 
Penicillins Ampicillin AMP Critically important 1 - 32 ≥ 32 
Phenicols Chloramphenicol CHL Highly important 2 - 32 ≥ 32 
Quinolones Ciprofloxacin CIP Critically important 0.015 - 4 ≥ 4 
Nalidixic acid NAL Critically important 0.5 - 32 ≥ 32 
Tetracyclines Tetracycline TET Highly important 4 - 32 ≥ 16 
 
a 
Breakpoints were based on Clinical Laboratory Standards Institute guidelines (147). 
b 
National Antimicrobial Resistance Monitoring System breakpoint was used (19). 
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Table 3.2.  Minimum inhibitory concentration (MIC) distribution (squashtogram) of E. coli (n = 1,152) isolated from fecal 
samples of weaned pigs supplemented with chlortetracycline, copper, both or neither 
a 
For abbreviations refer to Table 3.1. 
b 
Amikacin (n = 802) and azithromycin (n = 350) were tested with NARMS CMV1AGNF and CMV2AGNF panels respectively. 
c 
95% confidence interval for the percentage of isolates resistant was calculated by using the exact binomial method. 
d 
The unshaded areas indicate the range of dilutions tested for each antimicrobial.  The vertical bars indicate the breakpoints for 
resistance.  Numbers in the gray-shaded areas indicate the percentages of isolates with MICs greater than the highest concentration 
tested.  Numbers listed for the lowest tested concentration represent the percentages of isolates with MICs ≤ the lowest tested 
concentration. 
Antimic
robial
a 
  
% 
Resist
ant 95% CI
c 
Distribution of MICs in ug/ml (%)
d 
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 
AMI
b 
0.0 0.0, 0.5 
     
0.3 19.2 60.5 19.6 0.5 
      AZI
b 
6.3 4.0, 9.4  5.7 49.4 38.6 3.7 2.6 
AMP 74.6 71.9, 77.1 
      
1.2 10.1 13.5 0.1 0.6 1.4 73.2 
   AUG 70.2 67.5, 72.9 
      
0.4 3.4 20.7 4.2 1.2 46.7 23.4 
   AXO 68.9 66.0, 71.4 
    
28.7 1.2 1.2 0.2 5.6 19.7 33.0 9.9 0.5 0.1 
  CHL 38.5 35.6, 41.3 
       
3.9 36.3 17.5 3.9 3.7 34.8 
   CIP 0.0 0.0, 0.3 92.0 6.1 1.7 0.1 
   
0.2 
        SXT 4.1 3.0, 5.4 
   
35.7 47.1 11.7 1.2 0.2 0.2 3.9 
      FOX 66.9 64.1, 69.6 
      
0.4 9.8 17.6 0.9 4.4 22.4 44.5 
   GEN 42.3 39.4, 45.2 
    
4.3 36.6 13.5 1.4 0.9 1.1 9.2 33.1 
    KAN 23.5 21.1, 26.1 
         
66.2 10.1 0.3 0.3 23.3 
  NAL 0.0 0.0, 0.3 
     
0.1 6.2 63.0 29.1 1.5 0.2 
     FIS 82.3 80.0, 84.5 
          
13.3 2.7 1.5 0.1 0.2 82.3 
STR 71.0 68.3, 73.6 
           
29.0 10.7 60.3 
  TET 97.1 96.0, 98.0 
        
2.8 0.1 0.5 24.8 71.8 
   TIO 64.8 61.9, 67.5 
   
0.4 11.5 16.1 1.5 1.6 4.3 28.6 36.2 
     
113 
 
Table 3.3.  Antimicrobial resistance prevalence (95% CI) of E. coli isolated from fecal 
samples of weaned pigs supplemented with chlortetracycline (CTC), copper, both or 
neither cross tabulated by treatment group and period 
Antimicrob
ial agent
a
 
Treatment 
group 
Treatment period
b 
 
 Before (n = 48)
c 
During (n = 144)
c
 After (n = 96)
c
 P-
value
d 
AMP Control 79.2 (65.0, 89.5) 74.3 (66.4, 81.2) 76.0 (66.3, 84.2) 0.786 
CTC 77.1 (62.7, 88.0) 79.2 (71.6, 85.5) 60.4 (49.9, 70.3) 0.005 
Copper 91.7 (80.0, 97.7) 78.5 (70.9, 84.9) 53.1 (42.7, 63.4) <0.001 
Copper + CTC 89.6 (77.3, 96.5) 81.3 (73.9, 87.3) 66.7 (56.3, 76) 0.003 
P-value
e 
0.126 0.549 0.007  
AZI
f 
Control - 11.7 (4.8, 22.6); n=60 13.3 (3.8, 30.7); n=30 1.00 
CTC - 3.5 (0.4, 12.1); n=57 6.7 (0.8, 22.1); n=30 0.606 
Copper - 0.0 (0.0, 6.1); n=59 3.7 (0.09, 1.9); n=27 0.314 
Copper + CTC - 1.8 (0.04, 9.4); n=57 16.7 (5.6, 34.7); n=30 0.017 
P-value
e 
 0.011 0.379  
AUG Control 72.9 (58.2, 84.7) 68.1 (59.8, 75.6) 72.9 (62.9, 81.5) 0.664 
CTC 77.1 (62.7, 88.0) 70.8 (62.7, 78.1) 56.3 (45.7, 66.4) 0.017 
Copper 91.7 (80.0, 97.7) 75 (67.1, 81.9) 52.1 (41.6, 62.4) <0.001 
Copper + CTC 79.2 (65.0, 89.5) 78.5 (70.9, 84.9) 62.5 (52, 72.2) 0.016 
P- value
e
 0.085 0.199 0.017  
AXO Control 66.7 (51.6, 79.6) 66.7 (58.3, 74.3) 71.9 (61.8, 80.6) 0.939 
CTC 72.9 (58.2, 84.7) 72.2 (64.2, 79.4) 56.3 (45.7, 66.4) 0.552 
Copper 75.0 (60.4, 86.4) 75.7 (67.9, 82.4) 52.1 (41.6, 62.4) 0.027 
Copper + CTC 77.1 (62.7, 88.0) 77.1 (69.3, 83.7) 61.5 (51.0, 71.2) 0.356 
P- value
e
 0.693 0.199 0.030  
CHL Control 54.2 (39.2, 68.6) 41.0 (32.9, 49.5) 40.6 (30.7, 51.1) 0.237 
CTC 60.4 (45.3, 74.2) 21.5 (15.1, 29.1) 36.5 (26.9, 46.9) <0.001 
Copper 54.2 (39.2, 68.6) 29.2 (21.9, 37.3) 34.4 (25, 44.8) 0.008 
Copper + CTC 58.3 (43.2, 72.4) 40.3 (32.2, 48.8) 38.5 (28.8, 49) 0.056 
P-value
e
 0.902 0.001 0.828  
FIS Control 79.2 (65.0, 89.5) 78.5 (70.9, 84.9) 89.6 (81.7, 94.9) 0.059 
CTC 93.8 (82.8, 98.7) 81.3 (73.9, 87.3) 85.4 (76.7, 91.8) 0.102 
Copper 83.3 (69.8, 92.5) 71.5 (63.4, 78.7) 88.5 (80.4, 94.1) 0.004 
Copper + CTC 81.3 (67.4, 91.1) 81.9 (74.7, 87.9) 85.4 (76.7, 91.8) 0.731 
P-value
e 
0.153 0.134 0.752  
FOX Control 70.8 (55.9, 83.0) 67.4 (59.1, 74.9) 62.5 (52.0, 72.2) 0.567 
CTC 75.0 (60.4, 86.4) 70.8 (62.7, 78.1) 45.8 (35.6, 56.3) <0.001 
Copper 91.7 (80.0, 97.7) 75 (67.1, 81.8) 42.7 (32.7, 53.2) <0.001 
Copper + CTC 72.9 (58.2, 84.7) 77.8 (70.1, 84.3) 60.4 (49.9, 70.3) 0.015 
P-value
e
 0.034 0.205 0.008  
GEN Control 62.5 (47.4, 76.0) 40.3 (32.2, 48.8) 37.5 (27.8, 48) 0.011 
CTC 60.4 (45.3, 74.2) 29.2 (21.9, 37.3) 33.3 (24, 43.7) 0.093 
Copper 56.3 (41.2, 70.5) 39.6 (31.5, 48.1) 38.5 (28.8, 49.0) 0.001 
Copper + CTC 62.5 (47.4, 76.0) 47.9 (39.5, 56.4) 41.7 (31.7, 52.2) 0.060 
P-value
e
 0.914 0.012 0.692  
KAN Control 8.3 (2.3, 20.0) 11.8 (7.0, 18.2) 34.4 (25, 44.8) <0.001 
CTC 43.8 (29.5, 58.8) 24.3 (17.6, 32.1) 42.7 (32.7, 53.2) 0.003 
Copper 27.1 (15.3, 41.8) 13.2 (8.1, 19.8) 38.5 (28.8, 49.0) <0.001 
Copper + CTC 31.3 (18.7, 46.3) 11.1 (6.5, 17.4) 20.8 (13.2, 30.3) 0.005 
P-value
e
 0.001 0.008 0.007  
STR Control 58.3 (43.2, 72.4) 70.8 (62.7, 78.1) 71.9 (61.8, 80.6) 0.220 
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CTC 75.0 (60.4, 86.4) 79.2 (71.6, 85.5) 63.5 (53.1, 73.1) 0.028 
Copper 66.7 (51.6, 79.6) 67.4 (59.1, 74.9) 71.9 (61.8, 80.6) 0.716 
Copper + CTC 87.5 (74.8, 95.3) 72.2 (64.2, 79.4) 66.7 (56.3, 76) 0.019 
P-value
e
 0.009 0.142 0.522  
SXT Control 12.5 (4.7, 25.2) 0.7 (0.0, 3.8) 3.1 (0.6, 8.9) 0.002 
CTC 14.6 (6.1, 27.8) 2.1 (0.4, 6.0) 12.5 (6.6, 20.8) 0.001 
Copper 18.8 (8.9, 32.6) 0 .0 (0.0, 2.5) 0.0 (0.0, 3.8) <0.001 
Copper + CTC 12.5 (4.7, 25.2) 0.0 (0.0, 2.5) 0.0 (0.0, 3.8) <0.001 
P-value
e
 0.870 0.201 <0.001  
TET Control 91.7 (80.0, 97.7) 94.4 (89.3, 97.6) 92.7 (85.6, 97.0) 0.694 
CTC 97.9 (88.9, 99.9) 100 (97.5, 100) 100 (96.2, 100) 0.167 
Copper 91.7 (80.0, 97.7) 98.6 (95.1, 99.8) 97.9 (92.7, 99.7) 0.058 
Copper + CTC 97.9 (88.9, 99.9) 100 (97.5, 100) 95.8 (89.7, 98.9) 0.022 
P-value
e
 0.322 0.001 0.027  
TIO Control 66.7 (51.6, 79.6) 65.3 (56.9, 73.0) 61.5 (51, 71) 0.774 
CTC 68.8 (53.7, 81.3) 70.1 (62.0, 77.5) 49 (38.6, 59.4) 0.003 
Copper 75.0 (60.4, 86.4) 72.9 (64.9, 78.0) 41.7 (31.7, 52.2) <0.001 
Copper + CTC 68.8 (53.7, 81.3) 75.7 (67.9, 82.4) 59.4 (48.9, 69.3) 0.028 
P- value
e
 0.824 0.249 0.019  
 
a
AMP = ampicillin, AZI = azithromycin, AUG = amoxicillin/clavulanic acid, AXO = 
ceftriaxone, CHL = chloramphenicol, FIS = sulfisoxazole, FOX = cefoxitin, GEN = 
gentamicin, KAN = kanamycin, STR = streptomycin, SXT = trimethoprim/sulfamethoxazole, 
TET = tetracycline, TIO = ceftiofur.  Results were not shown for amikacin, ciprofloxacin and 
nalidixic acid since all isolates were susceptible by binary classification. 
b
Sampling days were categorized into treatment periods as pretreatment (day 0); treatment 
(days 7, 14, and 21) and post-treatment (days 28 and 35). 
c
Number of E. coli isolates per treatment group per treatment period. 
 
d
Likelihood ratio chi-square (LR χ2) P-value with 2 df comparing treatment periods by 
treatment group. 
eLR χ2 P-value with 3 df comparing treatment groups by treatment period. 
f
Azithromycin was tested only on 350 isolates using NARMS CMV2AGNF panel.  
Amikacin was tested on 802 isolates by using CMV1AGNF. 
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Table 3.4.  Prevalence (%) across all treatment periods of major antimicrobial resistance phenotypes of E. coli, isolated from 
weaned pigs fed diets supplemented with chlortetracycline (CTC), copper, both or neither 
No. of 
antimic
robials 
Phenotypic profile
a
 Treatment group Overall 
(n =1,152) Control 
(n = 288) 
Copper 
(n = 288) 
CTC 
(n = 288) 
Copper + CTC 
(n = 288) 
0 Pansusceptible 0.35 0.00 0.00 0.69 0.26 
1 tet  7.64 5.56 2.78 6.60 5.64 
Other phenotypes (amp, fis, str) 0.69 0.69 0.00 0.35 0.43 
2 fis_tet 0.69 2.08 1.39 1.74 1.48 
Other phenotypes (amp_fis, fis_fox, kan_tet, str_tet) 2.43 1.04 1.39 1.39 1.56 
3 fis_kan_tet 1.74 4.86 9.72 3.47 4.95 
chl_fis_tet 0.35 0.69 0.69 0.35 0.52 
fis_gen_tet 2.08 0.69 0.69 1.74 1.30 
Other phenotypes (too numerous to list) 2.78 1.04 0.00 0.35 1.04 
4 fis_kan_str_tet 4.86 10.42 8.33 5.21 7.20 
amp_fis_str_tet 1.39 1.39 2.43 1.74 1.74 
fis_gen_str_tet 1.04 1.74 0.00 1.74 1.13 
Other phenotypes (too numerous to list) 2.43 0.00 1.39 0.69 1.13 
5 amp_chl_fis_str_tet 0.35 0.00 1.04 0.00 0.35 
chl_fis_kan_str_tet 0.35 0.00 1.04 0.00 0.35 
Other phenotypes (too numerous to list) 1.04 0.00 1.39 0.35 0.69 
6 amp_aug_axo_fox_tet_tio 4.17 7.29 5.56 4.17 5.30 
Others phenotypes (too numerous to list) 1.04 1.39 1.39 1.39 1.30 
7 amp_aug_axo_fis_fox_tet_tio 4.86 5.90 0.69 4.17 3.91 
amp_axo_fis_fox_str_tet_tio 0.69 0.00 0.69 0.69 0.52 
Other phenotypes (too numerous to list) 3.47 2.08 1.04 1.74 2.08 
8 amp_aug_axo_fis_fox_str_tet_tio 7.99 9.38 15.28 14.24 11.72 
amp_aug_axo_chl_fis_gen_str_tet 0.35 1.74 1.04 1.04 1.04 
amp_aug_axo_chl_fis_str_tet_tio 0.69 0.69 0.69 0.35 0.61 
amp_aug_axo_fox_gen_str_tet_tio 2.78 5.21 5.21 2.78 3.99 
Other phenotypes (too numerous to list) 2.08 3.13 1.74 1.04 2.00 
9 amp_aug_axo_fis_fox_kan_str_tet_tio 1.74 1.04 3.47 1.74 2.00 
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amp_aug_axo_chl_fis_fox_gen_str_tet 1.74 1.74 1.04 0.69 1.30 
amp_aug_axo_chl_fis_fox_str_tet_tio 4.51 0.69 1.74 0.00 1.74 
amp_aug_axo_chl_fis_gen_str_tet_tio 1.39 0.35 1.04 0.35 0.78 
amp_aug_axo_fis_fox_gen_str_tet_tio 0.69 0.35 0.69 0.35 0.52 
Other phenotypes (too numerous to list) 1.04 0.00 1.04 0.00 0.52 
10 amp_aug_axo_chl_fis_fox_gen_str_tet_tio 22.57 22.57 12.85 31.94 22.48 
amp_aug_axo_chl_fis_fox_str_sxt_tet_tio 0.00 0.00 2.43 0.35 0.69 
amp_aug_axo_fis_fox_gen_kan_str_tet_tio 2.78 1.39 3.13 1.04 2.08 
Other phenotypes (too numerous to list) 1.39 0.00 0.00 0.00 0.35 
11 amp_aug_axo_chl_fis_fox_gen_str_sxt_tet-tio 2.78 1.74 3.47 1.39 2.34 
amp_aug_axo_chl_fis_fox_gen_kan_str_tet_tio 0.35 2.08 1.74 3.82 2.00 
Other phenotypes (too numerous to list) 0.35 0.00 1.04 0.00 0.35 
12 amp_aug_axo_chl_fis_fox_gen_kan_str_sxt_tet_tio 0.35 1.04 0.69 0.35 0.61 
 Total 100 100 100 100 100 
 
a
amp = ampicillin, aug = amoxicillin/clavulanic acid, axo = ceftriaxone, chl = chloramphenicol, fis = sulfisoxazole, fox = 
cefoxitin, gen = gentamicin, kan = kanamycin, str = streptomycin, sxt = trimethoprim/sulfamethoxazole, tet = tetracycline, tio = 
ceftiofur.  
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Table 3.5.  Model-defined pairwise correlations (with 95% CI) between phenotypic AMR of E. coli (n = 1,152), obtained from 
fecal samples of weaned pigs fed diets supplemented with chlortetracycline (CTC), copper, both or neither against different 
antimicrobials included in the multivariate probit analysis and adjusted for clustering by pen 
 AMP
 a, b
 AUG AXO CHL FIS FOX GEN STR TIO 
AMP 1         
AUG 0.94  
(0.87, 0.97) 
1        
AXO 0.95 
 (0.9, 0.97) 
0.97  
(0.95, 0.99) 
1       
CHL 0.54  
(0.45, 0.62) 
0.56  
(0.46, 0.64) 
0.55  
(0.46, 0.63) 
1      
FIS 0.28  
(0.10, 0.43) 
0.28  
(0.11, 0.44) 
0.30 
 (0.12, 0.47) 
0.61  
(0.51, 0.70) 
1     
FOX 0.90  
(0.83, 0.94) 
0.94 
 (0.92, 0.96) 
0.94 
 (0.91, 0.96) 
0.49  
(0.37, 0.59) 
0.26  
(0.08, 0.44) 
1    
GEN 0.57 
 (0.47, 0.66) 
0.59  
(0.49, 0.68) 
0.61 
 (0.51, 0.69) 
0.75  
(0.66, 0.81) 
0.41  
(0.24, 0.56) 
0.5 
 (0.38, 0.61) 
1   
STR 0.59  
(0.51, 0.66) 
0.59  
(0.52, 0.65) 
0.59 
 (0.51, 0.67) 
0.69  
(0.61, 0.76) 
0.66 
 (0.54, 0.76) 
0.52 
 (0.42, 0.62) 
0.72  
(0.64, 0.79) 
1  
TIO 0.94 
 (0.89, 0.97) 
0.96  
(0.92, 0.98) 
0.98  
(0.97, 0.99) 
0.49 
 (0.38, 0.59) 
0.28 
 (0.09, 0.44) 
0.95  
(0.93, 0.97) 
0.52 
 (0.39, 0.63) 
0.53  
(0.43, 0.63) 
1 
aAll pairwise correlations were significant (P ≤ 0.004). 
AMP = ampicillin, AUG = amoxicillin/clavulanic acid, AXO = ceftriaxone, CHL = chloramphenicol, FIS = sulfisoxazole,    FOX 
= cefoxitin, GEN = gentamicin, STR = streptomycin, TIO = ceftiofur. 
b
 Amikacin (AMI), kanamycin (KAN), trimethoprim/sulfamethoxazole (SXT), azithromycin (AZI), ciprofloxacin (CIP), nalidixic 
acid (NAL), and tetracycline (TET) were excluded from the model because of sparse cell counts.
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Chapter 4 - Effects of chlortetracycline and copper 
supplementations in the diet of weaned pigs on the prevalence of 
antimicrobial resistance genes in Escherichia coli isolated from feces 
 Abstract 
Chlortetracycline (CTC) and copper are commonly used growth promoters in U.S. pig 
production.  We investigated the impact of CTC, copper or their combined supplementations in 
weaned pigs on the prevalence of tetracycline (tetA, tetB, tetC and tetE), copper (pcoD) and 
ceftiofur (blaCMY-2) resistance genes in fecal Escherichia coli.  A total of 1,152 isolates obtained 
from 32 pens (5 pigs/pen) which were randomized to control, copper, CTC, or copper plus CTC 
treatment groups were tested for the tet genes, blaCMY-2 and pcoD genes by PCR.  The prevalence 
of tetA, pcoD and blaCMY-2 genes decreased over the treatment periods regardless of treatment 
groups; while that of tetB had increased.  Although CTC and copper supplementations were 
associated with increased tetB prevalence, their combination was paradoxically associated with 
reduced tetB prevalence.  tetA and blaCMY-2 were positively and strongly associated with each 
other; in turn, these were negatively associated with both tetB and pcoD.  The latter two genes 
were also positively associated with each other.  The tetA and blaCMY-2 genes were positively 
associated with multidrug resistance (MDR) counts, but tetB and pcoD were negatively 
associated with MDR counts.  The expansion of E. coli population harboring tetB over tetA 
associated with CTC supplementation most likely indicates gene substitution at the bacterial 
population level.  The high prevalence (72%) of the blaCMY-2 gene suggests that ceftiofur 
resistance is readily maintained in the absence of ceftiofur use in these pig cohorts, most likely 
through genetic linkage to tetA.  The roles of copper supplementation in pig production and pco-
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mediated copper resistance in E. coli need to be further explored because the strong negative 
association observed with tetA and blaCMY-2 points to potential opportunities to select for a more 
innocuous tetracycline resistance profile. 
 Introduction 
Antimicrobial resistance (AMR) is one of the greatest public health threats in the world 
(3) and is largely driven by the use and overuse of antimicrobial agents in humans and animals 
(191).  The selective pressure posed by use of antibiotics including antibiotic growth promoters 
(AGPs) in food animal production, could foster amplification and dissemination of antibiotic-
resistant bacteria and their resistance determinants (70, 75, 192).  Evidence of qualitative links 
between AGP use of antimicrobials in food animals and the emergence of antibiotic-resistant 
bacteria is mounting (11, 168, 193).  Tetracyclines have commonly been used in humans and 
agriculture (31) for more than six decades.  Chlortetracycline (CTC) and oxytetracycline are the 
most commonly used AGPs in U.S. swine production (17).  Tetracycline resistance is inducible 
(28) and is mainly the result of tetracycline resistance (tet) genes acquired through horizontal 
gene transfer (31).  Tetracycline resistance mechanisms include: 1) the efflux of tetracycline 
from the cell, 2) ribosomal protection from the action of tetracyclines, or 3) enzymatic 
degradation of tetracyclines (31).  A regularly updated online database reports the discovery of 
30 efflux, 12 ribosomal, 3 enzymatic, and 1 unknown tet or otr genes
3
.  
In swine, copper is an essential micronutrient required for normal physiological activities 
and is typically included in the diet as part of the trace mineral supplement at the National 
Research Council recommended dose (5-6 ppm) (39).  In the U.S. at higher dietary levels (100-
                                                 
3
 http://faculty.washington.edu.marilynr/ 
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250 ppm), it is also used for growth promotion purposes (39, 76).  Because copper is toxic to 
bacteria at high concentrations, E. coli and other Gram negative bacteria have developed tightly 
regulated mechanisms coded by genes on the chromosome or plasmids (49, 55, 122) to maintain 
copper homeostasis.  A copper resistance determinant (pco) identified on the pRJ1004 plasmid of 
E. coli (54) consists of seven genes, pcoABCDRSE, arranged in two operons, pcoABCD and 
pcoRS, and a separate pcoE gene (55).  The pcoABCD operon is regulated by its own two-
component regulatory genes: pcoRS and the expression of all the proteins (PcoABCD) are 
required to confer copper resistance (55).  PcoD is an inner membrane protein that pumps PcoC-
associated copper into the cytoplasm to be oxidized by multicopper oxidase, PcoA (55).  
Ceftiofur is an extended-spectrum third-generation cephalosporin that was first approved 
by the U.S. Food and Drug Administration (FDA) in 1988 for the treatment of bovine and swine 
respiratory diseases (57).  Its continued use in animals has been scrutinized as a result of cross-
resistance with ceftriaxone, a closely related antibiotic that is a first-line treatment of 
salmonellosis in children (58).  Ceftiofur resistance is mediated primarily by a widely 
disseminated plasmid-borne AmpC type β-lactamase, the blaCMY-2 cephamycinase gene (59, 60).  
E. coli can act as important reservoir of AmpC blaCMY genes and can be transferred to other, 
more pathogenic bacteria such as Salmonella enterica (61).  Previous phenotypic study has 
shown that subtherapeutic use of CTC resulted in the co-selection of third generation 
cephalosporin resistance (ceftriaxone) in enteric bacteria of pigs (23).  Furthermore a complete 
sequence of the IncA/C plasmids originated from cattle showed the presence of blaCMY-2 gene 
along with other multiple antimicrobial resistance genes such as tetA (64).   
Chlortetracycline and copper are commonly used for growth promotion in U.S. swine 
production system.  It has been shown that copper supplementation was associated with 
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increased prevalence of transferable copper resistance (tcrB) gene in enterococci in pigs (43, 44).  
However the impact of individual or combined supplementations of CTC and copper in weaned 
pigs on antimicrobial and copper resistance genes in E. coli has not been studied.  The objective 
of this study was to investigate the impact of CTC, copper or their combined supplementations in 
weaned pigs on the prevalence of tet genes (tetA, tetB, tetC and tetE), pcoD and blaCMY-2 genes 
in fecal E. coli. 
 Materials and methods 
 Experimental design and E. coli isolation  
A total of 160 weaned pigs that were obtained from a commercial pig farm were 
randomized to 32 pens (with five pigs per pen) blocked on body weight.  After two weeks of 
adaptation the pens were randomized to one of the four treatment groups in a two-by-two full 
factorial balanced design.  The treatment groups consisted of control (basal diet with required 
copper concentration at 16.5 mg/kg of feed), copper (copper sulfate fed at an elevated 
concentration of 125 mg/kg of feed), CTC (basal diet plus CTC at 550 mg/kg of feed), or copper 
plus CTC at above dosages.  Fecal samples were collected weekly for 6 weeks from three pigs 
out of five pigs housed in each of 32 pens.  A total of 1,152 E. coli strains isolated from 576 fecal 
samples (two isolates per sample) obtained from 160 weaned pigs were used in the study.  
 PCR detection of resistance genes 
 E. coli isolates were tested for tet (A, B, C, E), blaCMY-2 and pcoD genes.  DNA was 
extracted by heating a bacterial suspension in 500 µl of nuclease-free water at 95°C for 10 min.  
After centrifugation at 14,000 rpm for 2 min, the lysate was separated and used as template for 
PCR.  Primers and positive controls (and their sources) are shown in Table 4.1.  All PCR 
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reactions were performed in a Mastercycler gradient thermal cycler (Eppendorf, Germany), and 
PCR products were analyzed by capillary gel electrophoresis in the QIAxcel Fast Analyzer 
system (Qiagen, Valencia, CA).  
For the detection of tet (A, B, C, E) genes a multiplex PCR assay (194) was adapted 
using a pre-optimized commercially available multiplex PCR master mix kit (Qiagen) according 
to the manufacturer’s instructions.  First, 500 µl of primer mix was prepared by adding 10 µl of 
each of the primers from 100 µm stock concentration and nuclease free water to give a 
concentration of 2 µm of each primer.  The final PCR mixture of 50 µl consisted of 17 µl of 
nuclease-free water, 25 µl of master mix, 5 µl of primer mix, and 3 µl of DNA template.  PCR 
conditions were initial activation at 95°C for 15 min followed by 31 cycles of denaturation at 
94°C for 30 sec, annealing at 60°C for 90 sec, and extension at 72°C for 90 sec, followed by a 
final extension at 72°C for 10 min.  
For detection of the pcoD gene, a total of 25 µl of the PCR reaction mixture consisted of 
12.5 µl HotStarTaq master mix (Qiagen), 2 µl of each of the primers, 2 µl of DNA template, and 
6.5 µl of nuclease-free water.  The PCR thermal profile consisted of initial activation at 95°C for 
15 min followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 45 sec, 
and extension at 72°C for 1 min, followed by final extension at 72°C for 10 min.  For blaCMY-2 
(154), the final 25 µl PCR reaction mixture consisted of 8.5 µl of nuclease-free water, 12.5 µl of 
master mix (Promega Corporation, Madison, WI), 1 µl of each of the primers, and 2 µl of DNA 
template.  PCR conditions were initial denaturation for 2 min at 95°C followed by 30 cycles of 
denaturation at 95°C for 30 sec, annealing at 55°C for 45 sec, and extension at 72°C for 30 sec, 
with final extension at 72°C for 5 min.  
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 Statistical analysis  
 All data analysis was performed using STATA version 12.1 (StataCorp LP, College 
Station, TX), and P < 0.05 was considered significant.  A full factorial model to evaluate the 
effects of copper, CTC, and their interaction on the prevalence of resistance genes was used 
throughout the analysis.  Sampling days were further categorized into treatment periods as: 
baseline (day 0), treatment period (days 7, 14, and 21), and post-treatment period (days 28 and 
35).  For descriptive statistics, the binary outcomes (presence/absence) for each of the genes 
within an isolate were aggregated and expressed as proportions with exact 95% binomial 
confidence intervals.  Initially a likelihood ratio chi-square test was used to compare the 
unadjusted effects of treatment and treatment period.  tetC and tetE were not considered beyond 
descriptive statistics due to their sparse presence. 
Multilevel mixed-effects logistic regression model was used to model the fixed effects of 
treatments and treatment periods (and their interactions) along with random effects for repeats 
within pen and within individual fecal samples on each of the individual binary genotypic 
resistances.  The model was a three level hierarchical model consisting of isolate within sample 
and sample within pen.  The fixed effects of resistance genes (and their interactions) on the 
binary classified phenotypic MDR (resistance to ≥ 3 antimicrobial classes), according to 
NARMS classification (19), was also assessed by multilevel mixed-effects logistic regression, 
including random effects for fecal samples and pen.  Multivariate (162) and bivariate probit 
regression models were used to simultaneously model the effects of treatment and treatment 
period on multiple binary outcomes (presence or absence of the four resistance genes) and on the 
prevalence of just the tetA and tetB genes, respectively, and to adjust for the biological 
dependencies that can result from genetic linkages between different antimicrobial resistance 
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genes.  Cluster-adjusted robust standard errors (SE) were used to adjust for the pen effect.  A 
generalized ordered logistic regression model was used to further assess the associations of the 
resistance genes (tetA, tetB, blaCMY-2, and pcoD) with MDR counts, which were defined on the 
bases of the number of antimicrobial agents and classes to which isolates were resistant.  In all 
the regression models, first a full model with the main effects and all possible interactions was 
built and model selection was conducted in a backward manual selection method.  When 
interaction terms were not significant, only the main effects were evaluated.  Bonferroni test was 
used to adjust for multiple comparisons. 
 Results  
 Prevalence of resistance genes  
Out of 14 different tet genes originally targeted by four multiplex PCR assays, the vast 
majority of genes detected from the first 576 E. coli isolates tested (data not shown) were tetA 
and tetB, and to a lesser extent tetC and tetE.  Subsequently, we elected to target only these four 
tet genes (A, B, C, and E) in a multiplex PCR for the remaining 576 isolates.  Across all 
treatments, unadjusted prevalence of the resistance genes was as follows: tetA (66% [95% CI = 
64–69%]), tetB (48% [95% CI = 45–51%]), tetC 2.1% (95% CI = 1.3–3.1%), tetE 1.6% (95% CI 
= 0.9–2.5%), pcoD (16% [95% CI = 14–18%]) and  blaCMY-2 (72% [95% CI = 69–75%]).  As can 
be seen from the 95% CI, the prevalence of blaCMY-2 was significantly greater than that of tetA, 
which was in turn, significantly greater than that of tetB followed by pcoD.  The prevalence of 
each of the resistance genes cross-tabulated by treatment group and treatment period is 
summarized in Table 4.2.  In unadjusted analyses, prevalence of tetA was significantly higher 
among the E. coli isolates obtained from copper plus CTC–supplemented pigs during the 
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treatment period (76% vs 59%; P = 0.019) compared with isolates obtained from copper only 
group.  tetA was also significantly (72% vs. 51%; P = 0.024) higher in the isolates obtained from 
the copper plus CTC–supplemented group in the post-treatment period compared with isolates 
obtained from CTC-only–supplemented pigs during this period.  The prevalence of tetB was 
higher among E. coli isolates obtained from pigs supplemented with CTC (50%) or copper 
(50%) during the treatment period (P = 0.004) compared with the control (35%) and copper plus 
CTC (35%) groups.  The prevalence of tetC decreased during treatment and post treatment 
periods compared to the baseline in the copper (P = 0.004) and copper plus CTC (P < 0.001) 
supplemented groups.   tetE was detected more frequently from the copper supplemented group.  
Prevalence of tetA and blaCMY-2 exhibited a decreasing trend through subsequent treatment 
periods, regardless of treatment group; in contrast, the prevalence of tetB greatly increased 
across the same treatment periods.  The prevalence of pcoD decreased significantly (P = 0.007) 
through subsequent treatment periods in the control pigs.  tetA and blaCMY-2 were positively and 
strongly associated with each other; in turn, these were negatively associated with both tetB and 
pcoD.  The latter two genes were also positively associated with each other (Table 4.3).  
Model-adjusted prevalence from multilevel mixed-effects logistic regression analysis for 
each of the resistance genes is plotted across treatment periods in Fig 4.1.  Prevalence of tetA 
decreased through subsequent treatment periods: it was significantly lower during the treatment 
(P = 0.001; odds ratio (OR) 0.15 [95% CI = 0.05–0.46]) and post-treatment periods (P < 0.001; 
OR = 0.08 [95% CI = 0.02–0.26]) compared with day 0 isolates with no treatment effect.  The 
isolates obtained from the copper-supplemented group were 2.6 (95% CI = 1.0–7.0; P = 0.05) 
times more likely to have tetB than isolates from the control group using OR as the measure of 
association.  Similarly, CTC supplementation was significantly associated with increased 
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prevalence of tetB compared to the control group (OR= 3.3 [95% CI = 1.2–8.7]; P = 0.017).  
Paradoxically, copper plus CTC supplementation (i.e. treatment interaction) was significantly 
associated with decreased prevalence of tetB (OR = 0.14 [95% CI = 0.04–0.57], P = 0.006) 
compared with the control groups.  E. coli isolates in the post-treatment period exhibited higher 
prevalence of tetB (P = 0.024), which was 2.5 (95% CI = 1.13–5.5) times higher than for 
baseline samples.  The prevalence of pcoD was significantly lower among isolates during 
treatment (OR = 0.38 [95% CI = 0.14–0.99]; P = 0.047) and post-treatment periods (OR = 0.34 
[95% CI = 0.12–0.95]; P = 0.040) compared with pretreatment levels.  Similar to tetA, the 
prevalence of blaCMY-2 was significantly lower in the isolates from the post-treatment period 
compared with baseline isolates (OR = 0.2 [95% CI = 0.07-0.55]; P = 0.002).  In all resistance 
genes, treatment by day interaction was not significant (P > 0.05). 
Figure 4.2 shows the marginal plot of the adjusted prevalence of tetA and tetB genes 
across the treatment period as obtained from the bivariate probit analysis.  Detection of tetA 
alone decreased across the treatment periods in all treatment groups except in the copper plus 
CTC group, where it increased during the treatment period.  On the other hand, tetB-only 
prevalence increased across the treatment periods in all treatment groups.  Among isolates in 
which both tet genes were found, the pattern of decreasing prevalence through time was more 
similar to that of tetA than of tetB (Fig. 4.2).  The prevalence of both genes occurring together 
decreased significantly during treatment period (OR = 0.2; 95% CI = 0.1–0.4) and in the post-
treatment period (OR = 0.5; 95% CI = 0.3–0.9) compared to the baseline with no treatment 
effects (P > 0.05).  Only a few isolates (n = 48) harbored neither tetA nor tetB throughout, and 
this finding did not vary by treatment or treatment period (P > 0.05; Fig. 4.2). 
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From the bivariate probit regression output, overall detection of tetA, adjusted for tetB, 
decreased significantly both during treatment (OR = 0.65[95% CI = 0.48–0.87]; P = 0.004) and 
post-treatment (OR = 0.55 [95% CI = 0.38–0.78]; P = 0.001) periods compared with day 0 
where, as expected, no significant treatment differences (P > 0.05) were found.  However, both 
copper (OR = 1.4 [95% CI = 1.0–1.9]; P = 0.046) and CTC (OR = 1.5 [95% CI = 1.1–2.04]; P = 
0.010) supplementations were significantly associated with increased tetB prevalence relative to 
the control group across all treatment periods adjusted for tetA.  The combined supplementation 
of copper and CTC was significantly associated with decreased detection of tetB alone (OR = 
0.52 [95% CI = 0.33–0.82]; P = 0.004) compared with the control group.  Isolates obtained 
during the post-treatment period had significantly (P = 0.025) higher levels of tetB alone 
compared with day 0 isolates (OR = 1.4 [95% CI = 1.04–1.82]) across all isolates.  Treatment by 
sampling day interaction was not significant in the bivariate regression model (P > 0.05). 
 Resistance gene profiles 
Genotypic profiles for four of the resistance genes (excluding tetC and tetE) detected 
among E. coli are shown in Fig 4.3.  None of the four targeted genes was detected in 2% of the 
isolates studied (n = 1,152).  The most common singly carried gene was tetB (11%); on the other 
hand, tetA was the gene most commonly (38%) found in association with the blaCMY-2 gene.  The 
most common three-gene profile observed was tetA-tetB-blaCMY-2, accounting for 14% of the 
isolates tested.  Only about 4% of the isolates contained all the four genes together. 
 Tetracycline resistance gene profiles  
Table 4.4 shows the distribution of the four tet (A, B, C, and E) genes detected.  At least 
one of the four tet genes was detected in 97% (1,117 of 1,152) of the E. coli isolates.  Among 
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these (n = 1,117), about half of the tetracycline resistance was conferred by tetA (49%), followed 
closely by tetB (29.5%) and 19% of the isolates carried both tetA and tetB genes together.  The 
presence of tetA and tetB singly or in combination explained the majority of the observed 
phenotypic resistance to tetracycline, accounting for 99% of the isolates (n = 1,117) with at least 
one tet gene and 96% of all the isolates tested (n = 1,152).  The tetE gene was carried alone in 12 
(67%) of the 18 isolates that were positive for tetE.  The tetC gene, however, was always found 
along with tetA or tetB but never with tetE.  Except for tetC, these genes were mostly found 
individually in the E. coli isolates.  Out of 33 isolates that were phenotypically susceptible to 
tetracycline, 22 (67%) of them did not carry any of the four tet genes.  Out of 35 isolates in 
which none of the tet genes targeted were detected, 13 (37%) were phenotypically resistant to 
tetracycline.  Among phenotypically tetracycline-resistant E. coli (n = 1,119), 99% were positive 
for one or more of the four tet genes tested.  A duplex PCR targeting only tetA and tetB could 
explain 98% of the phenotypic tetracycline resistance (n = 1,119).  
 Associations between resistance genotypes and multidrug resistance  
On the basis of the number of antimicrobials (theoretically, from 0–15) to which 
individual E. coli isolates were resistant, the median MDR count was the highest when the 
blaCMY-2 gene was found in association with either tetA or tetB (Fig. 4.4).  Analyses of the 
generalized ordered logistic regression indicated that the presence of tetA (proportional OR = 3.3 
[95% CI = 2.1–5.0]; P < 0.001) and blaCMY-2 (prop OR = 22.2 [95% CI = 14.9–33.1]; P < 0.001) 
were significantly associated with a higher MDR count; however, tetB was not significantly (P = 
0.410) associated with MDR count (proportional OR = 1.2 [95% CI = 0.8–1.7]).  The association 
between pcoD gene and MDR count was inconsistent across counts.  Up to a MDR count of 5 
antimicrobials, the presence of the pcoD gene was negatively associated with MDR count (P < 
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0.05).  For resistance counts ranging from 6–7 antibiotics, there was no significant (P > 0.05) 
association between pcoD and MDR count.  Examined differently, by dichotomizing at an MDR 
count of 10, the presence of the pcoD gene was significantly (P = 0.003) and positively 
associated with E. coli isolates that were resistant to more than 10 antibiotics (OR = 3.5 [95% CI 
= 1.5–7.8]) compared with resistance counts of 10 antibiotics or less.  
Based on the number of different antimicrobial classes isolates were resistant to, 
generalized ordered logistic regression showed that both tetA and blaCMY-2 genes were 
significantly (P < 0.001) and positively associated with a higher MDR count.  tetB was not 
significantly (P = 0.462) associated with higher MDR class counts.  E. coli isolates carrying the 
pcoD gene were less likely (P < 0.001) to be classified as MDR when comparing >2 to ≤2 
classes of antibiotics than isolates with no pcoD gene (propOR = 0.25; 95% CI = 0.11–0.5).  
Beyond an MDR count of >3 antimicrobial classes, however, there was no significant (P > 0.05) 
association between pcoD and MDR.  
Among E. coli isolates (n = 1,043) that were MDR according to phenotypic binary 
classifications of NARMS based on resistance to ≥3 antimicrobial classes, 41% of them had tetA 
and blaCMY-2 genes together.  The presence of tetA (96% [95% CI = 94–97%] vs. 81% [95% CI = 
76–85%]) and blaCMY-2 (98% [95% CI = 97–99%] vs. 72% [95% CI = 66–76%]) were 
significantly (P<0.001) and positively associated with isolates being resistant to more than two 
antimicrobial classes.  On the other hand, the presence of tetB (87% [95% CI = 84–89%] vs. 
94% [95% CI = 92–96%]) and pcoD (69% [95% CI = 62–76%] vs. 95% [95% CI = 93–96%]) 
were significantly and negatively associated with MDR.  The presence of tetB and pcoD genes 
together were significantly (P < 0.001) associated with reduced MDR classification of the 
isolates.  
130 
 
 Discussion 
 Prevalence of resistance genes  
The combined effects of copper and CTC (that is CTC by copper interaction) on the 
prevalence of tetA were synergistic during the treatment period in that tetA was significantly (P 
= 0.019) higher in the copper plus CTC–supplemented group compared to the control group.  In 
contrast, the combined treatments (CTC by copper interaction) appeared to be antagonistic to 
tetB; that is, the prevalence of tetB was higher (P = 0.006) in the groups that received individual 
supplementations of copper or CTC.  Importantly, when examining multiple genes that exhibit 
negative correlations with one another, and when each gene explains similar phenotypes in 
isolates, gene substitution is to be expected.  In other words, when prevalence of one tet gene 
goes up, in the absence of true statistical independence, the other must go down.  As a result, 
explaining which gene was selected for and which was selected against remains difficult.  
Discerning the presence of this relationship is one of the advantages of genotypic analysis over 
the phenotypic testing.  
Another salient feature of the two genes is that whereas the prevalence of tetA seemed to 
decrease through time — irrespective of treatment groups — the prevalence of tetB increased.  
This longer-term secular trend suggests a form of gene substitution at the population (not at the 
individual isolate) level among isolates.  Put another way, this substitution does not occur within 
the isolates themselves; rather, it implies that isolates with tetB tended to outcompete those with 
tetA over time.  The features that result in a preferred ecological niche for the former may well 
have nothing to do with the specific tet genes themselves.  However it has been observed 
elsewhere (188, 189) that MDR is most common in neonatal farm animals and typically trends 
downward through time, and in our study tetA was significantly associated with higher MDR 
131 
 
counts than tetB.  Although the prevalence of tetA was higher in the CTC-supplemented group 
(69% (95% CI = 65–72%) than in the non-CTC–supplemented group (64% (95% CI = 60–68%), 
CTC did not significantly expand the tetA gene across all treatment periods.  Overall, the 
prevalence of tetB was 49% (95% CI = 45–54%) in the CTC-supplemented group and 47% (95% 
CI = 42–51%) in the non-CTC–supplemented group.  Adjusted for clustering effects by pen and 
repeated sampling, however, CTC and copper supplementations significantly expanded the tetB 
gene.  In contrast to previous studies (117, 195) that reported higher prevalence of tetB over tetA 
among porcine E. coli, our study indicated that the overall prevalence of tetA (66%: 95% CI = 
64–69%) is significantly higher than that of tetB (48%: 95% CI = 45–51%).  This difference is 
most readily explained by age differences in the study populations in that Boerlin et al., 2005 
(195) detected higher tetB in finisher pigs, which is in agreement with our observation that tetA 
was gradually replaced by tetB as the pigs aged.  Unlike our study, in which we tested all E. coli 
isolates for genotypes, Bryan et al., 2004 (117) tested only those portions of E. coli that had a 
tetracycline MIC value of ≥93 µg/ml.  We also observed that tetB confers a higher level of 
tetracycline resistance to E. coli isolates than other tet genes, typically at MIC values greater than 
32 µg/ml of tetracycline. 
The pcoD gene was selected in this study based on the fact that the gene products of the 
pcoABCD operon are expressed on polycistronic message from the same promoter that results in 
stoichiometric production of the four gene products (56) required for full copper resistance in E. 
coli (55).  This gene was also targeted previously by others (Dr. Henrik Hasman, National Food 
Institute, Lyngby, Denmark: personal communication).  The level of pcoD detection did not 
differ significantly (P > 0.05) by treatment group, suggesting that the pcoD gene did not 
contribute to copper resistance of the E. coli isolates in a meaningful way at this level of copper 
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supplementation.  High level of copper in the diets of pigs in this study did not appear to affect 
the prevalence of the gene (pcoD), which has been reported (55, 122) to be important for 
bacterial resistance among E. coli.  This result is in direct contrast with results seen for Gram 
positive enterococci in pigs and cattle when copper was supplemented at high levels, resulting in 
expansion of the isolates that harbor the tcrB gene (42-44).  A combination of both plasmid and 
chromosomal genes are required for copper resistance in E. coli, such that resistance to high 
copper concentrations can be expressed while maintaining the intracellular copper concentrations 
required for normal physiological functions (36).  The high doses of copper (125 to 250 ppm) 
used in U.S. swine production (46), or exposure to same in the ambient environment, for over six 
decades (36) may have led enteric Gram negative bacteria to become intrinsically adapted to 
higher copper concentrations.  This adaptability confers a survival advantage in the 
gastrointestinal tract in the presence of high copper concentration (156).  
The highest prevalence of blaCMY-2 (compared with other genes) observed in the present 
study, and its significant association with higher MDR counts in the absence of selective 
pressure by ceftiofur use in our study population, suggests its maintenance through genetic 
linkage with other antimicrobial resistance genes (particularly with tetA).  Factors that contribute 
to long-term maintenance of the blaCMY-2 gene in the absence of ceftiofur use, however, are 
unclear (58, 196).  The blaCMY-2 gene is commonly associated with large plasmids that can also 
carry other antimicrobial resistance genes (197) such as tetA (64); thus, selection pressure 
exerted by other antimicrobials such as tetracyclines could result in the dissemination of the 
blaCMY-2 gene (58).  Funk et al., 2006 (23), for example, reported that AGP use of CTC in pigs 
was positively associated with the occurrence of MDR (including resistance to ceftriaxone) 
Gram negative bacteria. 
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 Associations between phenotypic and genotypic resistance  
The prevalences of tetA, tetB and blaCMY-2 were significantly associated with 
phenotypically tetracycline resistance while no significant association was observed for pcoD 
gene.  The prevalence of tetA (67% [95% CI = 65–70%), tetB (49% [46–52%]) and blaCMY-2 
(73% [70–75%]) in the phenotypically tetracycline-resistant isolates (n = 1,119) were 
significantly higher than in the very few tetracycline-susceptible isolates (33 out of 1,152).  On 
the other hand, the corresponding prevalences in the phenotypically tetracycline-susceptible 
isolates (n = 33) were 27% (95% CI = 13–46%) for tetA, 9% (95% CI = 1.9–24%) for tetB, and 
45% (95% CI = 28–64%) for blaCMY-2; however, no significant difference was found between 
tetracycline-resistant and -susceptible isolates with respect to the prevalence of the pcoD gene (P 
= 0.808).  This indicates the presence of co-selection between tetracycline and ceftiofur 
resistances as previously reported (23) and lack of such co-selection between tetracycline and 
copper resistances in the E. coli population studied.  The detection of tet genes from 
phenotypically tetracycline susceptible isolates is an advantage of using direct genotypic 
examination of AMR since resistance genes might not be phenotypically expressed.    
The prevalence of tetB (61% [95% CI = 58–64%) was significantly higher among E. coli 
isolates (n = 827) with MIC values >32 µg/ml than in isolates (n = 325) with MIC values of ≤32 
µg/ml (15% [95% CI = 11–19%]).  On the other hand, tetA (90% [86–93%] vs. 57% [95% CI = 
53–60%]) and blaCMY-2 (85% [95% CI = 81–89%] vs. 67% [95% CI = 64–70%]) were 
significantly more likely in isolates with tetracycline MIC values ≤32 µg/ml than in isolates with 
MIC values >32 µg/ml.  This, perhaps paradoxically, suggests that use of higher sustained levels 
of tetracycline could favor lower MDR count isolates harboring tetB vs. higher MDR count 
isolates with tetA and blaCMY-2.  On the other hand, using lower levels of tetracycline, such as by 
134 
 
feeding tetracyclines for growth promotion, could result in a greater expansion of the high MDR 
count fraction, or the fraction of E. coli harboring a gene coding for resistance to a critical 
antimicrobial such as third generation cephalosporins (ceftiofur). 
  Whether or not isolates were phenotypically resistant to ceftiofur, the prevalence 
of both tetA and blaCMY-2, as expected, were significantly higher in the ceftiofur-resistant isolates 
(n = 746) than in the ceftiofur-susceptible isolates (n = 406) (79% [95% CI = 75–81%] vs. 44% 
[95% CI = 39–49%] for tetA and 97% [95% CI = 95–98%] vs. 27% [95% CI = 22–31%] for 
blaCMY-2).  For tetB and pcoD, however, the relationships were opposite.  The prevalence of tetB 
and pcoD were significantly higher in the ceftiofur-susceptible isolates than in ceftiofur-resistant 
isolates (68% [63–72%] vs. 37% [34–41%] for tetB and (29% [95% CI = 24–33%] vs. 9% [7–
11%] for pcoD).  This result once again indicates that the strong association observed between 
phenotypic ceftiofur and tetracycline resistances may be mediated mainly through tetA.  We also 
observed that tetA and blaCMY-2 were positively associated, supporting the premise that these two 
genes were likely co-localized on a single mobile genetic elements such as plasmids or 
transposons (195).  Previous reports found both genes harbored on the same IncA/C plasmid in 
cattle (64).  
The remarkably opposite features of tetA and tetB genotypic prevalence through time are 
vividly illustrated by the fact that they exhibit a strong (75%) negative association among 
themselves, most often avoiding joint carriage within the same isolate.  This negative association 
between tetA and tetB is also consistent with previous reports from porcine E. coli isolates (195). 
It is possible that tetA and tetB are carried on plasmids of the same incompatibility group (195) 
or that most of the tetB genes detected in our E. coli population are also carried on the 
chromosome (114, 115).  Carrying a duplicative resistance trait on a plasmid would yield little 
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fitness advantage.  The finding that tetB was not significantly associated with MDR suggests this 
could be due to its chromosomal location.  
Using a single multiplex PCR assay for tetA, tetB, tetC, and tetE showed 98% agreement 
between the detection of any of these genes and phenotypic tetracycline resistance.  The 
agreement between tetA or tetB detection (or both) and tetracycline resistance was 98%; thus, it 
seemed possible to predict most of the phenotypically expressed tetracycline resistance in these 
weaned pigs by targeting only tetA and tetB.  As previously reported (117, 195), tetracycline 
resistance in porcine E. coli is mainly conferred by tetA and tetB.  From the E. coli isolates that 
were phenotypically ceftiofur resistance (n = 746), 97% of them were also positive for blaCMY-2 
gene suggesting that targeting blaCMY-2 by PCR can predict most of phenotypic ceftiofur 
resistance in E. coli population. 
The median copper MIC (P < 0.05) and the survivor functions (log rank test χ2 (1df) = 
1.2; P = 0.2749) of the E. coli isolates did not significantly differ by pcoD gene carriage.  This 
indicates that the pco gene did not significantly confer copper resistance in the population of E. 
coli studied.  This finding is in contrast to Enterococcus spp., in which the presence of a single 
transferable copper resistance (tcrB) gene confers higher levels of resistance to copper, and MIC 
values are typically very low in its absence (42-44).  It has been reported that E. coli and other 
Gram negative enteric bacteria such as Salmonella are generally more tolerant to high copper 
concentration, perhaps through chromosomally mediated copper resistance, that gives them a 
survival advantage over other bacteria in the gut of pigs (156).   
 Association between resistance genes and multidrug resistance  
The most remarkable feature we observed was that higher phenotypic MDR counts 
(defined in terms of the number of antimicrobials to which E. coli isolates were resistant) were 
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typically associated with either blaCMY-2 or tetA.  On the other hand, the presence of either of 
tetB or pcoD was associated with lower MDR.  Despite the fact that elevated copper 
supplementations in our study did not appear to favor pcoD-containing isolates, that such a 
possibility exists to select for lower levels of copper resistance and against critically important 
antimicrobials is inviting.  In the absence of the following specific resistance genes, the median 
number of antimicrobials to which isolates were resistant was 4 (95% CI = 4–5) for tetA-
negative, 4 (95% CI = 3–4) for blaCMY-2-negative, and 8 (95% CI = 8–8) for tetB-negative or 
pcoD-negative isolates.  In the presence of the genes, the corresponding median values were 8 
(8–9) for tetA-positive, 9 (8–9) for blaCMY-2-positive, 6 (6–7) for tetB-positive, and 4 (95% CI 
=4–6) for pcoD-positive.  
A higher MDR count was found when the blaCMY-2 gene was detected in combination 
with tetA or tetB; in fact, 38% of the 1,152 isolates carried both tetA and blaCMY-2 and exhibited 
a median phenotypic MDR count of 9.  We observed the same scenario with a number of 
different antimicrobial classes (max of 8) to which isolates were resistant; the median number of 
antimicrobial classes to which isolates were resistant was 6 in the presence of tetA or blaCMY-2 
genes, but in their absence the median was 3.  In the presence of tetB or pcoD genes, the median 
was 5 and 4, respectively, and in their absence the median was 6.  The presence of blaCMY-2 in 
Salmonella has been reported to be associated with MDR (60).  The IncA/C plasmids known to 
carry blaCMY-2 can confer resistance to a diverse group of drugs and have wide host range (64, 
198, 199); thus, it is possible that tetA and blaCMY-2 genes are co-localized and widespread on 
these promiscuous plasmids.  On the other hand, tetB could be mainly chromosomal, or perhaps 
the plasmid carrying it does not harbor resistance to other drugs.  The plasmid carrying the pcoD 
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gene may be rare and seems less likely to carry resistance determinants to other drugs; however, 
our study did not include plasmid analyses, so such associations remain statistical in nature. 
Apart from E. coli, the pco gene can be found in other enteric Gram negative bacteria, 
such as Salmonella (36).  The pco gene has been argued to be auxiliary to the chromosomally 
mediated copper homeostasis mechanisms; thus, phenotypically observed high tolerance in our 
E. coli population could be a result of intrinsic tolerance to copper exposure and, therefore, less 
dependent on the pco gene (56).  In E. coli, plasmid-borne copper resistance is linked with the 
chromosomal system for full copper management (52, 56).  Thus, plasmid and chromosomally 
mediated copper handling in E. coli should be viewed together as conferring copper resistance 
together (46).  
In conclusion, CTC supplementation expanded the E. coli population harboring tetB over 
tetA, and gene substitution at the bacterial population level as pigs age likely explains the 
increase in tetB prevalence.  The observed high prevalence of the blaCMY-2 gene suggests that 
ceftiofur resistance is readily maintained in the absence of ceftiofur use in these pig cohorts, 
most likely through genetic linkage to tetA.  The role of copper supplementation in swine 
production and pco-mediated copper resistance in E. coli need to be further explored because the 
strong negative association with tetA and blaCMY-2 points to potential opportunities to select for a 
more innocuous tetracycline resistance profile. 
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Figure 4.1.  Adjusted predictions of the prevalence of resistance genes detected from E. coli (n = 1,152) obtained from fecal 
samples of weaned pigs supplemented with chlortetracycline (CTC), copper, both or neither.
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Figure 4.2.  Bivariate analysis of tetA and tetB genes detected from E. coli (n = 1,152) obtained from feces of weaned pigs 
supplemented with chlortetracycline (CTC), copper, both or neither.
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Figure 4.3.  Distribution of genotypic profiles for four resistance genes detected from E. coli 
isolates (n = 1,152) obtained from feces of weaned pigs supplemented with 
chlortetracycline, copper, both or neither.
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Figure 4.4.  Median multidrug resistance count of E. coli (n = 1,152) on the basis of the number of antimicrobials to which 
resistance was exhibited. 
 
A) Box plot depicting genotypic profiles (tetA, tetB, and blaCMY-2) vs. number of antimicrobial agents.  A = tetA, B = tetB, and CMY2 
= blaCMY-2; n represents the number of isolates with the unique genotypic combination.   
 
B) Bar graph of median number of antimicrobials phenotypically resistant vs. genotypic profiles.  Numbers on the bar graph represent 
the number of isolates with unique genotypic profiles.
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Table 4.1.  Primer sequences, amplicon size and positive control strains used for PCR detection of antimicrobial resistance 
genes from fecal E. coli (n = 1,152) obtained from weaned pigs that received chlortetracycline, copper, both or neither 
Primers used Positive control 
Resistance 
gene 
Primer Primer sequence (5’–3’) Amplicon 
size (bp) 
Reference E. coli 
strains 
Gene 
bank 
accession 
no. 
Source 
tetA tetA-F 
tetA-R 
GCT ACA TCC TGC TTG CCT TC 
CAT AGA TCG CCG TGA AGA GG 
210 (194) D20-15 X61367 Marilyn 
Roberts
a 
tetB tetB-F 
tetB-R 
TTG GTT AGG GGC AAG TTT TG 
GTA ATG GGC CAA TAA CAC CG 
659 (194) D20-16 J01830 >> >> 
tetC tetB-F 
tetB-R 
CTT GAG AGC CTT CAA CCC AG 
ATG GTC GTC ATC TAC CTG CC 
418 (194) D20-6 J01749 >> >> 
tetE tetB-F 
tetB-R 
AAA CCA CAT CCT CCA TAC GC 
AAA TAG GCC ACA ACC GTC AG 
278 (194) D22-14 L06940 >> >> 
blaCMY-2 585F 
1038R 
CAG ACG CGT CCT GCA ACC ATT AAA 
TAC GTA GCT GCC AAA TCC ACC AGT 
454 (154) M1  University of 
Illinois, 
Chicago  
pcoD pcoD-F 
pcoD-R 
CAGGAACGGTGATTGTTGTA 
CCGTAAAATCAAAGGGCTTA 
700 This study E. coli 
(pRJ1004) 
X83541.1 Henrik 
Hasman
b 
 
a 
University of Washington, Seattle, WA. 
b 
National Food Institute, Lyngby, Denmark.
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Table 4.2.  Prevalence (%) of resistance genes among fecal E. coli isolates (n = 1,152) from 
weaned pigs fed diets supplemented with chlortetracycline (CTC), copper, both or neither 
cross-tabulated by treatment group and period 
Resistance 
gene 
Treatment 
group 
Treatment period
a* 
 
Before (n = 48)
d 
During (n = 144)
d
 After (n = 96)
d
 P-value
b 
tetA Control 89.6 (77.3, 96.5) 64.6 (56.2, 72.4) 58.3 (47.8, 68.3) < 0.001 
CTC 81.3 (67. 4, 91.1) 63.2 (54.8, 71.1) 51.0 (40.6, 61.4) 0.001 
Copper 77.1 (62.7, 88.0) 59.0 (50.5, 67.1) 57.3 (46.8, 67.3) 0.041 
Copper + CTC 79.2 (65, 89.5) 75.7 (67.9, 82.4) 71.9 (61.8, 80.6) 0.610 
P-value
c 
0.371 0.019 0.024  
tetB Control 29.2 (17.0, 44.1) 35.4 (27.6, 43.8) 53.1 (42.7, 63.4) 0.005 
CTC 52.1 (37.2, 66.7) 50.0 (41.6, 58.4) 65.6 (55.2, 75.0) 0.048 
Copper 47.9 (33.3, 62.8) 50.0 (41.6, 58.4) 59.4 (48.9, 69.3) 0.274 
Copper + CTC 52.1 (37.2, 66.7) 34.7 (27.0, 43.1) 51.0 (40.6, 61.4) 0.016 
P- value
c
 0.067 0.004 0.161  
tetC Control 4.2 (0.5, 14.3) 1.4 (0.2, 4.9) 0.0 (0.0, 3.8) 0.111 
CTC 4.2 (0.5, 14.3) 0.7 (0.0, 3.8) 1.0 (0.0, 5.7) 0.167 
Copper 6.3 (1.3, 17.2) 0.0 (0.0, 2.5) 0.0 (0.0, 3.8) 0.004 
Copper + CTC 18.8 (8.9, 32.6) 2.8 (0.8, 7.0) 0.0 (0.0, 3.8) <0.001 
P- value
c
 0.044 0.226 1.000  
tetE Control 0.0 (0.0, 7.4) 2.8 (0.8, 7.0) 0.0 (0.0, 3.8) 0.228 
CTC 0.0 (0.0, 7.4) 0.7 (0.0, 3.8) 2.1 (0.3, 7.3) 0.581 
Copper 4.2 (0.5, 14.3) 4.2 (1.5, 8.8) 1.0 (0.0, 5.7) 0.350 
Copper + CTC 0.0 (0.0, 7.4) 1.4 (0.2, 4.9) 0.0 (0.0, 3.8) 0.666 
P-value
c
 0.132 0.231 0.622  
blaCMY-2 Control 77.1 (62.7, 88.0) 69.4 (61.2, 76.8) 70.8 (60.7, 79.7) 0.586 
CTC 79.2 (65.0, 89.5) 75.0 (67.1, 81.8) 60.4 (49.9, 70.3) 0.007 
Copper 77.1 (62.7, 88.0) 76.4 (68.6, 83.1) 58.3 (47.8, 68.3) 0.021 
Copper + CTC 83.3 (69.8, 92.3) 79.2 (71.6, 85.5) 65.6 (55.2, 75.0) 0.023 
P-value
c
 0.854 0.283 0.267  
pcoD Control 25.0 (13.6, 39.6) 18.8 (12.7, 26.1) 7.3 (3.0, 14.4) 0.007 
CTC 18.8 (8.9, 32.6) 15.3 (9.8, 22.2)  14.6 (8.2, 23.3) 0.170 
Copper 16.7 (7.5, 30.2) 11.1 (6.5, 17.4) 19.8 (12.4, 29.2) 0.781 
Copper + CTC 29.2 (17.0, 44.1) 13.9 (8.7, 20.6) 15.6 (9.0, 24.5) 0.057 
P-value
c
 0.458 0.338 0.083  
*Mean proportions of isolates and exact binomial 95% confidence interval. 
a
Treatment period (before = day 0), during (days 7, 14, and 21), and after (days 28 and 35). 
 
bLR χ2 P-value with 2 df comparing treatment periods by treatment group. 
cLR χ2 P-value with 3 df comparing treatment group by treatment period. 
d
Number of E. coli isolates per treatment group per treatment period. 
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Table 4.3.  Model-defined pairwise correlations (with 95% CI) based on a multivariate probit model, among four resistance 
genes in fecal E. coli (n = 1,152) from weaned pigs fed diets supplemented with chlortetracycline, copper, both or neither  
 tetA tetB blaCMY-2 pcoD 
tetA 1    
tetB -75.3 (-81.0, -67.8) 1   
pcoD -20.9 (-38.0, -2.2) 33.4 (18.9, 46.4) -39.7 (-53.5, -23.9) 1 
blaCMY-2 63.5 (50.4, 73.8) -38.5 (-51.7, -23.4) 1  
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Table 4.4. Distribution of tetracycline resistance genes detected from fecal E. coli isolates 
obtained from weaned pigs experimentally supplemented with chlortetracycline, copper, 
both or neither 
tet genes Frequency Percentage 
tetA 544 47.2 
tetB 329 28.6 
tetC 1 0.1 
tetE 12 1.0 
tetA-tetB 202 17.5 
tetA-tetC 5 0.4 
tetA-tetE 3 0.3 
tetB-tetC 8 0.7 
tetB-tetE 3 0.3 
tetA-tetB-tetC 10 0.9 
none  35 3.0 
Total 1,152 100.0 
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Chapter 5 - Effects of chlortetracycline and copper supplementation 
on the prevalence, distribution, and quantity of antimicrobial 
resistance genes in the feces of weaned pigs 
 Abstract 
Use of antibiotics such as chlortetracycline (CTC) in food animals is fiercely debated as a 
cause of antimicrobial resistance (AMR) in human pathogens and alternatives to antibiotics such 
as heavy metals have been proposed.  We used metagenome-based approaches to investigate the 
effects of CTC and copper supplementation on AMR in the gut microbial ecology of pigs.  Total 
community DNA was extracted from 569 fecal samples collected over a 6-week period from 
groups of 5 pigs housed in 32 pens that were randomized to receive either control, CTC, copper, 
or copper plus CTC regimens.  Qualitative and quantitative PCR were used to detect the presence 
of 14 tetracycline resistance (tet) genes and to quantify gene copies of tetA, tetB, blaCMY-2 (for 
ceftiofur resistance gene), and pcoD (copper resistance genes), respectively.  The prevalence of 
tetA and tetB detection decreased over the treatment periods, whereas the prevalence of tetC and 
tetA(P) increased.  CTC and copper plus CTC supplementation increased both the prevalence and 
gene copy numbers of tetA, while decreasing both the prevalence and gene copies of tetB, when 
compared with the control group.  Although the mean log10 gene copies of tetA, tetB, and 
blaCMY-2 decreased with time and as pigs aged, that of pcoD initially increased during the first 
and second weeks of the treatment period and thereafter declined.  In conclusion, tet genes were 
initially very diverse in the gut bacterial community of weaned pigs; thereafter, copper and CTC 
supplementation differentially impacted the prevalence and quantity of tetracycline, ceftiofur and 
copper resistance genes. 
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 Introduction 
Antimicrobial resistance (AMR) is one of the major public health challenges of the 21st 
century (1, 66, 200), and international collaboration is needed to combat this complex and 
multifactorial issue (67, 85).  Public health concern about AMR is largely focused on the use of 
antimicrobial growth promoters (AGP) in livestock; however, prevention and control uses of 
antibiotics are also under considerable scrutiny (11).  Chlortetracycline (CTC) and 
oxytetracycline are among the most commonly used antibiotics in pig production in the United 
States (17, 18).  Tetracycline resistance is acquired mainly through mobile genetic elements 
(plasmids and transposons) (31) and represents the most commonly observed resistance among a 
wide range of bacteria (105, 201).  Forty-six tetracycline resistance (tet and otr) genes are 
currently known
4
.  
Alternatives to antimicrobials are being sought because of the public health risk of AMR 
associated with the use of AGPs in animals; one option is to use metals such as copper and zinc 
(35).  Copper is an essential trace element that is sometimes used as a growth promoter at a dose 
elevated beyond that which is required for basic metabolic needs (46).  Bacteria exposed to 
metals have also developed the ability to resist high concentrations of metals, including copper 
(79).  Among E. coli, in addition to chromosomally mediated copper homeostasis, a plasmid-
borne copper resistance determinant (pco) has been suggested to confer resistance to copper.  
The pco determinant consists of seven genes arranged in two operons, pcoABCD and pcoRS, 
with pcoE as a separate gene (55, 122).  The pcoABCD genes are normally expressed as a  
polycistronic message from the same promoter under a two-component pcoRS regulatory 
                                                 
4 
http://faculty.washington.edu.marilynr/ 
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system, with stoichiometric production of the four gene products (56); importantly, expression of 
all four genes is required for full resistance (55).  On the other hand, the pcoE gene is not strictly 
required for full expression of copper resistance; however, it acts as a sponge to sequester toxic 
copper which provides additional time needed for the expression of the other pco genes (55).  
Antimicrobial resistance has been studied largely using culture-based methods, which 
typically involve bacterial isolation followed by sensitivity testing, or sometimes by testing 
bacterial DNA for the presence of AMR genes (149).  These isolate-based methods 
underestimate the true magnitude and also the dynamics of AMR because the majority of 
bacteria are non-cultivatable on culture media (202).  Quantitative methods, based on the 
determination of gene copies from total community DNA, can give more accurate information on 
the impact of antimicrobial use on AMR load in any given bacterial ecology (149), such as the 
pig gut.  Complete sequence analysis of IncA/C plasmids originating from cattle E. coli has 
shown that this plasmid typically carries two copies of the blaCMY-2 genes, along with other 
resistance genes including tetA (64).  Copper supplementation favoring plasmid-borne pco genes 
also could select for antibiotic resistance such as tetracycline and ceftiofur (50).  Therefore, we 
used a culture-independent total community DNA approach to investigate the impact of 
therapeutic doses of in-feed CTC and elevated levels of copper supplementation on antimicrobial 
and copper resistance genes among the gut bacteria of pigs.  Our hypotheses were that the in-
feed use of tetracycline (CTC) expands certain tetracycline resistance genes and that copper 
supplementation in pigs differentially co-selects for certain tetracycline and ceftiofur resistance 
genes. 
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 Materials and methods 
 Experimental design and DNA extraction 
The study included a total of 569 fecal samples collected over 6 weeks from 4 treatment 
groups (8 replicates of 5 pigs per pen; n = 160 weaned pigs total), starting at three weeks of age, 
that were fed either: only the basal diet (control), the basal diet supplemented with copper at 125 
mg/kg of feed, the basal diet plus CTC at 550 mg/kg of feed of CTC, or else copper plus CTC at 
above dosages.  The experimental design is schematically illustrated in Fig. 5.1.  The study was 
performed in the segregated early weaning facility at Kansas State University, and animal use 
protocols were approved by the university institutional animal care and use committee (IACUC# 
2773).   
Total community DNA was extracted from 200 mg of the fecal samples using a QIAamp 
DNA Stool Mini Kit (QIAGEN, Valencia, CA) following the manufacturer’s instructions.  The 
DNA concentration was measured using a NanoDrop 8000 spectrophotometer (Thermo Fisher 
Scientific Inc., Waltham, MA) and stored at -20
0
C until used.  E. coli strains positive for tet 
genes were obtained from the laboratory of Dr. Marilyn Roberts (Washington State University).  
Positive E. coli strain for blaCMY-2 was originally obtained from University of Illinois (203) and 
positive E. coli strain with pRJ1004 for pcoD was obtained from Dr. Henrik Hasman (the 
National Food Institute, Technical University of Denmark).  DNA used as positive controls were 
extracted from these E. coli strains with the PureYield Plasmid Miniprep System (Promega 
Corporation, Madison, WI) following overnight culture in Luria-Bertani broth (Difco, BD, 
Sparks, MD) incubated at 37°C.  
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 PCR detection of tetracycline resistance genes 
A previously developed multiplex PCR protocol and primers (194) with a pre-optimized 
multiplex PCR master mix kit (QIAGEN, Valencia, CA) were used to detect 14 different tet 
genes, grouped into 4 multiplex PCR assays, from each fecal sample (Table 5.1).  E. coli strains 
with tet-positive plasmids were obtained from the laboratory of Dr. Marilyn Roberts 
(Washington State University).  A multiplex PCR reaction mixture of 50 µl consisted of 17 µl of 
nuclease-free water, 25 µl of master mix, 5 µl of the primer mix, and 3 µl of DNA template.  A 
positive control mixture for each of the multiplex assays and a no-template control were included 
on each plate.  Thermal cycling conditions were initial activation at 95°C for 15 min followed by 
31 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 90 s, and extension at 72°C for 
90 s with a final extension at 72°C for 10 min.  PCR products were analyzed using capillary gel 
electrophoresis in the QIAxcel system (QIAGEN, Valencia, CA).  
 Quantification of resistance genes from fecal community DNA 
We used Brilliant II SYBR green master mix (Agilent technologies, La Jolla, CA)–based 
qPCR for quantification of tetA, tetB, blaCMY-2, and pcoD genes from total fecal community 
DNA.  All qPCR assays were performed in duplicate reactions in Mx3005P thermocycler 
(Stratagene Corporation, La Jolla, CA), and amplification data were analyzed with MXPro 4.1 
(Stratagene Corporation, La Jolla, CA) software.  The qPCR standard curves, defined as gene 
copy numbers versus cycle threshold (Ct) values, were generated using purified PCR products 
obtained from positive controls for each of the four genes.  Ten-fold serial dilutions were made 
from known concentrations of purified PCR products and 10
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copies per reaction were used to create a standard curve for tetA and pcoD genes.  For tetB and 
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dilutions were used to generate the standard curves.  
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Standard curves were run in triplicate on every plate for all unknown samples.  Non-template 
control (NTC), ATCC 25922 E. coli strain (negative control strain), along with template DNA 
from the positive control strains (positive control) were included in all qPCR reaction plates.  
The primers used for the quantification of the resistance genes are given in Table 5.2. 
For the quantification of tetA, total qPCR reaction mixture of 20 µl consisted of 6.25 µl 
water, 10 µl master mix (Agilent Technologies, La Jolla, CA), 0.75 µl reference dye (30 nm), 0.5 
µl each of the primers, and 2 µl template DNA.  The thermal cycling program was 45 cycles of 
denaturation at 95°C for 15 s, annealing at 60°C for 30 s, and extension at 72°C for 28 s.  For 
tetB quantification, a total volume of 20 µl reaction consisted of 6.825 µl of water, 10 µl of 
master mix, 0.375 µl of reference dye, 0.4 µl of each of the primers, and 2 µl of template DNA.  
Thermal reaction conditions were 40 cycles of denaturation at 95°C for 30 s, annealing at 60°C 
for 30 s, and extension at 72°C for 30 s.  Gene copies of the blaCMY-2 gene were quantified in a 
20-µl mixture consisting of 5.25 µl of water, 10 µl of master mix, 0.75 µl of reference dye, 1 µl 
each of the primers, and 2 µl of template DNA.  Thermal profiles consisted of 40 cycles of 
denaturation at 95°C for 10 s, annealing at 52°C for 30 s, and extension at 79°C for 17 s.  For 
pcoD gene quantification, 20-µl reaction volume comprised of 6.45 µl of water, 10 µl of master 
mix, 0.75 µl of reference dye, and 0.4 µl of the primers and 2 µl of DNA template.  The qPCR 
thermal conditions were 35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, 
and extension at 72°C for 1min.  In all qPCR assays, melting curve analysis was performed with 
a final dissociation step at 95°C for 1 min, 55°C for 30 s, and 95°C for 30 s.  All qPCR assays 
were initiated by a denaturation step of 95°C for 10 min to activate the HotStarTaq DNA 
polymerase enzyme. 
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 Statistical analysis  
A full factorial analysis in STATA 12.1 (STATA Corporation, College Station, TX) was 
used to analyze the effects of treatments over the treatment periods.  In all statistical analyses a 
P-value < 0.05 was considered significant for identifying differences across treatment groups or 
treatment periods and Bonferroni-adjusted significance tests were used for multiple comparisons.  
Model selection was based on manual elimination of non-significant terms starting with a full 
model (a model that included all 3- and 2-way interactions and the main effects of the two 
treatments and treatment period), and thereafter first removing the non-significant highest-order 
interaction, then 2-way interactions, and finally main effects terms, where applicable.  
For analysis of the prevalence of tet genes, the weekly sampling dates were categorized 
into pretreatment (day 0), during treatment (days 7, 14, 21), and post-treatment periods (days 28 
and 35).  Binary outcomes (presence/absence) of the tet genes were initially presented as 
percentages along with the 95% exact binomial confidence intervals, and Fisher’s exact test or 
the likelihood ratio test (LRT) were used, as appropriate, to contrast the prevalence of the genes 
by treatment group and treatment period.  The median (with 95% CI) was used to compare the 
number of tet genes detected per fecal sample by treatment groups using Kruskal-Wallis test.  
Because all other genes had sparse cells, indicating either low prevalence or high saturation, 
further multivariable statistical analyses were performed only for tetA, tetB, and tetA(P) genes.  
Random effects logistic regression was used to analyze the fixed effects of treatment, treatment 
period, and their interactions by including pen as a random effect in the model.  Bivariate probit 
regression with a robust clustered standard error accounting for pen effect was used to model the 
binary outcomes of tetA and tetB simultaneously to adjust for their biological dependencies.   
Ordinal logistic regression with a robust standard error to adjust for clustering by pen was fit to 
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evaluate the effect of treatment and treatment period on the number of different tet genes 
detected per fecal sample.  Our unit of analysis was the binary outcome for each fecal sample 
(presence or absence of the tet genes) and our experimental unit was pen.  
 Quantitative data were analyzed using multilevel mixed-effects linear regression models 
to assess the effects of the two treatments and sampling day on three outcomes: 1) absolute (non-
standardized) gene copy numbers per gram of feces; (2) standardized quantities of the genes 
normalized to the total DNA concentration in the original fecal samples; and (3) relative 
quantities of tetA to tetB per gram of feces.  The ratio of tetA to tetB was derived by dividing 
tetA gene copies by tetB gene copies present in 1 g of feces.  Genes were normalized by dividing 
gene copies per µl to the initial DNA concentration (expressed as ng/µl) and were subsequently 
log10 transformed.  The normality of the log10 transformed gene copies per gram of wet feces was 
tested graphically by histogram and Q-Q plots.  The model was a three-level hierarchical model 
in which individual gene copy readings (our unit of analysis) were nested within fecal sample 
(duplicate reactions per sample), which in turn was nested within pen (our experimental unit).  
Each reaction reading from qPCR was used as the unit of analysis.  On each sampling day fecal 
samples were collected from three pigs among the five pen mates; therefore, pig was not 
included as a random effect in the model.  The model included the random effects of duplicate 
reactions per sample and pen, and fixed effects of treatments, sampling day, and their 
interactions.  Three reactions for tetA and 11 reactions for blaCMY-2 had no CT values.  Only one 
of the duplicate readings had no CT value, which did not yield a negative result at the sample 
level.  To deal with missing observations, these observations were assigned a value of zero, and 
for later analyses, we added half the value of the lowest nonzero value observed in the samples 
(following Boyer et al., 2013 (204)) to all observations.  The estimated gene copy numbers in 
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each reaction were back-calculated to gene copies per gram of wet feces for each sample, which 
was then transformed to log10 to achieve normality.   Multivariate multiple linear regression 
models were used to simultaneously model the four resistance genes (tetA, tetB, blaCMY-2 and 
pcoD) together to account for their biological dependencies; that is, the genes were quantified 
from the same fecal sample arising from pigs under the same treatment and day effects.  Pairwise 
Pearson correlations between resistance genes with Bonferroni-adjusted significance tests to 
adjust for multiple comparisons were calculated, and scatter plots were generated to display these 
relationships.  
 Results  
 Prevalence of tet genes  
Three genes, tetD, tetK, and tetS, were not detected in any of the fecal samples, and tetE 
(from two control pens) and tetG (one sample from a control and copper pen) were each detected 
in only two fecal samples.  The tetO, tetQ, and tetX genes were detected in 100% of the fecal 
samples, regardless of the treatment groups.  The prevalence and distribution of the remaining 
six genes (tetA, tetB, tetC, tetL, tetM and tetA(P)), cross tabulated by treatment groups and 
treatment period, are shown in Table 5.3.  Prevalence of tetB was marginally different 
(Bonferonni-adjusted P = 0.04) among the treatment groups during the treatment period.  The 
prevalence of tetA(P) was significantly higher (P = 0.003) in the CTC plus copper supplemented 
group (86%; 95% CI = 76-93%) compared with the control group (60%; 95% CI = 48-71%) 
during the treatment period.   While the prevalence of tetB significantly (P < 0.001) decreased 
over the subsequent treatment periods, that of tet(P) increased significantly (P < 0.001), 
reflecting a secular trend (Table 5.3).  In the copper supplemented group, the prevalence of tetA 
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in the post-treatment samples (63%; 95% CI = 22-51%) was significantly (P = 0.011) lower than 
in the pre-treatment samples (95%; 95% CI = 76-100%).  Since regression models for most of 
the individual tet genes failed to converge, either as a result of scarcity or saturation, only tetA, 
tetB and tetA(P) were modeled beyond these descriptive analyses. 
 Multilevel mixed-effects logistic regression analysis for the prevalence of tetA, tetB 
and tetA(P)  
Results of individual multilevel mixed-effects logistic regression analysis for tetA, tetB, 
and tetA(P) analyses are shown in Fig. 5.2.  The single three way (CTC*copper* treatment 
period) and all two way interactions (CTC*copper, CTC* treatment period and copper* 
treatment period) were not significant (P > 0.05).  Overall, CTC supplementation was 
significantly associated with increased detection of tetA (OR = 1.7 [95% CI = 1.1-2.8).  The 
detection of both tetA and tetB decreased significantly (P < 0.001) through the treatment period.  
Interestingly, the level of detection of tetA(P) demonstrated a significantly increasing (P < 0.05) 
secular trend across subsequent treatment periods.   
Across all treatment groups and sampling days, unadjusted prevalence of tetA (77% 
[95% CI = 74– 81%]) was significantly higher than that of tetB (57% [95% CI = 53–61%]).  The 
prevalence of tetA was significantly (P < 0.05) higher than that of tetB in the post-treatment 
samples, except for in the CTC-supplemented group.  The prevalence of tetA (83% [95% CI = 
72–91%]) was significantly higher than that of tetB (46.5% [95% CI = 35–59%]) in the copper 
plus CTC–supplemented groups during the treatment period.  Bivariate probit analysis of tetA 
and tetB showed that probability of detecting both genes together dropped significantly from pre-
treatment levels through the treatment period.  Adjusted for biological interdependences (and pen 
effect), a significant (P < 0.001) 3-way interaction was observed between treatment period, 
156 
 
copper, and CTC supplementation for both genes.  The combined supplementation of copper and 
CTC tended to increase tetA only detection, whereas it did not affect tetB only detection in fecal 
samples compared to the control group (Fig 5.3). 
 Analysis of multiple co-detected tet genes using ordinal logistic regression 
The median number of tet genes detected per fecal sample was eight across all samples. 
The median number of tet genes detected per sample did not differ significantly (P > 0.05) 
among the treatment groups across all treatment periods.  The number of genes detected per fecal 
sample ranged from 4–10 (control), 5–9 (copper), 6–9 (CTC), and 5–9 (copper plus CTC).  The 
distributions of the number of tet genes detected per fecal sample is illustrated in Fig. 5.4.  The 
frequency and distribution of the different tet genes combinations is listed in Table 5.4.  Across 
all samples, 26 distinct tet gene combinations were observed.  Control, CTC, and copper plus 
CTC groups each contained 13 unique genotypic profiles, whereas the copper group had 14 
unique profiles.  The top three most common genotypic profiles observed were of 8- and 9-gene 
combinations.  Fecal samples obtained during the treatment period (proportional OR = 0.5 [95% 
CI = 0.3–0.7]) and post-treatment period (proportional OR = 0.5 [95% CI = 0.3–0.9) tended to 
have fewer numbers of tet genes, suggesting a decreasing trend in the diversity of tet genes in the 
fecal flora over time.   
 Quantification of resistance genes from fecal samples 
Model-adjusted mean log10 copies per gram of feces for each of the 4 genes are depicted 
in Fig. 5.5.  Mean log10 copies of tetA, tetB, and blaCMY-2 decreased significantly (P < 0.05) over 
time; however, mean log10 copies of pcoD gene increased significantly (P < 0.001) on days 7 and 
14 and then returned to baseline following day 21.  Mean pcoD gene quantities were 
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significantly higher in the control group than in other treatment groups on day 14, but pcoD gene 
copies in the copper plus CTC group were significantly higher than the control samples on days 
21 and 35 (Fig. 5.5). 
Multivariate analysis (analyzing tetA, tetB, blaCMY-2 and pcoD genes together) gave the 
same conclusion as the individual gene results, with small differences seen in the coefficients 
and the P-values.  The independent variables (copper, CTC, day, and all possible interactions) 
were significant as a group (F23, 1112 = 9.89, P < 0.0001).  Following the multivariate regression, 
all pairwise correlations between residual values of the genes were positive except for tetA and 
pcoD.  The Breusch-Pagan test of independence was significant (χ26 = 590.544, P < 0.0001), 
indicating, as expected, that the residuals of the four genes were not independent from each 
other.  Pairwise correlation analysis of the raw data for the four genes also indicated the presence 
of a significant (P < 0.05) correlation, except between tetA and pcoD genes (Fig. 5.6).  The 
highest (66%) correlation was observed between tetA and blaCMY-2 when compared with the rest 
of the pairwise correlations.  
Results of resistance gene copies, adjusted to initial DNA concentration of the total 
community DNA in the fecal samples, essentially gave the same results as the analysis based on 
non-standardized copies of genes, with minor differences in the coefficients and P-values (Fig. 
5.7).  
Considering the relative ratios of tetA to tetB, the mean copies of tetA generally were 
higher than tetB copies.   The tetA to tetB ratio was significantly different from unity (equality) 
on days 7 (P = 0.015) and 14 (P = 0.006) across all samples and treatment groups compared with 
the baseline.  Copper plus CTC supplementation drove tetA copies even higher on days 14 and 
158 
 
21 when compared to those of control and copper-only supplemented samples on the same 
respective days (Fig. 5.8).  
 Discussion 
Antimicrobial resistance studies in pigs have focused largely on specific bacterial species 
rather than the entire gut microbiota and have mainly used culture-based approaches (25, 205, 
206).  Recently, culture independent approaches based on total community DNA have been used 
to study  the ecology of antimicrobial resistance genes in cattle (149, 154, 207) and in pigs (208, 
209).  In this study, we investigated the effects of supplementation of CTC and copper over a 3-
week period on tetracycline, ceftiofur, and copper resistance elements in the pig metagenome.   
 Tetracycline resistance genes  
We investigated the impact of in-feed CTC and copper supplementations on the 
prevalence and distribution of 14 tet genes (out of potentially 46 genes) based on previous 
reports from cattle (207) and pig (208) metagenomes.  We found a large diversity of tet genes in 
the pig gut, including in control pigs that were not directly exposed to CTC or copper.  This 
result is consistent with previous reports (74, 209-212) indicating high background tetracycline 
resistance in pigs; this can make it difficult to compare and contrast the effects of treatment 
interventions.  The predominant tet genes detected were tetO, tetQ, tetX, tetM, and tetL. The 
tetO, tetQ, and tetM genes encode for ribosomal protection proteins and are found in both Gram 
positive and Gram negative bacteria (28, 29).  The tetL gene, which codes for an efflux protein, 
has been reported mainly from Gram positive bacteria and less frequently from Gram negative 
bacteria (28, 29).  Unlike most of the efflux genes, tetL is found mainly on small transmissible 
plasmids that can integrate into the chromosome of some Gram positive bacteria (28, 29).   
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Similar to our finding, Holman and Chenier (74) also reported tetO and tetQ from 100% of the 
fecal samples of pigs studied, regardless of treatment group.  They also detected tetL and tetM 
among at least 50% of the fecal samples in each treatment group.  Tet(X) is a flavin-dependent 
monooxygenase that inactivates 1st-, 2nd-, and 3rd-generation tetracyclines such as tigecycline 
(15, 120, 121). 
In contrast to the 0% prevalence of tetD and tetS that we observed, Harvey et al., 2009 
(207) reported 87% and 100% prevalence of these genes, respectively, in the feces of beef cattle.  
This result may be attributed to differences in the gut microbiome of cattle versus pigs.  Similar 
to our finding, Harvey et al (207) did not detect tetK from the cattle fecal samples.  In general, 
tetD and tetS genes have been reported exclusively from Gram negative and Gram positive 
bacteria, respectively, of both animal and human origin, whereas tetK is reported both from 
Gram positive (frequently) and Gram negative bacteria (less frequently) (28, 29).  The tetE and 
tetG genes are reported almost exclusively from limited genera of Gram negative bacteria, 
including Salmonella (28, 29); thus, the low prevalence of such genera in these pigs could result 
in low detection of the genes. 
The efflux genes tetA and tetB, found only in Gram negative enteric bacteria, are carried 
on large conjugative plasmids, which also can carry other antimicrobial as well as heavy metal 
resistance genes.  This contributes to a widespread dissemination of multidrug-resistant enteric 
bacteria (28).  The tetB gene has the widest host range among tet genes in Gram negative 
bacteria.  We observed a decrease in the prevalence of both tetA and tetB in fecal community 
DNA across subsequent treatment periods, which could be attributed to an aging effect.  On the 
other hand, we observed an upward trend across the same aging of the pigs in the prevalence of 
tetC and tetA(P) detection.   This overall trend could be the result of a gradual shift in the 
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microbial population of the gut as pigs age and consume more solid feedstuffs (202).  This is 
supported by the increase, or more stable occurrence, of the predominantly Gram positive tet 
genes (A(P), O, Q, L, and M) and a decrease in Gram negative tet genes (A and B).  The tetC 
gene, which encodes for efflux pump proteins, has been reported from most genera of the 
Enterobacteriacae family. Copper supplementation significantly increased the prevalence of 
tetA(P) during the treatment period.  tetA(P), efflux gene, was previously reported from 
Clostridium species, which initially expand and then contract in numbers as pigs age (202, 213).  
Ribosomal protection genes, including tetM-- which has the widest host range, are not 
commonly found among the Gram negative enteric bacteria, probably due to lower levels of 
resistance conferred by this mechanism when compared with the efflux pump genes.  Ribosomal 
protection genes do not appear to provide a major survival advantage for Gram negative enteric 
bacteria, which are likely to be constantly exposed to tetracycline from the modern pig gut 
environment (29).  
Interestingly, in the bivariate analysis of tetA and tetB, tetA only prevalence was 
significantly higher in the copper plus CTC–supplemented group during the treatment period 
compared with the control group.  This result contrasted sharply with the prevalence of tetB-only 
detection which was significantly lowered compared to the control group.  This clearly indicates 
that CTC supplementation, either alone or in combination with copper, selects for a broader 
bacterial population harboring tetA (Fig. 5.3).   
 Quantification of resistance genes 
Quantitative measurements in longitudinal studies of antimicrobial resistance genes based 
on the entire microbiome are crucial to better monitor the dynamics of AMR (62, 154).  To our 
knowledge, this is the first longitudinal study to quantitatively measure and directly compare the 
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abundance of two tet genes (tetA and tetB), a ceftiofur resistance gene (blaCMY-2), and a Gram 
negative copper resistance determinant (pcoD) among fecal samples obtained from pigs treated 
or untreated with copper or CTC.  Log10 mean copies of tetA, tetB, and blaCMY-2 genes all 
decreased over time.  In some measure of contrast, pcoD gene quantities increased at first during 
treatment, followed by a gradual decrease through the remaining sampling days.  All of these 
declines in resistance elements may be due to the aging effect of the pigs as previously reported 
elsewhere (188, 189).  This declining trend in gene copy numbers also could be attributed to 
changes in the underlying bacterial population, with Gram positive bacteria gradually replacing 
Gram negative bacteria as pigs move from post-weaning to grower stages of production (202).   
The four resistance genes we targeted exclusively confer resistance to Gram negative bacteria, 
whereas the underlying bacterial population (as represented by the total community DNA) 
largely expands as a result of an increase in Gram positive bacteria.  
Supplementation with copper alone had opposing effects on the abundance of the tet 
genes as it tended to decrease gene copies of tetA but increase the levels of tetB (Figs. 5.5, 5.7 
and 5.8).  Interestingly, we observed that copper and CTC supplementation significantly reduced 
the quantities of blaCMY-2 on the 7th day after treatment; however, as with tetA, when CTC was 
supplemented alone blaCMY-2 gene copies were higher than in the control group during the 
treatment period (Figs. 5.5 and 5.7).  Paradoxically, the log10 mean copies of pcoD in the control 
group were significantly higher than the copper treatment groups on day 14 (Fig. 5.5).  The pcoD 
gene copies remained more or less constant through time in the entire treatment group.  This 
finding remains unexplained; however, it may be that the advantages conferred by the copper 
resistance gene for Gram negative bacteria (pco) versus that for Gram positive bacteria (tcrB) are 
relatively of a lesser magnitude, as has been shown in MIC distributions in work by others (41, 
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42, 44).  Thus, high doses of copper may select for copper resistant Gram positives like 
Enterococcus spp., where the tcrB gene confers very high levels of resistance, and away from E. 
coli, as an example.  Rouch and Brown (56) earlier pointed out that pco-mediated copper 
resistance is an auxiliary mechanism that cooperates with the host bacterial cell copper 
management systems; in essence, it can modestly extend the range of environmental copper 
concentrations over which the bacterial cell can survive.  
Generally, the gene copies of tetA were several orders of magnitude higher than those of 
tetB and blaCMY-2, indicating that the overall microbial population possesses more tetA.  This 
result was also reflected in the analysis of the ratio of tetA to tetB, in which tetA concentration 
was generally much higher than that of tetB.  Yu et al., 2005 (214) also reported greater 
abundance of tetA from pig manure using qPCR absolute quantification.  The high correlation 
between tetA and blaCMY-2 we observed could indicate that these two genes are genetically linked 
as reported (64) and that ceftiofur resistance can be maintained through co-selection by CTC 
supplementation in pig feed, and in the absence of direct selective pressure from ceftiofur (181).  
We used a relative quantification method by normalizing resistance gene copies to the total DNA 
concentration (instead of a variable referent gene such as 16s rRNA (154)) in the fecal sample.  
This method was also used by Holman and Chenier  (74) to investigate the impact of 
subtherapeutic doses of tylosin and CTC on tet and erm gene copies from pig fecal samples.  In 
our analysis, both non-standardized and standardized methods produced the same conclusions.  
A total fecal community DNA approach does not differentiate whether bacterial DNA is from 
live or dead bacteria; although this is of little consequence for studying gut microflora, it could 
have an impact on studies that extend into the farm environment.  The AMR gene pools can 
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serve as a constant source of horizontal gene transfer among bacterial population sharing the 
same ecology (70).  
The major drawback of the total community approach is that it is impossible to attribute 
the resistance genes to particular bacteria.  In essence, this makes such analysis classically 
ecological in nature, albeit in an opposite (micro) direction than the usual analyses, which are 
typically macro-ecological and well-documented in the epidemiological and even in the 
sociological literature.  Thus, the approach is subjected to a unique form of bias known as the 
“ecological fallacy,” in which an inference made at the aggregated level (in this study of genes 
interpreted at pen or sample level) should not be assumed to apply at the disaggregated level 
(bacteria level).  Overall, such an approach gives an overall picture of the resistance genes in the 
gut at a micro-ecological level for evaluating the impact of growth promoters in agriculture.  It is 
not a stand-alone approach; rather, it should be relied upon to supplement other approaches such 
as isolate-based analysis to avoid making inappropriate policy decisions on the basis of a single 
outcome measure. 
 Conclusions 
This is the first experimental study to investigate the individual or combined effects of 
CTC and copper supplementation on the distribution of tet genes and quantities of tetracycline 
and cephalosporin resistance genes in the gut microbial ecology of pigs.  Overall, tet genes were 
diverse in the total gut bacterial community of the study pigs; importantly, copper and CTC 
supplementation differentially expanded several of the resistance genes studied.  This result 
suggests that such supplementation may favor gene expansion of certain target bacteria, perhaps 
at the expense of other gene targets or bacteria.  Community DNA analyses provide an adjunct 
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approach to evaluating effects on the microbial ecology of the gut that complements, but does 
not replace, phenotypic and genotypic analysis of cultivatable bacteria. 
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Overall, 32 pens with 5 pigs per pen were randomized to pen-level treatments (n = 160 pigs)  
 
    
    
CONTROL group (8 pens) 
(n = 40 animals; 5 pigs per pen) 
CTC group (8 pens) 
(n = 40 animals; 5 animals per 
pen) 
COPPER  group (8 pens)  
(n = 40 animals; 5 animals per 
pen) 
COPPER + CTC  group 
(8 pens) 
(n = 40 animals; 5 animals 
per pen) 
    
    
    
Received basal diet (CuSO4  at 
16.5 mg/kg of feed) 
Received basal diet + CTC 
(at 550 mg/kg of feed) 
Received  elevated copper 
 (at 125 mg/kg of feed)   
Received elevated copper  
plus CTC 
(at above doses) 
    
    
    
Fecal samples collected from 3 
animals per pen each week for 6 
weeks (n = 144 total samples) 
Fecal samples collected from 3 
animals per pen each week for 6 
weeks (n = 144 total samples) 
Fecal samples collected from 3 
animals per pen each week for 6 
weeks (n = 144 total samples) 
Fecal samples collected 
from 3 animals per pen 
each week for 6 weeks (n 
= 144 total samples) 
    
    
    
Fecal samples available for 
analysis (n = 143) 
Fecal samples available for 
analysis (n = 142) 
Fecal samples available for 
analysis (n = 141) 
Fecal samples available 
for analysis (n = 143) 
 
Figure 5.1.  Schematic representation of the trial design used to evaluate the effect of chlortetracycline (CTC), copper, neither 
or their combined supplementation in weaned pigs on the level of resistance genes detected in fecal community DNA.
166 
 
 
 
 
 
 
 
 
Figure 5.2.  Model adjusted prevalences of tetA, tetB, and tetA(P) from the fecal community 
DNA of weaned pigs receiving chlortetracycline (CTC), copper, both or neither across 
three treatment periods.
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Figure 5.3.  Bivariate distribution of tetA and tetB detection from fecal samples (n = 569) of 
pigs supplemented with chlortetracycline (CTC), copper or their combination by treatment 
period. 
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Figure 5.4.  Bar graph showing the percentage of fecal samples plotted against the number of tetracycline resistance genes 
detected from a single fecal sample from pigs supplemented with chlortetracycline (CTC), copper, both or neither.
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Figure 5.5.  Non-standardized mean log10 copies of resistance genes from total community DNA obtained from fecal samples (n 
= 569) of weaned pigs supplemented with chlortetracycline (CTC), copper, both or neither over treatment period. 
170 
 
  
  
  
 
Figure 5.6.  Pairwise correlations between resistance genes quantified from fecal samples of 
weaned pigs receiving copper, chlortetracycline, both or neither.
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Figure 5.7.  Mean log10 copies of resistance genes standardized to initial total DNA concentration obtained from fecal samples 
(n = 569) of weaned pigs supplemented with chlortetracycline (CTC), copper, both or neither over treatment period. 
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Figure 5.8.  Ratios of tetA to tetB genes quantified from the fecal samples of weaned pigs supplemented with chlortetracycline, 
copper, both or neither over the treatment period.  
 
The horizontal line serves as reference at ratio of 1.
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Table 5.1.  Primers used in multiplex PCR assays for the detection of tet genes from fecal samples (n = 569) of weaned pigs 
supplemented with chlortetracycline, copper both or neither 
Multiplex 
group 
Resistance 
gene
 
Resistance mechanism Primer sequence (5’-3’) Amplicon size 
(bp) 
Genebank 
accession No. 
I tetB Efflux pump TTG GTT AGG GGC AAG TTT TG 
GTA ATG GGC CAA TAA CAC CG 
659 X61367 
 tetC Efflux pump CTT GAG AGC CTT CAA CCC AG 
ATG GTC GTC ATC TAC CTG CC 
418 J01830 
 tetD Efflux pump AAA CCA TTA CGG CAT TCT GC 
GAC CGG ATA CAC CAT CCA TC 
787 J01749 
II tetA Efflux pump GCT ACA TCC TGC TTG CCT TC 
CAT AGA TCG CCG TGA AGA GG 
210 L06798 
 tetE Efflux pump AAA CCA CAT CCT CCA TAC GC 
AAA TAG GCC ACA ACC GTC AG 
278 L06940 
 tetG Efflux pump GCT CGG TGG TAT CTC TGC TC 
AGC AAC AGA ATC GGG AAC AC 
844 S52437 
 tetK Efflux pump TCG ATA GGA ACA GCA GTA 
CAG CAG ATC CTA CTC CTT 
169 S67449 
III tetL Efflux pump TCG TTA GCG TGC TGT CAT TC 
GTA TCC CAC CAA TGT AGC CG 
267 U17153 
 tetM Ribosomal protection CTG TTG AAC CGA GTA AAC CT 
GCA CTA ATC ACT TCC ATT TG 
406 X90939 
 tetO Ribosomal protection AAC TTA GGC ATT CTG GCT CAC 
TCC CAC TGT TCC ATA TCG TCA 
515 Y07780 
 tetS Ribosomal protection CAT AGA CAA GCC GTT GAC C 
ATG TTT TTG GAA CGC CAG AG 
667 X92946 
IV tetA(P) Efflux pump CTT GGA TTG CGG AAG AAG AG 
ATA TGC CCA TTT AAC CAC GC 
676 L20800 
 tetQ Ribosomal protection TTA TAC TTC CTC CGG CAT CG 
ATC GGT TCG AGA ATG TCC AC 
904 X58717 
 tetX Enzymatic inactivation CAA TAA TTG GTG GTG GAC CC 
TTC TTA CCT TGG ACA TCC CG 
468 M37699 
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Table 5.2.  Primers used for the quantification of resistance genes from fecal samples of weaned pigs supplemented with 
chlortetracycline, copper, both or neither 
 Primer Primer sequence (5’-3’) Amplicon 
size (bp) 
Reference 
tetA tetA-F GCT ACA TCC TGC TTG CCT TC  
210 
(194) 
tetA-R CAT  AGA TCG CCG TGA AGA GG 
tetB tetB-F1 CAG CAA GTG CGC TTT GGA TGC TG  
101 
 
tetB-R1 TGA GGT GGT ATC GGC AAT GA (153) 
 585F CAG ACG CGT CCT GCA ACC ATT AAA   
454 
 
blaCMY-2
a
 1038R TAC GTA GCT GCC AAA TCC ACC AGT  (154) 
pcoD
b 
pcoD-F ATC AGCA GGC AGG ACA ATA C  
This study 
 pcoD-R CTG ATG TGG GTA TTA GCT GGA TT 103 
 
a
Positive E. coli strain for blaCMY-2was obtained from University of Illinois (Odeh et al., 2002 (203)). 
b
Positive E. coli with pRJ1004 for pcoD was obtained from  Dr. Henrik Hasman (the National Food Institute, Technical University 
of Denmark).
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Table 5.3.  Prevalence (95% CI) of the various tet genes detected by multiplex PCR from 
total community DNA obtained from fecal samples (n = 569) of weaned pigs fed diets 
supplemented with chlortetracycline (CTC), copper, both or neither 
tet genes Treatment 
group 
Treatment period
a 
 
 Before (n = 24)
b 
During (n = 72)
b 
After (n = 48)
b 
P-value
c 
tetA Control 91.3 (72.0–98.9) 68.1 (56.0–78.6) 68.8 (53.7–81.3) 0.071 
CTC 95.5 (77.2– 99.9) 73.6 (61.9–83.3) 77.1 (62.7–88.0) 0.082 
Copper 95.2 (76.2–99.9) 73.6 (61.9–83.3) 62.5 (47.4–76.0) 0.011 
Copper + CTC 100 (85.8–100) 83.1 (72.3–91.0) 81.3 (67.4–91.1) 0.053 
P-value 
d 
0.591 0.206 0.164  
tetB Control 87.0 (66.4–97.2) 63.9 (51.7–74.9) 35.4 (22.2–50.5) < 0.001 
CTC 100 (84.6–100) 51.4 (39.3–63.3) 41.7 (27.6–56.8) < 0.001 
Copper 90.5 (69.6–98.8) 66.7 (54.6–77.3) 35.4 (22.2–50.5) < 0.001 
Copper + CTC 95.8 (78.9–99.9) 46.5 (34.5–58.7) 45.8 (31.4–60.8) < 0.001 
P-value
d 
0.326 0.040 0.667  
tetC Control 95.7 (78.1–99.9) 100 (95.0–100) 100 (92.6–100) 0.161 
CTC 100 (84.6–100) 95.8 (88.3–99.1) 100 (92.6–100) 0.401 
Copper 85.7 (63.7–97.0) 100 (95.0–100) 100 (92.6–100) 0.003 
Copper + CTC 95.8 (78.9–99.9) 95.8 (88.1 –99.1) 100 (92.6–100) 0.381 
P- value
d 
0.211 0.073 –  
tetL Control 95.7 (78.1–99.9) 100 (95.0–100) 100 (92.6–100) 0.161 
CTC 100 (84.6–100) 98.6 (92.5–100) 100 (92.6–100) 1.00 
Copper 100 (83.9–100) 100 (95.0–100) 100 (92.6–100) – 
Copper + CTC 100 (85.8–100) 100 (94.9–100) 100 (92.6–100) – 
P-value
d 
0.733 1.00 –  
tetM Control 100 (85.2–100) 100 (95.0–100) 97.9 (88.9–99.9) 0.497 
CTC 100 (84.6–100) 100 (95.0–100) 97.9 (88.9–99.9) 0.493 
Copper 100 (83.9–100) 97.2 (90.3–99.7) 100 (92.6–100) 0.650 
Copper + CTC 100 (85.8–100) 95.8 (88.1–99.1) 97.9 (88.9–99.9) 0.661 
P-value – 0.087 1.00  
tetA(P) Control 39.1 (19.7–61.5) 59.7 (47.5–71.1) 95.8 (85.7–99.5) < 0.001 
CTC 31.8 (13.9–54.9) 66.7 (54.6–77.3) 79.2 (65.0–89.5) 0.001 
Copper 14.3 (3.0–36.3) 73.6 (61.9–83.3) 89.6 (77.3–96.5) < 0.001 
Copper + CTC 37.5 (18.8–59.4) 85.9 (75.6–93.0) 81.3 (67.4–91.1) < 0.001 
P-value
d 
0.252 0.003 0.050  
 
a
P-values are based on Fisher’s exact test or LR as appropriate. 95% confidence interval (CI) 
is an exact confidence interval based on binomial distribution. 
b
Number of fecal samples tested per treatment group. Ranged from 22–24 (pretreatment 
period), 71–72 (treatment period), and was constant at 48 post-treatment period.  
c LR χ2 p-value with 2 d.f. comparing treatment periods within treatment group.  
d LR χ2 p-value with 3 d.f. comparing treatment groups within treatment period.  
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Table 5.4.  Frequency distribution of tet genes detected from fecal samples of pigs 
supplemented with chlortetracycline (CTC), copper, both or neither
 
Genotypic profiles
a 
Control
b 
(n = 143) 
CTC 
(n = 142) 
Copper 
(n = 141) 
Copper + CTC 
(n = 143) 
Total 
(n = 569) 
a_b_c_e_l_m_o_p_q_x 1 (0.7) 0 (0) 0 (0) 0 (0) 1 (0.2) 
a_b_c_e_l_m_o_q_x 1 (0.7) 0 (0) 0 (0) 0 (0) 1 (0.2) 
a_b_c_g_l_m_o_q_x 0 (0) 0 (0) 1 (0.7) 0 (0) 1 (0.2) 
a_b_c_l_m_o_p_q_x 43 (30.1) 38 (26.8) 40 (28.4) 41 (28.7) 162 (28.5) 
a_b_c_l_m_o_q_x 24 (16.8) 27 (19) 26 (18.4) 27 (18.9) 104 (18.3) 
a_b_c_l_o_p_q_x_ 0 (0) 1 (0.7) 0 (0) 0 (0) 1 (0.2) 
a_b_c_l_o_q_x_ 0 (0) 0 (0) 0 (0) 1 (0.7) 1 (0.2) 
a_b_c_m_o_q_x_ 0 (0) 1 (0.7) 0 (0) 0 (0) 1 (0.2) 
a_b_l_m_o_p_q_x_ 0 (0) 1 (0.7) 0 (0) 2 (1.4) 3 (0.5) 
a_b_l_m_o_q_x_ 0 (0) 0 (0) 1 (0.7) 0 (0) 1 (0.2) 
a_c_g_l_m_o_p_q_x_ 1 (0.7) 0 (0) 0 (0) 0 (0) 1 (0.2) 
a_c_l_m_o_p_q_x_ 24 (16.8) 32 (22.5) 26 (18.4) 44 (30.8) 126 (22.1) 
a_c_l_m_o_q_x_ 9 (6.3) 10 (7) 7 (5) 4 (2.8) 30 (5.3) 
a_c_l_o_p_q_x_ 0 (0) 0 (0) 1 (0.7) 2 (1.4) 3 (0.5) 
a_l_m_o_p_q_x_ 0 (0) 1 (0.7) 0 (0) 1 (0.7) 2 (0.4) 
a_l_m_o_q_x_ 0 (0) 0 (0) 1 (0.7) 0 (0) 1 (0.2) 
b_c_l_m_o_p_q_x_ 7 (4.9) 7 (4.9) 12 (8.5) 6 (4.2) 32 (5.6) 
b_c_l_m_o_q_x_ 7 (4.9) 4 (2.8) 3 (2.1) 1 (0.7) 15 (2.6) 
b_l_m_o_q_x_ 0 (0) 0 (0) 1 (0.7) 0 (0) 1 (0.2) 
c_l_m_o_p_q_x_ 21 (14.7) 12 (8.5) 20 (14.2) 12 (8.4) 65 (11.4) 
c_l_m_o_q_x_ 3 (2.1) 7 (4.9) 1 (0.7) 1 (0.7) 12 (2.1) 
c_l_o_p_q_x_ 1 (0.7) 0 (0) 0 (0) 0 (0) 1 (0.2) 
c_l_o_q_x_ 0 (0) 0 (0) 1 (0.7) 0 (0) 1 (0.2) 
l_m_o_p_q_x_ 0 (0) 1 (0.7) 0 (0) 0 (0) 1 (0.2) 
l_o_p_q_x_ 0 (0) 0 (0) 0 (0) 1 (0.7) 1 (0.2) 
m_o_q_x_ 1 (0.7) 0 (0) 0 (0) 0 (0) 1 (0.2) 
 
a
Lowercase letters represent the different tet genes (i.e., tetA, B, C, E, G, L, M, O, P, Q, X). 
b
The distribution of the genes is given as the frequency (percentage calculated from the total 
number of fecal samples tested per treatment group). 
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Chapter 6 - Summary and conclusions 
Antimicrobial resistance (AMR) creates a challenge for the treatment of bacterial 
infections in both human and veterinary medicine; further, it is a global problem in both 
developed and developing countries alike.  The epidemiology of AMR is complex and clearly 
calls for collaborative approaches among medical, veterinary and public health agencies in order 
to effectively address the issue.  Thus, AMR truly represents a “One Health” problem.  The 
magnitude of the AMR problem is directly related to the use of antibiotics for any purpose 
(whether therapy, prophylaxis, metaphylaxis or growth promotion).  The use of antibiotics forms 
an integral part of livestock production: increased productivity, improved animal health, 
enhanced food safety and protection of the public health and the environment.   
Paradoxically, such uses of antibiotics in agriculture can create a breeding ground for 
antibiotic resistant bacteria that can be disseminated in the environment and which can be further 
transferred to humans through the food chain or via direct contact with carrier animals.  The use 
of in-feed antibiotics for growth promotion in animals is of particularly great concern.  The use 
of antibiotics for growth promotion has been completely banned from EU countries and is 
increasingly being scrutinized in the United States (75).  Thus, alternatives to antibiotics such as 
the use of heavy metals (copper and zinc) are actively being researched at this time.  Previous 
reports have shown that the transferable copper resistance determinant (tcrB) in Enterococcus is 
linked with macrolide and glycopeptide resistance (41).  We therefore hypothesized that 
experimental supplementation of copper either alone or in combination with CTC may also be 
associated with other antimicrobial resistances of E. coli in nursery pigs.  
This PhD dissertation was aimed at experimentally investigating the impacts of 
supplementing feed-grade chlortetracycline (CTC) and elevated levels of copper in weaned pigs 
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on the AMR of the gut microbial flora.  To quantify the effects, two approaches – culture 
dependent and culture independent methods – were used.  For the culture based approach, E. coli 
isolates were derived from fecal samples and characterized for phenotypic resistance to 15 
antibiotics and copper; and for genotypic resistance to 4 tetracycline (tetA, B, C and E), one 
plasmid borne copper resistance (pcoD) and one ceftiofur (blaCMY-2) resistance gene.  The culture 
independent approach was based on the qualitative detection of 14 tet genes and quantification of 
the gene copies of each of tetA, tetB, pcoD and blaCMY-2 arising from the fecal metagenome.   
The phenotypic susceptibility results indicated that E. coli isolates were highly resistant 
to most of the antibiotics studied before the start of the experiment, and throughout the trial in 
the control pigs which were not exposed to antibiotics during the experiment.  Resistance to 
antibiotics that have been used for a great many years (e.g., ampicillin, amoxicillin/clavulanic 
acid, sulfisoxazole, streptomycin and tetracycline) ranged from 58% (streptomycin) to 98% 
(tetracycline) before the start of the experiment.  More pressing, was the observation that 
resistance to the relatively new antibiotics of the cephalosporin classes (cefoxitin, ceftriaxone 
and ceftiofur) was also similarly high (above 67% resistance) even in the absence of direct 
selective pressure from this class of antibiotics during the experiment.  This high resistance, both 
to the older and relatively newer antibiotics, could be a result of co-and cross-resistance leading 
to multidrug resistance (MDR).   
The E. coli isolates were of especially high counts of MDR: most of the isolates being 
resistant to 7 (out of 8) different antimicrobial classes.  Tetracycline and ceftiofur resistances 
were significantly associated with each other, both phenotypically and genotypically indicating 
genetic linkage for co-selection.  The high AMR observed in this study could be reflective of the 
unknown antibiotic use history of the breeder farm from which the experimental pigs were 
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acquired, or more likely could be associated with widespread dissemination of resistance 
determinants following the use of antibiotics for over 60 years, and especially evident in very 
young livestock.  Though reducing unnecessary use of antibiotics, especially in the feed, would 
likely somewhat decrease the magnitude of AMR in pig production thus increase public 
confidence, it will not result in the elimination of the AMR problem.  The use of antibiotic 
growth promotion (AGPs) in pig farms should be justified by evidence-based decisions.  Recent 
studies have shown that in-feed antibiotics do not always significantly improve the growth of 
pigs under current pig production systems (73, 74).  Existing evidence shows that the effect of 
in-feed antibiotics is the highest in the weaned pigs and thereafter decreases as pigs get older. 
Therefore, there is room to reduce antibiotic use by limiting the use of in-feed antibiotics to those 
in the early production phase, and only if their benefit is scientifically justified (9, 40, 71-73).  
  CTC supplementation was associated with increased phenotypic and genotypic 
resistance of E. coli to tetracycline, even beyond the already very high background levels of 
resistance.  This increase in tetracycline resistance was usually mediated through tetB gene since 
CTC supplementation was also associated with an increased detection of tetB and with little or 
no effect on tetA.  tetB also confers higher levels of tetracycline resistance than tetA (as 
measured via MIC distribution) and gene substitution at the population (metagenomic) level was 
observed as tetB detection increased over time while tetA decreased.  Copper supplementation 
also increased tetB detection while paradoxically the combined supplementation of copper and 
CTC appeared to decrease its probability of detection.  CTC supplementation was associated 
with increased MDR counts.  At the genetic level, this association was largely due to tetA.  tetA 
and blaCMY-2 genes were positively associated with each other reflecting their co-selection.  
These genes were significantly associated with higher counts of MDR.  Of particular interest, 
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tetB and pcoD were positively associated with each other and negatively associated with tetA 
and blaCMY-2; furthermore, they were associated with lower MDR counts.  It is possible that the 
use of low levels of CTC in the pig diet as AGP may well select for higher MDR by favoring co-
selection of tetA with blaCMY-2 gene.  
Copper supplementation was associated with reduced AMR to most of the antibiotics, 
including the cephalosporins, over the treatment periods.  Furthermore, E. coli from the CTC 
supplemented group exhibited modestly increased susceptibility to copper.  Surprisingly, neither 
the distribution of copper MIC, nor the probability of detection of the pcoD gene, was 
meaningfully affected by the level of copper supplementation in the experimental diet.  This 
suggests that the E. coli population did not rely on acquired copper resistance that is mediated by 
pco gene in order to survive and proliferate in the presence of elevated copper supplementation.  
This could be due to the fact that either the level of copper used (125 ppm) in the experiment was 
not sufficient to favor any such acquired resistance, or it could reflect the generalized 
adaptability and tolerance of E. coli and other Enterobacteriaceae to high levels of copper.  The 
findings could be also as result of the presence of other unknown mechanisms, besides the pco 
determinant, encoding for copper resistance.  The presence of multiple chromosomally mediated 
intrinsic mechanisms of intracellular copper regulation in E. coli makes it particularly 
challenging for conducting epidemiological and other field-based studies.  In vitro findings often 
do not translate well into in vivo findings, with even further difficulty in interpretation when 
taken further afield.  It was reported elsewhere (156) that the Gram negative enteric bacteria 
(e.g., Salmonella and E. coli) were more tolerant to copper than their Gram positive counterparts 
(e.g., enterococci and staphylococci).   
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The fecal metagenome held a diverse set of tetracycline resistance (tet) genes, with 11 
(out of 14) tet genes being detected from at least one fecal sample and with a median number of 
8 tet genes detected per fecal sample.  This diversity in tet genes detected from the fecal samples 
appeared to decrease over the subsequent treatment periods.  Most of the tet genes were found in 
high prevalence.  The prevalence of the Gram negative associated tet genes tetA and tetB (as 
opposed to the isolate based approach) significantly decreased over the treatment period, 
whereas that of the predominantly Gram positive associated tet genes tetC and tetP significantly 
increased.  This finding could be explained by the gradual substitution of tetracycline resistant 
Gram negative bacteria by tetracycline resistant Gram positive bacteria in the gut microbial 
ecology of the pigs as they aged.  CTC supplementation was associated with an increased 
detection of tetA, but with no apparent effect on tetB.  This was in contrast to what was observed 
in the E. coli isolate analysis where CTC supplementation resulted in increased tetB detection in 
E. coli, with no apparent effect on tetA detection.  As expected, the prevalences of tetA (77%) 
and tetB (57%) detected from the fecal metagenome were significantly higher compared to their 
prevalence from E. coli (66% and 48% respectively).  
The mean log10 copies of tetA, tetB and blaCMY-2 genes decreased over time while that of 
pcoD increased during the first week of the experiment and later gradually decreased.  Most 
likely this reflects the aging effect of the pigs and represents a gradual change in the microbial 
composition of the gut, with predominantly Gram positive bacteria expanding their dominance, 
since the four genes studied quantitatively largely confer resistance to Gram negative bacteria.  
In support of this hypothesis, we observed a decrease in the prevalence of Gram negative tet 
genes (tetA and tetB) while Gram positive tet genes were increased or else remained stable at a 
higher prevalence among the fecal samples.  Similar to the isolate based approach, copper 
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supplementation tended to decrease the abundance of tetA while increasing that of tetB gene 
copies.  CTC supplementation was associated with increased gene copies of tetA and blaCMY-2 as 
opposed to the isolate based finding.  Similar to isolate based findings, gene copies of pcoD were 
significantly higher in the control group when compared to the treatment groups, which remains 
inexplicable given its purported function.  
Table 6.1 summarizes the resistance genes and their associations based on both isolate 
and metagenome based approaches across all E. coli isolates and fecal samples studied.  tetA and 
tetB, either alone or in combination, were detected in 98% of phenotypically tetracycline 
resistant isolates.  Similarly 97% of the E. coli isolates that were phenotypically ceftiofur 
resistant were also positive to the blaCMY-2 gene.  In conclusion, antimicrobial resistance (both in 
isolate based and metagenomic approaches) reflecting the gut microbial ecology of the weaned 
pigs studied was very high at the baseline which then gradually decreased over time.  Copper 
supplementation seemed on the surface to be a promising alternative to antibiotics since it was 
associated with decreased AMR, including to the critically important cephalosporins.  However, 
the roles of copper supplementation and the pco gene, in particular, on the gut microbial ecology 
of pigs should be further studied under both laboratory and field conditions.
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Table 6.1. Summary and comparison of the resistance genes based on isolate and metagenome approaches across all the E. coli 
isolates and fecal samples tested 
 
 
Antimicrobial  
 E. coli (n = 1,152) Metagenome (n = 569) 
Number (%) 
resistant 
Gene Prevalence (%)
a
  
n = 1,152 
% Phenotypically 
resistant
a 
Prevalence (%)
a 
n = 569
 
Mean log10 gene 
copies/g
b 
Tetracycline 1,119 (97%) tetA 66 (64-69) 67 (65-70) 77 (74-81) 5.2 (5.1-5.3) 
  tetB 48 (45-51) 49 (46-52) 57 (53-61) 4.7 (4.6-4.8) 
Ceftiofur  746 (65%) blaCMY-2 72 (69-75) 97 (95-98) N/A
d 
4.5 (4.4-4.6) 
Copper
c
  1,076 (93%) pcoD 16 (14-18) 16 (14-18) N/A
d 
5.0 (4.9-5.0) 
 
a 
Values were expressed as percentage (95% confidence interval, CI) prevalence or percentage resistant  
b 
Values were expressed as mean log10 gene (95% CI) copies/g of feces 
c
18 mM concentration of copper was used as a non-standardized breakpoint 
d
N/A= Not tested 
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